

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057857 A2(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US03/00398

(22) International Filing Date: 6 January 2003 (06.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/041,860 7 January 2002 (07.01.2002) US(71) Applicant (for all designated States except US): AB-
GENIX, INC. [US/US]; 6701 Kaiser Drive, Fremont, CA
94555 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CORVALAN, Jose,
R., F. [CL/US]; 125 Williams Street, Foster City, CA94404 (US). JIA, Xiao-Chi [US/US]; 22 Murray Court,
San Mateo, CA 94403 (US). FENG, Xiao [US/US];
135 Red Cedar Lane, Union City, CA 94587 (US).
YANG, Xiao-Dong [CN/US]; 2833 Bryant Street, Palo
Alto, CA 94306 (US). CHEN, Francine [US/US]; 2660
31st Avenue, San Francisco, CA 94116 (US). GAZIT,
Gadi [US/US]; 521 Del Medio Avenue, #118, Mountain
View, CA 94040 (US). WEBER, Richard [US/US];
2537 Pacheco Street, San Francisco, CA 94116 (US).
BEZABEH, Binyam [US/US]; 314 Perkins Street, #105,
Oakland, CA 94610 (US).(74) Agent: HUNT, Dale, C.; Knobbe, Martens, Olson & Bear,
LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).(81) Designated States (national): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,

[Continued on next page]

(54) Title: ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

CTAAAAATATGTTCTCTACAAACCAAGGCTCATTAAAAATATTTTAAATATTATATACAT
 TTCTTCTGTGAGAAATACATAAACTTTATTATATCAGCGCAGGGCGGCGCGCGTCCGCTCC
 CGGGAGCAGAACCCGGCTTTTCTTGGAGCGACGCTGTCTCTAGTCGCTGATCCCAAATGCA
 CGGGCTCATCTTTGTCTACACTCTAATCTGCGCAAACTTTGCGAGCTGTGGGACACTTCTG
 CAACCCCGCAGAGCGCATCCATCAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGAGAGC
 AATCACCTCACAGACTTGTACCGAAGAGATGAGACCATCCAGGTGAAAGGAAACGGTACGCT
 GCAGAGTCTTAGATTCCCGAACAGCTACCCAGGAACCTGCTCTGACATGGCGGCTTCACT
 CTCAGGAGAAATACCGGATACAGCTAGTGTGTGACAATCAGTTTGGATTAGAGGAAGCAGAA
 AATGATATCTGTAGGTATGATTTTGTGGAAAGTTGAAGATATATCCGAAACAGTACCATAT
 TAGAGGACGATGTTGTGGACACAAGGAAGTTCTCCAGGATAAAATCAAGAACGAACCAAA
 TTAATACATTCAAGTCCGATGACTTCTTGTGGCTAAACCTGGATTCAAGATTATTAT
 TCTTTGCTGGAAGATTTCACCCGACAGCTTCAGAGACCAACTGGGAATCTGTACAAAG
 CTCTATTTCAGGGGTATCCTATACTCTCCATCAGTAACGGATCCCACTCTGATTGGGATG
 CTCTGGACAAAAAATTGCAAGATTGATACAGTGGAAAGATCTGCTCAAGTACTTCAATCCA
 GAGTCATGGCAAGAAGATCTTGAGAATATGATCTGGACACCCCTCGGTATCGAGGCAGGTC
 ATACCATGACCCGAAGTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTACA
 GTTGCACTCCCGAAGTACTCGGTCAATATAAGAGAAGAGCTGAAGTTGGCCAATGTGGTC
 TTCTTTCCACGTTGCCCTCTCGTGCAGCGCTGTGGAGGAAATTTGGGCTGTGGAACTGTCAA
 CTGGAGGTCCTGCACATGCCAATTTCAGGGAAAAACCGTGAAGAAATATCATGAGGTATTACAGT
 TTGAGCCTGGCCACATCAAGAGGAGGGGTAGAGCTAAGACCATGGCTCTAGTTGACATCCAG
 TTGGATCACCATGAACGATGTGATTGTATCTGCAGCTCAAGACCACTCGATAAGAGAATGT
 GCACATCCTTACATTAAAGCTGAAAGAACCTTTAGTTTAAAGAGGGTGAGATAAGAGACCTT
 TTCTTACAGCAACCAAACTTACTACTAGCTGCAATGCAATGAACACAAGTGGTGTCTGA
 GTCTCAGCCTTGCTTTGTTTAAATGCCATGGCAAGTAGAAGGTATATCATCAACTTCTATACC
 TAAGATATAGGATTGCATTTAATAATAGTGTGTTGAGGTTATATATGCACAAACACACAG
 AATATATTATGCTCTATGTGTATATAGATCAAAATGTTTTTTTGGTATATATAACCAAGTA
 CACCAGAGCTTACATATGTTTGAAGTTAGACTCTTAAATCCTTTGCCAAAATAAGGGATGGT
 CAAATATATGAACATGTCTTTAGAAAATTTAGGAGATAAATTTATTTTAAATTTTGAAC
 ACAAAACAATTTGAATCTTGCTCTCTTAAGAAAGCATCTGTATATATAAAATCAARA
 TGAGGCTTTCTTACATATACATCTTAGTTG (SEQ ID NO: 50)

(57) Abstract: The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

WO 03/057857 A2



MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF**BACKGROUND OF THE INVENTION****1. Summary of the Invention**

5 The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or
10 complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

2. Background of the Technology

15 Polypeptide growth factors exerting effects in a variety of tissues have been described. Such growth factors include platelet-derived growth factor (PDGF).

The platelet derived growth factor (PDGF) family currently consists of at least 3 distinct genes, PDGF A, PDGF B, and PDGF C whose gene products selectively signal through two PDGFRs to regulate diverse cellular functions. PDGF A, PDGF B, and PDGF C dimerize in solution to form homodimers, as well as the heterodimer.

20 Expression of RNA encoding the PDGF A and PDGF B subunits of has been reported in vascular tissues involved in atherosclerosis. PDGF A and PDGF B mRNA have been reported to be present in mesenchymal-appearing intimal cells and endothelial cells, respectively, of atherosclerotic plaques. In addition, PDGF receptor mRNA has also been localized predominantly in plaque intimal cells.

25 The PDGF B is related to the transforming gene (v-sis) of simian sarcoma virus. The PDGF B has also been reported to be mitogen for cells of mesenchymal origin. The PDGF B has in addition been implicated in autocrine growth stimulation in the pathologic proliferation of endothelial cells characteristically found in glioblastomas. PDGF has also been reported to promote cellular proliferation and inhibits apoptosis.

30 A novel PDGF, PDGF-D, has recently been cloned and characterized. See LaRochelle et al. *Nature Cell Biology* 3:517 (2001), GenBank Accession No. AF335584, International Patent Application No. WO 01/25433, USSN 60/158,083, filed October 7, 1999; USSN 60/159,231, filed October 13, 1999; USSN 60/174,485 filed January 4, 2000; USSN 60/186,707 filed March 3, 2000; USSN 60/188,250, filed March 10, 2000; USSN 60/223,879, filed August 8, 2000; USSN 60/234,082,
35 filed on September 20, 2000; USSN 09/685,330, filed on October 5, 2000; PCT Application US00/27671, filed October 6, 2000; USSN 09/688,312, filed October 13, 2000 and USSN

09/715,332, filed November 16, 2000. Because of its expression profile and sequence homology and/or similarity to the above-discussed genes and gene products, antibodies to the PDGF-D antigen could be useful therapeutically.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

5 Figure 1 is a representation of the nucleotide sequence of the human PDGFD gene (SEQ ID NO:50).

Figure 2 is a representation of the nucleotide (SEQ ID NO:50) and deduced amino acid (SEQ ID NO:12) sequence of the human PDGF D gene.

10 Figure 3 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.6 of the invention, with Figure 3A representing the nucleotide sequence encoding the variable region of the heavy chain (SEQ.ID.NO: 55), Figure 3B (SEQ.ID.NO: 13) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 3A, Figure 3C (SEQ.ID.NO: 56) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 3D (SEQ.ID.NO: 14) representing the amino acid sequence encoded by the
15 nucleotide sequence shown in Figure 3C.

Figure 4 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.11 of the invention, with Figure 4A representing the nucleotide sequence encoding the variable region of the heavy chain (SEQ.ID.NO: 57)Figure 4B (SEQ.ID.NO: 15) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 4A, Figure 4C (SEQ.ID.NO: 58) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 4D (SEQ.ID.NO: 16) representing the amino acid sequence encoded by the
20 nucleotide sequence shown in Figure 4C.

25 Figure 5 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.17 of the invention, with Figure 5A (SEQ.ID.NO: 59) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 5B (SEQ.ID.NO: 17) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 5A, Figure 5C (SEQ.ID.NO: 60) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 5D (SEQ.ID.NO: 18) representing the amino acid sequence encoded by the
30 nucleotide sequence shown in Figure 5C.

Figure 6 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.18 of the invention, with Figure 6A (SEQ.ID.NO: 61) representing the
35 nucleotide sequence encoding the variable region of the heavy chain, Figure 6B (SEQ.ID.NO: 19)

representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 6A, Figure 6C (SEQ.ID.NO: 62) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 6D (SEQ.ID.NO: 20) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 6C.

5 Figure 7 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.19 of the invention, with Figure 7A (SEQ.ID.NO: 63) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 7B (SEQ.ID.NO: 21) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 7A, Figure 10 7C (SEQ.ID.NO: 64) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 7D (SEQ.ID.NO: 22) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 7C.

 Figure 8 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma 15 cell line designated Cur 2-1.23 of the invention, with Figure 8A (SEQ.ID.NO: 65) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 8B (SEQ.ID.NO: 23) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 8A, Figure 8C (SEQ.ID.NO: 66) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 8D (SEQ.ID.NO: 24) representing the amino acid sequence encoded by the 20 nucleotide sequence shown in Figure 8C.

 Figure 9 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.24 of the invention, with Figure 9A (SEQ.ID.NO: 67) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 9B (SEQ.ID.NO: 25) 25 representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 9A, Figure 9C (SEQ.ID.NO: 68) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 9D (SEQ.ID.NO: 26) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 9C.

 Figure 10 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma 30 cell line designated Cur 2-1.25 of the invention, with Figure 10A (SEQ.ID.NO: 69) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 10B (SEQ.ID.NO: 27) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 10A, Figure 10C (SEQ.ID.NO: 70) representing the nucleotide sequence encoding the variable region of the light 35 chain, and Figure 10D (SEQ.ID.NO: 28) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 10C.

Figure 11 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.29 of the invention, with Figure 11A (SEQ.ID.NO: 71) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 11B (SEQ.ID.NO: 29) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 11A, Figure 11C (SEQ.ID.NO: 72) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 11D (SEQ.ID.NO: 30) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 11C.

Figure 12 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.33 of the invention, with Figure 12A (SEQ.ID.NO: 73) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 12B (SEQ.ID.NO: 31) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 12A, Figure 12C (SEQ.ID.NO: 74) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 12D (SEQ.ID.NO: 32) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 12C.

Figure 13 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.38 of the invention, with Figure 13A (SEQ.ID.NO: 75) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 13B (SEQ.ID.NO: 33) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 13A, Figure 13C (SEQ.ID.NO: 76) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 13D (SEQ.ID.NO: 34) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 13C.

Figure 14 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.39 of the invention, with Figure 14A (SEQ.ID.NO: 77) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 14B (SEQ.ID.NO: 35) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 14A, Figure 14C (SEQ.ID.NO: 78) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 14D (SEQ.ID.NO: 36) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 14C.

Figure 15 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.40 of the invention, with Figure 15A (SEQ.ID.NO: 79) representing the

nucleotide sequence encoding the variable region of the heavy chain and Figure 15B (SEQ.ID.NO: 37) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 15A.

Figure 16 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.45 of the invention, with Figure 16A (SEQ.ID.NO: 80) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 16B (SEQ.ID.NO: 38) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 16A, Figure 16C (SEQ.ID.NO: 81) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 16D (SEQ.ID.NO: 39) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 16C.

Figure 17 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.46 of the invention, with Figure 17A (SEQ.ID.NO: 82) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 17B (SEQ.ID.NO: 40) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 17A, Figure 17C (SEQ.ID.NO: 83) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 17D (SEQ.ID.NO: 41) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 17C.

Figure 18 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.48 of the invention, with Figure 18A (SEQ.ID.NO: 84) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 18B (SEQ.ID.NO: 42) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 18A, Figure 18C (SEQ.ID.NO: 85) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 18D (SEQ.ID.NO: 43) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 18C.

Figure 19 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.49 of the invention, with Figure 19A (SEQ.ID.NO: 86) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 19B (SEQ.ID.NO: 44) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 19A, Figure 19C (SEQ.ID.NO: 87) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 19D (SEQ.ID.NO: 45) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 19C.

Figure 20 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma

cell line designated Cur 2-1.51 of the invention, with Figure 20A (SEQ.ID.NO: 88) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 20B (SEQ.ID.NO: 46) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 20A, Figure 20C (SEQ.ID.NO: 89) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 20D (SEQ.ID.NO: 47) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 20C.

Figure 21 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-6.4 of the invention, with Figure 21A (SEQ.ID.NO: 90) representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 21B (SEQ.ID.NO: 48) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 21A, Figure 21C (SEQ.ID.NO: 91) representing the nucleotide sequence encoding the variable region of the light chain, and Figure 21D (SEQ.ID.NO: 49) representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 21C.

Figure 22 is a table showing VDJ gene utilization of antibodies of the invention and indicating nucleotide/amino acid changes between the antibodies and the V, D, or J genes from which they are derived in the antibodies FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 regions.

Figure 23 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.6 of the invention and the V gene from which it is derived. Figure 23A represents the alignment of the heavy chain amino acid sequence CUR2.1.6.1 HC (SEQ. ID. NO: 270) and VH2-21 (SEQ. ID. NO: 271), the consensus being shown below (SEQ. ID. NO: 272). Figure 23B represents the alignment of the light chain amino acid sequence of CUR2.1.6.1 LC (SEQ. ID. NO: 273) and A30 (SEQ. ID. NO: 274), with the consensus sequence being shown below (SEQ. ID. NO: 275).

Figure 24 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.11 of the invention and the V gene from which it is derived. Figure 24A represents the alignment of the heavy chain amino acid sequence CUR2.1.11.1 HC (SEQ. ID. NO: 276) and VH3-53 (SEQ. ID. NO: 277), the consensus being shown below (SEQ. ID. NO: 278). Figure 24B represents the alignment of the light chain amino acid sequence of CUR2.1.11.1 LC (SEQ. ID. NO: 279) and A19 (SEQ. ID. NO: 280), with the consensus sequence shown below (SEQ. ID. NO: 281).

Figure 25 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated CR 2-1.17.1 of the invention and the V gene from which it is derived. Figure 25A represents the alignment of the heavy chain amino acid sequence CR 2-1.17.1 HC (SEQ. ID. NO: 282) and VH3-53 (SEQ. ID. NO: 283), the consensus being shown below (SEQ. ID. NO: 284). Figure 25B represents

the alignment of the light chain amino acid sequence of CR 2-1.17.1 LC (SEQ. ID. NO: 285) and A30 (SEQ. ID. NO: 286), with the consensus sequence being shown below (SEQ. ID. NO: 287).

Figure 26 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.18 of the invention and the V gene from which it is derived. Figure 26A represents the alignment of the heavy chain amino acid sequence CR2-1.18 HC (SEQ. ID. NO: 288) and VH1-8 (SEQ. ID. NO: 289), the consensus being shown below (SEQ. ID. NO: 290). Figure 26B represents the alignment of the light chain amino acid sequence of CR2-1.18 LC (SEQ. ID. NO: 291) and A30 (SEQ. ID. NO: 292), with the consensus sequence being shown below (SEQ. ID. NO: 293).

Figure 27 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.19 of the invention and the V gene from which it is derived. Figure 27A represents the alignment of the heavy chain amino acid sequence CUR2.1.19.1 HC (SEQ. ID. NO: 294) and VH1-8 (SEQ. ID. NO: 295), the consensus being shown below (SEQ. ID. NO: 296). Figure 27B represents the alignment of the light chain amino acid sequence of CUR2.1.19.1 LC (SEQ. ID. NO: 297) and A30 (SEQ. ID. NO: 298), with the consensus sequence being shown below (SEQ. ID. NO: 299).

Figure 28 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.23 of the invention and the V gene from which it is derived. Figure 28A represents the alignment of the heavy chain amino acid sequence CUR2.1.23.1 HC (SEQ. ID. NO: 300) and VH5-51 (SEQ. ID. NO: 301), the consensus being shown below (SEQ. ID. NO: 302). Figure 28B represents the alignment of the light chain amino acid sequence of CUR2.1.23.1 LC (SEQ. ID. NO: 303) and A30 (SEQ. ID. NO: 304), with the consensus sequence being shown below (SEQ. ID. NO: 305).

Figure 29 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.24 of the invention and the V gene from which it is derived. Figure 29A represents the alignment of the heavy chain amino acid sequence CUR2.1.24.1 HC (SEQ. ID. NO: 306) and VH3-33 (SEQ. ID. NO: 307), the consensus being shown below (SEQ. ID. NO: 308). Figure 29B represents the alignment of the light chain amino acid sequence of CUR2.1.24.1 LC (SEQ. ID. NO: 309) and A30 (SEQ. ID. NO: 310), with the consensus sequence being shown below (SEQ. ID. NO: 311).

Figure 30 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.25 of the invention and the V gene from which it is derived. Figure 30A represents the alignment of the heavy chain amino acid sequence VH5-51 (SEQ. ID. NO: 312) and CUR2.1.25.1 HC (SEQ. ID. NO: 313), the consensus being shown below (SEQ. ID. NO: 314). Figure 30B represents

the alignment of the light chain amino acid sequence of A30 (SEQ. ID. NO: 315) and CUR2.1.25.1 LC (SEQ. ID. NO: 316), with the consensus sequence shown below (SEQ. ID. NO: 317).

Figure 31 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
5 Cur 2-1.29 of the invention and the V gene from which it is derived. Figure 31A represents the alignment of the heavy chain amino acid sequence VH5-51 (SEQ. ID. NO: 318) and CUR2.1.29 HC (SEQ. ID. NO: 319), the consensus being shown below (SEQ. ID. NO: 320). Figure 31B represents the alignment of the light chain amino acid sequence of A19 (SEQ. ID. NO: 321) and CUR2.1.29 LC (SEQ. ID. NO: 322), with the consensus sequence being shown below (SEQ. ID. NO: 323).

10 Figure 32 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.33 of the invention and the V gene from which it is derived. Figure 32A represents the alignment of the heavy chain amino acid sequence VH1-18 (SEQ. ID. NO: 324) and CR2.1.33 HC (SEQ. ID. NO: 325), the consensus being shown below (SEQ. ID. NO: 326). Figure 32B represents
15 the alignment of the light chain amino acid sequence of A20 (SEQ. ID. NO: 327) and CR2.1.33 LC (SEQ. ID. NO: 328), with the consensus sequence being shown below (SEQ. ID. NO: 329).

Figure 33 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.38 of the invention and the V gene from which it is derived. Figure 33A represents the
20 alignment of the heavy chain amino acid sequence VH3-33 (SEQ. ID. NO: 330) and CR2.1.38.1 HC (SEQ. ID. NO: 331), the consensus being shown below (SEQ. ID. NO: 332). Figure 33B represents the alignment of the light chain amino acid sequence of A20 (SEQ. ID. NO: 334) and CUR2.1.38.1 LC (SEQ. ID. NO: 335), with the consensus sequence being shown below (SEQ. ID. NO: 336).

Figure 34 is a series of alignments of the heavy chain and light chain variable region amino
25 acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.39 of the invention and the V gene from which it is derived. Figure 34A represents the alignment of the heavy chain amino acid sequence VH5-51 (SEQ. ID. NO: 336) and CR2.1.39.1 HC (SEQ. ID. NO: 337), the consensus being shown below (SEQ. ID. NO: 338). Figure 34B represents the alignment of the light chain amino acid sequence of A30 (SEQ. ID. NO: 339) and CR2.1.39.1 LC
30 (SEQ. ID. NO: 340), with the consensus sequence being shown below (SEQ. ID. NO: 341).

Figure 35 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.45 of the invention and the V gene from which it is derived. Figure 35A represents the
alignment of the heavy chain amino acid sequence VH1-8 (SEQ. ID. NO: 342) and CR2.1.45.1 HC
35 (SEQ. ID. NO: 343), the consensus being shown below (SEQ. ID. NO: 344). Figure 35B represents

the alignment of the light chain amino acid sequence of A20 (SEQ. ID. NO: 345) and CUR2.1.45.1 LC (SEQ. ID. NO: 346), with the consensus sequence being shown below (SEQ. ID. NO: 347).

Figure 36 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.46 of the invention and the V gene from which it is derived. Figure 36A represents the alignment of the heavy chain amino acid sequence VH1-8 (SEQ. ID. NO: 348) and CR2.1.46.1 HC (SEQ. ID. NO: 349), the consensus being shown below (SEQ. ID. NO: 350). Figure 36B represents the alignment of the light chain amino acid sequence of A30 (SEQ. ID. NO: 351) and CR2.1.46.1 LC (SEQ. ID. NO: 352), with the consensus sequence being shown below (SEQ. ID. NO: 353).

Figure 37 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.48 of the invention and the V gene from which it is derived. Figure 37A represents the alignment of the heavy chain amino acid sequence CR2.1.48.1 HC (SEQ. ID. NO: 354) and VH1-18 (SEQ. ID. NO: 355), the consensus being shown below (SEQ. ID. NO: 356). Figure 37B represents the alignment of the light chain amino acid sequence of CR2.1.48.1 LC (SEQ. ID. NO: 357) and L5 (SEQ. ID. NO: 358), with the consensus sequence being shown below (SEQ. ID. NO: 359).

Figure 38 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.49 of the invention and the V gene from which it is derived. Figure 38A represents the alignment of the heavy chain amino acid sequence CR2.1.49.1 HC (SEQ. ID. NO: 360) and VH1-8 (SEQ. ID. NO: 361), the consensus being shown below (SEQ. ID. NO: 362). Figure 38B represents the alignment of the light chain amino acid sequence of CUR2.1.49.1 LC (SEQ. ID. NO: 363) and A19 (SEQ. ID. NO: 364), with the consensus sequence being shown below (SEQ. ID. NO: 365).

Figure 39 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.51 of the invention and the V gene from which it is derived. Figure 39A represents the alignment of the heavy chain amino acid sequence CR2.1.51.1 HC (SEQ. ID. NO: 366) and VH5-51 (SEQ. ID. NO: 367), the consensus being shown below (SEQ. ID. NO: 368). Figure 39B represents the alignment of the light chain amino acid sequence of CR2.1.51.1 LC (SEQ. ID. NO: 369) and A27 (SEQ. ID. NO: 370), with the consensus sequence being shown below (SEQ. ID. NO: 371).

Figure 40 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-6.4 of the invention and the V gene from which it is derived. Figure 40A represents the alignment of the heavy chain amino acid sequence CUR2.6.4.1 HC (SEQ. ID. NO: 372) and VH1-8 (SEQ. ID. NO: 373), the consensus being shown below (SEQ. ID. NO: 374). Figure 40B represents:

the alignment of the light chain amino acid sequence of CUR2.6.4.1 LC (SEQ. ID. NO: 375) and A27 (SEQ. ID. NO: 376), with the consensus sequence being shown below (SEQ. ID. NO: 377).

Figure 41 is a table showing VDJ gene utilization of the 1.19.1 and 6.4.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 42 is a table showing VDJ gene utilization of the 1.6.1, 1.11.1, and 1.23.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 43 is a table showing VDJ gene utilization of the 1.19.1, 6.4.1, 1.6.1, 1.11.1, 1.23.1, 1.17.1, 1.18, 1.24.1, 1.25.1, 1.29, 1.33, 1.38.1, 1.39.1, 1.40.1, 1.45, 1.46.1, 1.46.2, 1.48.1, 1.49.1, and 1.51.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 44 is a bar graphic representation comparing the levels of BrdU incorporation in NIH 3T3 cells upon exposure to various human anti-PDGFD monoclonal antibodies of the invention.

Figure 45 is a bar graphic representation comparing the levels of BrdU incorporation in NIH 3T3 cells upon exposure to various human anti-PDGFD monoclonal antibodies of the invention at varying doses as compared to a control run utilizing PDGFBB at varying concentrations.

Figure 46 is a bar graphic representation comparing the levels of BrdU incorporation in NIH 3T3 cells upon exposure to various human anti-PDGFD monoclonal antibodies of the invention at varying doses as compared to a control run utilizing PDGFBB at varying concentrations.

Figure 47 is a bar graphic representation comparing the levels of BrdU incorporation in NIH 3T3 cells upon exposure to various human anti-PDGFD monoclonal antibodies of the invention at varying doses as compared to a control run utilizing PDGFBB at varying concentrations.

Figure 48 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention indicating locations of the CDRs of the antibodies. Heavy chain sequences shown are: 1.19H (SEQ. ID. NO: 199); 6.4H (SEQ. ID. NO: 200); 1.18H (SEQ. ID. NO: 201); 1.40H (SEQ. ID. NO: 202); 1.45H (SEQ. ID. NO: 203); 1.46H (SEQ. ID. NO: 204); 1.49H (SEQ. ID. NO: 205); 1.33H (SEQ. ID. NO: 206); 1.48H (SEQ. ID. NO: 207); 1.6H (SEQ. ID. NO: 208); 1.17H (SEQ. ID. NO: 209); 1.24H (SEQ. ID. NO: 210); 1.38H (SEQ. ID. NO: 211); 1.11H (SEQ. ID. NO: 212); 1.23H (SEQ. ID. NO: 213); 1.25H (SEQ. ID. NO: 214); 1.29H (SEQ. ID. NO: 215); 1.39H (SEQ. ID. NO: 216); and 1.51H (SEQ. ID. NO: 217).

Figure 49 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention indicating locations of the CDRs of the antibodies. Light chain sequences shown are: 1.48L (SEQ. ID. NO: 218); 1.49L (SEQ. ID. NO: 219); 1.11L (SEQ. ID. NO: 220); 1.29L (SEQ. ID. NO: 221); 1.45L (SEQ. ID. NO: 222); 1.33L (SEQ. ID. NO: 223); 1.38L (SEQ. ID. NO: 224); 6.4L (SEQ. ID. NO: 225); 1.51L (SEQ. ID. NO: 226); 1.19L (SEQ.

ID. NO: 227); 1.18L (SEQ. ID. NO: 228); 1.16L (SEQ. ID. NO: 229); 1.23L (SEQ. ID. NO: 230); 1.25L (SEQ. ID. NO: 231); 1.39L (SEQ. ID. NO: 232); 1.17L (SEQ. ID. NO: 233); 1.24L (SEQ. ID. NO: 234); and 1.46L (SEQ. ID. NO: 235).

5 Figure 50 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 1-8 gene with CDRs indicated. Heavy chain sequences shown are: 1.19H (SEQ. ID. NO: 236); 6.4H (SEQ. ID. NO: 237); 1.18H (SEQ. ID. NO: 238); 1.40H (SEQ. ID. NO: 239); 1.45H (SEQ. ID. NO: 240); 1.46H (SEQ. ID. NO: 241); and 1.49H (SEQ. ID. NO: 242).

10 Figure 51 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 1-18 gene with CDRs indicated. Heavy chain sequences shown are: 1.33H (SEQ. ID. NO: 243) and 1.48H (SEQ. ID. NO: 244).

15 Figure 52 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 3-33 gene with CDRs indicated. Heavy chain sequences shown are: 1.17H (SEQ. ID. NO: 245); 1.24H (SEQ. ID. NO: 246); and 1.38H (SEQ. ID. NO: 247).

20 Figure 53 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 5-51 gene with CDRs indicated. Heavy chain sequences shown are: 1.23H (SEQ. ID. NO: 248); 1.25H (SEQ. ID. NO: 249); 1.29H (SEQ. ID. NO: 250); 1.39H (SEQ. ID. NO: 251); and 1.51H (SEQ. ID. NO: 252).

25 Figure 54 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A19 gene with CDRs indicated. Light chain sequences shown are: 1.49L (SEQ. ID. NO: 253); 1.11L (SEQ. ID. NO: 254); and 1.29L (SEQ. ID. NO: 255).

30 Figure 55 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A20 gene with CDRs indicated. Light chain sequences shown are: 1.45L (SEQ. ID. NO: 256); 1.33L (SEQ. ID. NO: 257); and 1.38L (SEQ. ID. NO: 258).

Figure 56 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A27 gene with CDRs indicated. Light chain sequences shown are: 6.4L (SEQ. ID. NO: 259) and 1.51L (SEQ. ID. NO: 260).

35 Figure 57 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A30 gene with CDRs indicated. Light chain sequences shown are: 1.19L (SEQ. ID. NO: 261); 1.18L (SEQ. ID.

NO: 262); 1.16L (SEQ. ID. NO: 263); 1.23L (SEQ. ID. NO: 264); 1.25L (SEQ. ID. NO: 265); 1.39L (SEQ. ID. NO: 266); 1.17L (SEQ. ID. NO: 267); 1.24L (SEQ. ID. NO: 268); and 1.46L (SEQ. ID. NO: 269).

SUMMARY OF THE INVENTION

5 In accordance with a first aspect of the present invention, there is provided a human monoclonal antibody that binds to PDGFD and has a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOS: 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 40, 42, 44, 46, and 48. In one embodiment, the antibody further comprises a light chain amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 39,
10 41, 43, 45, 47, and 49.

In accordance with a second aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a heavy chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VH 1-8 gene and any of the amino acid differences shown in Figure 50 and comprising a CDR3 sequence selected from the group consisting
15 of the CDR3 sequences shown in Figure 50.

In accordance with a third aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a heavy chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VH 1-18 gene and any of the amino acid differences shown in Figure 51 and comprising a CDR3 sequence selected from the group consisting of the CDR3
20 sequences shown in Figure 51.

In accordance with a fourth aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a heavy chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VH 3-33 gene and any of the amino acid differences shown in Figure 52 and comprising a CDR3 sequence selected from the group consisting
25 of the CDR3 sequences shown in Figure 52.

In accordance with a fifth aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a heavy chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VH 5-51 gene and any of the amino acid differences shown in Figure 53 and comprising a CDR3 sequence selected from the group consisting of the CDR3
30 sequences shown in Figure 53.

In accordance with a sixth aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a light chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VK A19 gene and any of the amino acid differences shown in Figure 54 and comprising a CDR3 sequence selected from the group consisting of the CDR3
35 sequences shown in Figure 54.

In accordance with a seventh aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a light chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VK A20 gene and any of the amino acid differences shown in Figure 55 and comprising a CDR3 sequence selected from the group consisting of the CDR3 sequences shown in Figure 55.

In accordance with an eighth aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a light chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VK A27 gene and any of the amino acid differences shown in Figure 56 and comprising a CDR3 sequence selected from the group consisting of the CDR3 sequences shown in Figure 56.

In accordance with a ninth aspect of the present invention there is provided a human antibody that binds to PDGFD that comprises a light chain amino acid sequence corresponding substantially to the amino acid sequence encoded by the VK A30 gene and any of the amino acid differences shown in Figure 57 and comprising a CDR3 sequence selected from the group consisting of the CDR3 sequences shown in Figure 57.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A novel PDGF, PDGF-D, has recently been cloned and characterized. *See* LaRochelle et al. *Nature Cell Biology* 3:517 (2001), GenBank Accession No. AF335584, International Patent Application No. WO 01/25433, USSN 60/158,083, filed October 7, 1999; USSN 60/159,231, filed October 13, 1999; USSN 60/174,485 filed January 4, 2000; USSN 60/186,707 filed March 3, 2000; USSN 60/188,250, filed March 10, 2000; USSN 60/223,879, filed August 8, 2000; USSN 60/234,082, filed on September 20, 2000; USSN 09/685,330, filed on October 5, 2000; PCT Application US00/27671, filed October 6, 2000; USSN 09/688,312, filed October 13, 2000 and USSN 09/715,332, filed November 16, 2000. Because of its expression profile and sequence homology and/or similarity to the above-discussed genes and gene products, antibodies to the PDGF-D antigen could be useful therapeutically. Because of its expression profile and sequence homology and/or similarity to the above-discussed genes and gene products, antibodies to the PDGF-D antigen could be useful therapeutically.

The nucleotide and translated amino acid sequence, respectively, of PDGF-D is set forth in Figures 1 and 2.

The similarities of the disclosed PDGFD polypeptides to previously described BMP-1 VEGF-E and PDGF polypeptides indicate a similarity of functions by the PDGFD nucleic acids and polypeptides of the invention. These utilities are described in more detail below.

PDGFD nucleic acids and polypeptides may be use to induce formation of cartilage, as BMP-1 is also capable of inducing formation of cartilage *in vivo* (Wozney et al., *Science* 242: 1528-1534 (1988)).

An additional use for the PDGFD nucleic acids and polypeptides is in the modulation of collagen formation. Recombinantly expressed BMP1 and purified procollagen C proteinase (PCP), a secreted metalloprotease requiring calcium and needed for cartilage and bone formation, are, in fact, identical. See, Kessler *et al.*, *Science* 271:360-62 (1996). BMP-1 cleaves the C-terminal propeptides of procollagen I, II, and III and its activity is increased by the procollagen C-endopeptidase enhancer protein. PDGFD nucleic acids and polypeptides may play similar roles in collagen modulation pathways.

PDGFD nucleic acids and polypeptides can also be used to stage various cancers. For example, bone metastases can almost universally be correlated to the morbidity and mortality of certain prostate cancers. For example, bone morphogenetic proteins are implicated as having important roles in various cancers. Overexpression of bone morphogenetic protein-4 ("BMP-4") and BMP-2 mRNA has been reported in gastric cancer cell lines of poorly differentiated type. See, Katoh *et al.*, *J. Gastroenterol* 31(1):137-9 (1996). This observation may have implications regarding the poor prognosis of patients with diffuse osteoplastic bone metastasis of gastric cancer. Additionally, osteosarcomas producing bone morphogenetic protein ("BMP") differed in clinical features from those not producing BMP. See, Yoshikawa *et al* *Cancer* 56: 1682-7 (1985) They were characterized radiologically by perpendicular spicules, histologically by osteoblastic type cells, and clinically by an increased serum alkaline phosphatase level, relative resistance to preoperative chemotherapy with Adriamycin (doxorubicin) plus high-dose methotrexate, and a tendency to metastasize to other bones and the lungs.

The relatedness of PDGFD polypeptides to VEGF- reveals uses for PDGFD nucleic acids and polypeptides in modulating angiogenesis. Angiogenesis is a process which contributes to the development of new blood vessels. During angiogenesis, new capillaries sprout from existing vessels. See, Risau *FASEB J.* 9(10): 926-33 (1995); Risau *et al.*, *Ann.Rev. Cell Dev Biol.* 11: 73-91 (1995). In adult mammals, new blood vessels are produced through angiogenesis. Pathological states in which angiogenesis contributes to the appearance and maintenance of the pathology include tumor development and growth. vascular endothelial growth factor F has been reported to be involved in angiogenesis.

Vascular endothelial growth factor ("VEGF") is a multifunctional cytokine expressed and secreted at high levels by many tumor cells in both nonhumans and humans. See review in Ferrara, *Curr Top Microbiol Immunol* 237: 1-30 (1999). VEGF exerts its effects on the vascular endothelium through at least two receptors that are expressed on the cell surface. The first is kinase insert domain-containing receptor ("KDR")/fetal liver kinase 1 ("Flk-1"), and the second is FLT-1 (Warren *et al.*, *J Clin Invest* 95: 1789-97 (1995)). These two receptors have different affinities for VEGF and appear to have different cellular responses. See, Athanassiades *et al.*, *Placenta* 19(7): 465-73 (1998); Li *et al. Cell Res* 9: 11-25 (1999). FLT-1 null mice die in the embryonic stage, at about day 8.5, whereas KDR

null mice survive through birth and retain endothelial and hematopoietic cell development. Activation of KDR leads to mitogenesis and to up-regulation of e-nitric oxide synthase (eNOS) and inducible NOS, enzymes in the nitric oxide pathway that contribute to regulation of vasodilation and that play a role in vascular tumor development.

5 It has been also been reported that VEGF acts as a survival factor for newly formed blood vessels. In the developing retina, for example, vascular regression in response to hyperoxia has been correlated with inhibition of VEGF release by glial cells. See, Alon *et al.*, *Nat Med* 1: 1024-8(1995). Furthermore, administration of anti-VEGF monoclonal antibodies results in regression of already established tumor-associated vasculature in xenograft models. See, Yuan, *et al.*, *Proc Natl Acad Sci*
10 *U S A* 93: 14765-70(1996). Therefore, antibodies to PDGFD polypeptides may also be used to induce or promote regression of newly formed blood vessels.

Tumor cells additionally respond to hypoxia by secreting VEGF. This response promotes neovascularization and consequently permits tumor growth. Furthermore, it has been found that several tumor cells, including hematopoietic cells (Bellamy *et al.*, *Cancer Res* 59(3): 728-33 (1999)),
15 breast cancer cells (Speirs *et al.*, *Br J Cancer* 80(5-6): 898-903(1999)), and Kaposi's sarcoma (Masood *et al.*, *Proc Natl Acad Sci U S A* 94(3): 979-84 (1997)), express the KDR receptor. Such results suggest that in these tumors VEGF is acting not only in a paracrine fashion to stimulate angiogenesis, but also via an autocrine mechanism as well to stimulate proliferation and/or survival of endothelial cells, and/or promoting survival of tumor cells. Accordingly, modulation of angiogenesis
20 by PDGFD antibodies, or other antagonists of PDGFD nucleic acid or polypeptide function, can be used in anoxia-associated conditions to inhibit endothelial cell proliferation, and/or tumor cells such as hematopoietic cells, breast cancer cells, and Kaposi's sarcoma cells.

The similarity between PDGFD polypeptides and VEGF polypeptides suggests that PDGFD nucleic acids and their encoded polypeptides can be used to modulate cell survival. It has been
25 reported that VEGF signaling is important for cell survival. Binding of VEGF to its receptor, VEGF receptor-2 (VEGFR-2/Flk1/KDR), is reported to induce the formation of a complex of VE-cadherin, β -catenin, phosphoinositide-3-OH kinase (PI3-K), and KDR. PI3-K in this complex activates the serine/threonine protein kinase Akt (protein kinase B) by phosphorylation. See, Carmeliet *et al.*, 1999 *Cell* 98(2): 147-57. Activated Akt is then thought to be necessary and sufficient to mediate the VEGF-
30 dependent survival signal. See, Gerber *et al.* 1998 *J. Biol. Chem.* 273(46): 30336-43. These findings indicate that there is a relationship between VEGF signaling and cell survival.

The similarity between PDGFD polypeptides and PDGF polypeptides suggests that PDGFD nucleic acids and their encoded polypeptides can be used in various therapeutic and diagnostic applications. For example, PDGFD nucleic acids and their encoded polypeptides can be used to treat
35 cancer, cardiovascular and fibrotic diseases and diabetic ulcers. In addition, PDGFD nucleic acids and their encoded polypeptides will be therapeutically useful for the prevention of aneurysms and the

acceleration of wound closure through gene therapy. Furthermore, PDGFD nucleic acids and their encoded polypeptides can be utilized to stimulate cellular growth.

PDGFD nucleic acids according to the invention can be used to identify various cell types, including cancerous cells. For example, PDGFD is strongly expressed specifically in CNS cancer, lung cancer and ovarian cancer. It is also shown in the PDGFD produces a gene product which either persists intact in conditioned medium arising from transfecting HEK 293 cells, or is processed to provide fragments of the gene product. The activities ascribed to either one or both of these substances include the ability to stimulate net DNA synthesis as monitored by incorporation of BrdU into DNA, proliferation of cell number, the ability to transform cells in culture, and the ability to induce tumor formation *in vivo*. These various activities occur in a variety of cell types. Additional activities include inducing the phosphorylation of tyrosine residues of receptor protein molecules.

A PDGFD nucleic acid or gene product, is useful as a therapeutic agent in promoting wound healing, neovascularization and tissue growth, and similar tissue regeneration needs. More specifically, a PDGFD nucleic acid or polypeptide may be useful in treatment of anemia and leukopenia, intestinal tract sensitivity and baldness. Treatment of such conditions may be indicated in, e.g., patients having undergone radiation or chemotherapy. It is intended in such cases that administration of a PDGFD nucleic acid or polypeptide or a nucleic acid sequence encoding these polypeptides will be controlled in dose such that any hyperproliferative side effects are minimized.

Alternatively, in cases of tumors, such as CNS cancer and ovarian cancer, in which PDGFD nucleic acids is expressed at high levels it is desired to inhibit or eliminate the effects of production of a PDGFD nucleic acid or gene product. For example, this may be accomplished by administration of an antibody directed against PDGFD identified herein. An alternative example involves identifying the putative protease implicated in the formation of p35 from p85 (*see* WO 01/25433 4/12/2001). Administration of a substance that specifically inhibits the activity of this protease, but not the activity of other proteases, will be effective to prevent formation of the active p35 form of a PDGFD polypeptide.

Based on the roles of molecules related to PDGFD polypeptides and nucleic acids, (e.g., BMP-1 and VEGF-like polypeptides such as fallotein) in malignant disease progression and the gene expression profile described herein, it is foreseen that, for a subset of human gliomas and ovarian epithelial carcinomas, targeting of a PDGFD polypeptide using an antibody has an inhibitory effect on tumor growth, matrix invasion, chemo-resistance, radio-resistance, and metastatic dissemination. In various embodiments, the PDGFD polypeptide is linked to a monoclonal antibody, a humanized antibody or a fully human antibody.

Furthermore, based on chromosomal location analysis (*see* WO 01/25433 4/12/2001) the PDGFD nucleic acids localize to chromosome 11q23-24. This chromosomal locus to D maps is a region of genomic instability (Kurahashi *et al.*, Hum. Mol. Genet. 9, 1665-1670 (2000)) altered in

various neoplasias (Ferti-Passantonopoulou, *et al.* Cancer Genet. Cytogenet. 51, 183-188 (1991); Tarkkanen *et al.*, Genes Chromosomes Cancer 25, 323-331 (1999)) and Jacobsen's syndrome (Pivnick *et al.*, J. Med. Genet. 33, 772-778 (1996)) that might be explained in part through abnormal growth factor expression. Jacobsen's syndrome is marked by craniofacial abnormalities, heart defects, glandular abnormalities and lack of brain development (Pivnick *et al.* (1996)). Accordingly, the PDGFD nucleic acids and polypeptides according to the invention may be used in various diagnostic and therapeutic applications of these disease states.

Additionally, rearrangements resulting in amplification or deletions about the 11q23-24 locus have been reported in breast cancer (Ferti-Passantonopoulou, *et al.* Cancer Genet. Cytogenet. 51, 183-188 (1991); Shen *et al.*, J. Surg. Oncol. 74, 100-107 (2000)), primary sarcomas, their pulmonary metastasis (Tarkkanen *et al.* (1999)), and myeloid leukemias (Michaux *et al.*, Genes Chromosomes Cancer 29, 40-47 (2000); Crossen, *et al.* Cancer Genet. Cytogenet. 112, 144-148 (1999)). Thus, PDGFD nucleic acids polypeptides and antibodies according to the invention may also have diagnostic and therapeutic applications in the detection and treatment these cancers.

A PDGFD polypeptide can potentially block or limit the extent of tumor neovascularization. In addition to classical modes of administration of potential antibody therapeutics newly developed modalities of administration may be useful. For example, local administration of ¹³¹I-labeled monoclonal antibody for treatment of primary brain tumors after surgical resection has been reported. Additionally, direct stereotactic intracerebral injection of monoclonal antibodies and their fragments is also being studied clinically and pre-clinically. Intracarotid hyperosmolar perfusion is an experimental strategy to target primary brain malignancy with drug conjugated human monoclonal antibodies.

Additionally, the nucleic acids of the invention, and fragments and variants thereof, may be used, by way of nonlimiting example, (a) to direct the biosynthesis of the corresponding encoded proteins, polypeptides, fragments and variants as recombinant or heterologous gene products, (b) as probes for detection and quantification of the nucleic acids disclosed herein, (c) as sequence templates for preparing antisense molecules, and the like. Such uses are described more fully in the following disclosure.

Furthermore, the proteins and polypeptides of the invention, and fragments and variants thereof, may be used, in ways that include (a) serving as an immunogen to stimulate the production of an anti-PDGFD antibody, (b) a capture antigen in an immunogenic assay for such an antibody, (c) as a target for screening for substances that bind to a PDGFD polypeptide of the invention, and (d) a target for a PDGFD-specific antibody such that treatment with the antibody inhibits cell growth. These utilities and other utilities for PDGFD nucleic acids, polypeptides, antibodies, agonists, antagonists, and other related compounds uses are disclosed more fully below. In view of its strong effects in modulating cell growth, an increase of PDGFD polypeptide expression or activity can be used to

promote cell survival. Conversely, a decrease in PDGFD polypeptide expression can be used to induce cell death.

PDGFD Agonists And Antagonists

The present invention also pertains to variants of a PDGFD protein that function as either PDGFD agonists (mimetics) or as PDGFD antagonists. Variants of a PDGFD protein can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of the PDGFD protein. An agonist of the PDGFD protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the PDGFD protein. An antagonist of the PDGFD protein can inhibit one or more of the activities of the naturally occurring form of the PDGFD protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the PDGFD protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the PDGFD protein.

Variants of the PDGFD protein that function as either PDGFD agonists (mimetics) or as PDGFD antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the PDGFD protein for PDGFD protein agonist or antagonist activity. In one embodiment, a variegated library of PDGFD variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of PDGFD variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential PDGFD sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of PDGFD sequences therein. There are a variety of methods which can be used to produce libraries of potential PDGFD variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential PDGFD variant sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu Rev Biochem* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucl Acid Res* 11:477).

Definitions

Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and

hybridization described herein are those well known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. *See e.g.*, Sambrook et al. *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

The term "isolated polynucleotide" as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.

The term "isolated protein" referred to herein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein" (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g. free of murine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus. Preferred polypeptides in accordance with the invention comprise the human heavy chain immunoglobulin molecules represented by Figures 1, 5, 9, 13, 17, 21, 25, and 29 and the human kappa light chain immunoglobulin molecules represented by Figures 3, 7, 11, 15, 19, 23, 27, and 31, as well as antibody molecules formed by combinations comprising the heavy chain immunoglobulin molecules with light chain immunoglobulin molecules, such as the kappa light chain immunoglobulin molecules, and vice versa, as well as fragments and analogs thereof.

The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present

in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.

The term "operably linked" as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably
5 linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The term "control sequence" as used herein refers to polynucleotide sequences which are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such
10 control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion
15 partner sequences.

The term "polynucleotide" as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA.

The term "oligonucleotide" referred to herein includes naturally occurring, and modified
20 nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g. for probes; although oligonucleotides may be double stranded, e.g. for use in the construction of a gene mutant.
25 Oligonucleotides of the invention can be either sense or antisense oligonucleotides.

The term "naturally occurring nucleotides" referred to herein includes deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "oligonucleotide linkages" referred to herein includes oligonucleotides linkages such as phosphorothioate, phosphorodithioate,
30 phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche et al. *Nucl. Acids Res.* 14:9081 (1986); Stec et al. *J. Am. Chem. Soc.* 106:6077 (1984); Stein et al. *Nucl. Acids Res.* 16:3209 (1988); Zon et al. *Anti-Cancer Drug Design* 6:539 (1991); Zon et al. *Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al.
35 U.S. Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990). An oligonucleotide can include a label for detection, if desired.

The term "selectively hybridize" referred to herein means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M.O., in *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotides or amino acid sequences may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2)

may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks, or MacVector software packages), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

The term "sequence identity" means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See *Immunology - A Synthesis* (2nd Edition, E.S. Golub and D.R. Gren, Eds.,

Sinauer Associates, Sunderland, Mass. (1991)). Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic-aspartic, and asparagine-glutamine.

As discussed herein, minor variations in the amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into

families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Assays are described in detail herein. Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. *Science* 253:164 (1991). Thus, the foregoing examples demonstrate that those of skill in the art can recognize sequence motifs and structural conformations that may be used to define structural and functional domains in accordance with the invention.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in *Proteins, Structures and Molecular Principles* (Creighton, Ed., W. H. Freeman and Company, New York (1984)); *Introduction to Protein Structure* (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al. *Nature* 354:105 (1991).

The term "polypeptide fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full-length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14 amino acids long, more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long. The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has at least one of the following properties: (1) specific binding to a PDGFD, under suitable binding conditions, (2) ability to block appropriate PDGFD binding, or (3) ability to inhibit PDGFD expressing cell growth *in vitro* or *in vivo*. Typically, polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compounds are termed "peptide mimetics" or "peptidomimetics". Fauchere, *J. Adv. Drug Res.* 15:29 (1986); Veber and Freidinger *TINS* p.392 (1985); and Evans et al. *J. Med. Chem.* 30:1229 (1987). Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: $-\text{CH}_2\text{NH}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$ (cis and trans), $-\text{COCH}_2-$, $-\text{CH}(\text{OH})\text{CH}_2-$, and $-\text{CH}_2\text{SO}-$, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo and Gierasch *Ann. Rev. Biochem.* 61:387 (1992)); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

"Antibody" or "antibody peptide(s)" refer to an intact antibody, or a binding fragment thereof that competes with the intact antibody for specific binding. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab', F(ab')₂, Fv, and single-chain antibodies. An antibody other than a "bispecific" or "bifunctional" antibody is understood to have each of its binding sites identical. An

antibody substantially inhibits adhesion of a receptor to a counterreceptor when an excess of antibody reduces the quantity of receptor bound to counterreceptor by at least about 20%, 40%, 60% or 80%, and more usually greater than about 85% (as measured in an *in vitro* competitive binding assay).

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is $\leq 1 \mu\text{M}$, preferably $\leq 100 \text{ nM}$ and most preferably $\leq 10 \text{ nM}$.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

As used herein, the terms "label" or "labeled" refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

The term "pharmaceutical agent or drug" as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient. Other chemistry terms herein are used according to conventional usage in the art, as exemplified by *The McGraw-Hill Dictionary of Chemical Terms* (Parker, S., Ed., McGraw-Hill, San Francisco (1985)).

The term "antineoplastic agent" is used herein to refer to agents that have the functional property of inhibiting a development or progression of a neoplasm in a human, particularly a malignant (cancerous) lesion, such as a carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is frequently a property of antineoplastic agents.

As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object

species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

The term patient includes human and veterinary subjects.

Antibody Structure

The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function. Human light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See generally, *Fundamental Immunology* Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)). The variable regions of each light/heavy chain pair form the antibody binding site.

Thus, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same.

The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat *Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk *J. Mol. Biol.* 196:901-917 (1987); Chothia et al. *Nature* 342:878-883 (1989).

A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann *Clin. Exp. Immunol.* 79: 315-321 (1990), Kostelny et al. *J. Immunol.* 148:1547-1553 (1992). Production of bispecific antibodies can be a relatively labor intensive process compared with production of conventional antibodies and yields and degree of purity are generally lower for

bispecific antibodies. Bispecific antibodies do not exist in the form of fragments having a single binding site (e.g., Fab, Fab', and Fv).

Human Antibodies and Humanization of Antibodies

Human antibodies avoid certain of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a patient. In order to avoid the utilization of murine or rat derived antibodies, it has been postulated that one can develop humanized antibodies or generate fully human antibodies through the introduction of human antibody function into a rodent so that the rodent would produce fully human antibodies.

Human Antibodies

The ability to clone and reconstruct megabase-sized human loci in YACs and to introduce them into the mouse germline provides a powerful approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. Furthermore, the utilization of such technology for substitution of mouse loci with their human equivalents could provide unique insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.

An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated offers the opportunity to study the mechanisms underlying programmed expression and assembly of antibodies as well as their role in B-cell development. Furthermore, such a strategy could provide an ideal source for production of fully human monoclonal antibodies (Mabs) - an important milestone towards fulfilling the promise of antibody therapy in human disease. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which require repeated antibody administrations.

One approach towards this goal was to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci in anticipation that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve the large variable gene diversity as well as the proper regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should yield high affinity antibodies against any antigen of interest,

including human antigens. Using the hybridoma technology, antigen-specific human Mabs with the desired specificity could be readily produced and selected.

This general strategy was demonstrated in connection with our generation of the first XenoMouse™ strains as published in 1994. *See* Green et al. *Nature Genetics* 7:13-21 (1994). The XenoMouse™ strains were engineered with yeast artificial chromosomes (YACs) containing 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain locus and kappa light chain locus, respectively, which contained core variable and constant region sequences. *Id.* The human Ig containing YACs proved to be compatible with the mouse system for both rearrangement and expression of antibodies and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development, to produce an adult-like human repertoire of fully human antibodies, and to generate antigen-specific human Mabs. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization. The work of Green et al. was recently extended to the introduction of greater than approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and kappa light chain loci, respectively, to produce XenoMouse™ mice. *See* Mendez et al. *Nature Genetics* 15:146-156 (1997) and U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996.

Such approach is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, filed 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430, 938, April 27, 1995, 08/464,584, filed June 5, 1995, 08/464,582, filed June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995, 08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859, filed June 5, 1995, 08/462,513, filed June 5, 1995, 08/724,752, filed October 2, 1996, and 08/759,620, filed December 3, 1996 and U.S. Patent Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598 and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2. *See also* Mendez et al. *Nature Genetics* 15:146-156 (1997) and Green and Jakobovits *J. Exp. Med.* 188:483-495 (1998). *See also* European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000.

In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H

genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al. and U.S. Patent Nos. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 each to
 5 Lonberg and Kay, U.S. Patent No. 5,591,669 and 6,023,010 to Krimpenfort and Berns, U.S. Patent Nos. 5,612,205, 5,721,367, and 5,789,215 to Berns et al., and U.S. Patent No. 5,643,763 to Choi and Dunn, and GenPharm International U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,068, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131,
 10 filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994. *See also* European Patent No. 0 546 073 B1, International Patent Application Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884 and U.S. Patent No. 5,981,175. *See*
 15 *further* Taylor et al., 1992, Chen et al., 1993, Tuailon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuailon et al., (1995), Fishwild et al., (1996).

The inventors of Surani et al., cited above and assigned to the Medical Research Counsel (the "MRC"), produced a transgenic mouse possessing an Ig locus through use of the minilocus approach. The inventors on the GenPharm International work, cited above, Lonberg and Kay, following the lead
 20 of the present inventors, proposed inactivation of the endogenous mouse Ig locus coupled with substantial duplication of the Surani et al. work.

An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals. Commensurately, however, a significant disadvantage of the minilocus approach is that, in theory, insufficient diversity is
 25 introduced through the inclusion of small numbers of V, D, and J genes. Indeed, the published work appears to support this concern. B-cell development and antibody production of animals produced through use of the minilocus approach appear stunted. Therefore, research surrounding the present invention has consistently been directed towards the introduction of large portions of the Ig locus in order to achieve greater diversity and in an effort to reconstitute the immune repertoire of the animals.

30 Kirin has also demonstrated the generation of human antibodies from mice in which, through microcell fusion, large pieces of chromosomes, or entire chromosomes, have been introduced. *See* European Patent Application Nos. 773 288 and 843 961.

Human anti-mouse antibody (HAMA) responses have led the industry to prepare chimeric or otherwise humanized antibodies. While chimeric antibodies have a human constant region and a
 35 murine variable region, it is expected that certain human anti-chimeric antibody (HACA) responses will be observed, particularly in chronic or multi-dose utilizations of the antibody. Thus, it would be

desirable to provide fully human antibodies against PDGFD in order to vitiate concerns and/or effects of HAMA or HACA response.

Humanization and Display Technologies

As was discussed above in connection with human antibody generation, there are advantages to producing antibodies with reduced immunogenicity. To a degree, this can be accomplished in connection with techniques of humanization and display techniques using appropriate libraries. It will be appreciated that murine antibodies or antibodies from other species can be humanized or primatized using techniques well known in the art. See e.g., Winter and Harris *Immunol Today* 14:43-46 (1993) and Wright et al. *Crit. Reviews in Immunol.* 12:125-168 (1992). The antibody of interest may be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (see WO 92/02190 and U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,761, 5,693,792, 5,714,350, and 5,777,085). Also, the use of Ig cDNA for construction of chimeric immunoglobulin genes is known in the art (Liu et al. *P.N.A.S.* 84:3439 (1987) and *J.Immunol.* 139:3521 (1987)). mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest may be amplified by the polymerase chain reaction using specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes may be found in Kabat et al. (1991) *Sequences of Proteins of Immunological Interest*, N.I.H. publication no. 91-3242. Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effector functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1, IgG3 and IgG4. Either of the human light chain constant regions, kappa or lambda, may be used. The chimeric, humanized antibody is then expressed by conventional methods.

Antibody fragments, such as Fv, F(ab')₂ and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab')₂ fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.

Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL

sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g. SV-40 early promoter, (Okayama et al. *Mol. Cell. Bio.* 3:280 (1983)), Rous sarcoma virus LTR (Gorman et al. *P.N.A.S.* 79:6777 (1982)), and moloney murine leukemia virus LTR (Grosschedl et al. *Cell* 41:885 (1985)). Also, as will be appreciated, native Ig promoters and the like may be used.

Further, human antibodies or antibodies from other species can be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art. Wright and Harris, *supra.*, Hanes and Plutchau *PNAS USA* 94:4937-4942 (1997) (ribosomal display), Parmley and Smith *Gene* 73:305-318 (1988) (phage display), Scott *TIBS* 17:241-245 (1992), Cwirla et al. *PNAS USA* 87:6378-6382 (1990), Russel et al. *Nucl. Acids Research* 21:1081-1085 (1993), Hoganboom et al. *Immunol. Reviews* 130:43-68 (1992), Chiswell and McCafferty *TIBTECH* 10:80-84 (1992), and U.S. Patent No. 5,733,743. If display technologies are utilized to produce antibodies that are not human, such antibodies can be humanized as described above.

Using these techniques, antibodies can be generated to PDGFD expressing cells, PDGFD itself, forms of PDGFD, epitopes or peptides thereof, and expression libraries thereto (*see e.g.* U.S. Patent No. 5,703,057) which can thereafter be screened as described above for the activities described above.

Additional Criteria for Antibody Therapeutics

As discussed herein, the function of the PDGFD antibody appears important to at least a portion of its mode of operation. By function, we mean, by way of example, the activity of the PDGFD antibody in operation PDGFD. Accordingly, in certain respects, it may be desirable in connection with the generation of antibodies as therapeutic candidates against PDGFD that the antibodies be capable of fixing complement and participating in CDC. There are a number of isotypes of antibodies that are capable of the same, including, without limitation, the following: murine IgM, murine IgG2a, murine IgG2b, murine IgG3, human IgM, human IgG1, and human IgG3. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather, the antibody as generated can possess any isotype and the antibody can be isotype switched thereafter using conventional techniques that are well known in the art. Such techniques include the use of direct recombinant techniques (*see e.g.*, U.S. Patent No. 4,816,397), cell-cell fusion techniques (*see e.g.*, U.S. Patent Nos. 5,916,771 and 6,207,418), among others.

In the cell-cell fusion technique, a myeloma or other cell line is prepared that possesses a heavy chain with any desired isotype and another myeloma or other cell line is prepared that possesses the light chain. Such cells can, thereafter, be fused and a cell line expressing an intact antibody can be isolated.

5 By way of example, the PDGFD antibody discussed herein is a human anti- PDGFD IgG2 antibody. If such antibody possessed desired binding to the PDGFD molecule, it could be readily isotype switched to generate a human IgM, human IgG1, or human IgG3 isotype, while still possessing the same variable region (which defines the antibody's specificity and some of its affinity). Such molecule would then be capable of fixing complement and participating in CDC.

10 Accordingly, as antibody candidates are generated that meet desired "structural" attributes as discussed above, they can generally be provided with at least certain of the desired "functional" attributes through isotype switching.

Design and Generation of Other Therapeutics

15 In accordance with the present invention and based on the activity of the antibodies that are produced and characterized herein with respect to PDGFD, the design of other therapeutic modalities beyond antibody moieties is facilitated. Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.

20 In connection with the generation of advanced antibody therapeutics, where complement fixation is a desirable attribute, it may be possible to sidestep the dependence on complement for cell killing through the use of bispecifics, immunotoxins, or radiolabels, for example.

For example, in connection with bispecific antibodies, bispecific antibodies can be generated that comprise (i) two antibodies one with a specificity to PDGFD and another to a second molecule
25 that are conjugated together, (ii) a single antibody that has one chain specific to PDGFD and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to PDGFD and the other molecule. Such bispecific antibodies can be generated using techniques that are well known for example, in connection with (i) and (ii) *see e.g.*, Fanger et al. *Immunol Methods* 4:72-81 (1994) and Wright and Harris, *supra.* and in connection with (iii) *see e.g.*, Traunecker et al. *Int. J. Cancer (Suppl.)* 7:51-52 (1992). In each case, the second specificity can be made to the heavy chain
30 activation receptors, including, without limitation, CD16 or CD64 (*see e.g.*, Deo et al. 18:127 (1997)) or CD89 (*see e.g.*, Valerius et al. *Blood* 90:4485-4492 (1997)). Bispecific antibodies prepared in accordance with the foregoing would be likely to kill cells expressing PDGFD, and particularly those cells in which the PDGFD antibodies of the invention are effective.

35 In connection with immunotoxins, antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. *See e.g.*, Vitetta *Immunol Today* 14:252 (1993).

See also U.S. Patent No. 5,194,594. In connection with the preparation of radiolabeled antibodies, such modified antibodies can also be readily prepared utilizing techniques that are well known in the art. See e.g., Junghans et al. in *Cancer Chemotherapy and Biotherapy* 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). See also U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (RE 35,500), 5,648,471, and 5,697,902. Each of immunotoxins and radiolabeled molecules would be likely to kill cells expressing PDGFD, and particularly those cells in which the antibodies of the invention are effective.

In connection with the generation of therapeutic peptides, through the utilization of structural information related to PDGFD and antibodies thereto, such as the antibodies of the invention (as discussed below in connection with small molecules) or screening of peptide libraries, therapeutic peptides can be generated that are directed against PDGFD. Design and screening of peptide therapeutics is discussed in connection with Houghten et al. *Biotechniques* 13:412-421 (1992), Houghten *PNAS USA* 82:5131-5135 (1985), Pinalla et al. *Biotechniques* 13:901-905 (1992), Blake and Litzi-Davis *BioConjugate Chem.* 3:510-513 (1992). Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.

Assuming that the PDGFD molecule (or a form, such as a splice variant or alternate form) is functionally active in a disease process, it will also be possible to design gene and antisense therapeutics thereto through conventional techniques. Such modalities can be utilized for modulating the function of PDGFD. In connection therewith the antibodies of the present invention facilitate design and use of functional assays related thereto. A design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444. Design and strategies for gene therapy are well known. However, in particular, the use of gene therapeutic techniques involving intrabodies could prove to be particularly advantageous. See e.g., Chen et al. *Human Gene Therapy* 5:595-601 (1994) and Marasco *Gene Therapy* 4:11-15 (1997). General design of and considerations related to gene therapeutics is also discussed in International Patent Application No. WO 97/38137.

Small molecule therapeutics can also be envisioned in accordance with the present invention. Drugs can be designed to modulate the activity of PDGFD based upon the present invention. Knowledge gleaned from the structure of the PDGFD molecule and its interactions with other molecules in accordance with the present invention, such as the antibodies of the invention, and others can be utilized to rationally design additional therapeutic modalities. In this regard, rational drug design techniques such as X-ray crystallography, computer-aided (or assisted) molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can be utilized to focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with the molecule or specific forms thereof which can be used

to modify or modulate the activity of PDGFD. Such structures can be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al. *Genetically Engineered Human Therapeutic Drugs* (Stockton Press, NY (1988)). Further, combinatorial libraries can be designed and synthesized and used in screening programs, such as high throughput screening efforts.

Therapeutic Administration and Formulations

It will be appreciated that administration of therapeutic entities in accordance with the invention will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." *Regul. Toxicol. Pharmacol.* 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." *Int. J. Pharm.* 203(1-2):1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." *J Pharm Sci.* 89(8):967-78 (2000), Powell et al. "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

Preparation of Antibodies

Antibodies in accordance with the invention are preferably prepared through the utilization of a transgenic mouse that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine, antibodies. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents, applications, and references disclosed in the Background, herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996 and International Patent Application Nos. WO 98/24893, published June 11, 1998 and WO 00/76310, published December 21, 2000. *See also* Mendez et al. *Nature Genetics* 15:146-156 (1997).

Through use of such technology, we have produced fully human monoclonal antibodies to a variety of antigens. Essentially, we immunize XenoMouse™ lines of mice with an antigen of interest, recover lymphatic cells (such as B-cells) from the mice that express antibodies, fuse such recovered cells with a myeloid-type cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. We utilized these techniques in accordance with the present invention for the preparation of antibodies specific to PDGFD. Herein, we describe the production of multiple hybridoma cell lines that produce antibodies specific to PDGFD. Further, we provide a characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies.

The hybridoma cell lines discussed herein are designated 1.6.1, 1.11.1, 1.17.1, 1.18.1, 1.19.1, 1.23.1, 1.24, 1.25, 1.29, 1.33, 1.38, 1.39, 1.40, 1.45, 1.46, 1.48, 1.49, 1.51, and 6.4.1. Each of the antibodies produced by the aforementioned cell lines possess fully human IgG2 heavy chains with human kappa light chains. In general, antibodies in accordance with the invention possess high affinities, typically possessing Kd's of from about 10^{-6} through about 10^{-11} M, when measured by either solid phase and solution phase.

As will be appreciated, antibodies in accordance with the present invention can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used for transformation of a suitable mammalian host cell. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455. The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated

transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive PDGFD binding properties.

Antibodies in accordance with the present invention are capable of binding to PDGFD. Further, antibodies of the invention are useful in the detection of PDGFD in patient samples and accordingly are useful as diagnostics as described hereinbelow. In addition, based on the potent inhibition of growth of fibroblast cells observed through use of antibodies of the invention, it is expected that such antibodies will have therapeutic effect in the treatment of malignant tissue growth and/or disease, such as cancer and obstructive tissue growths as discussed hereinbelow.

EXAMPLES

The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting upon the present invention.

EXAMPLE 1

Antibodies to PDGFD were generated as described in International Patent Application No. WO 01/25433 using an active protein fragment of the gene product from clone 30664188.0.99 arises in the conditioned medium obtained when HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188 (see Examples 17 and 18). This vector harbors a fragment of the gene product of clone 30664188.0.99 that encompasses the entire amino acid sequence except for the predicted N-terminal signal peptide. The active fragment is termed the p35 form of the 30664188.0.99, or "p35" herein.

The active fragment p35 was employed as the immunogen to stimulate an immune response in XenoMouse® animals. Monoclonal antibodies directed against p35 were prepared by hybridoma technology from p35-immunized XenoMouse animals in standard fashion.

Several fully human monoclonal antibody clones were isolated from such immunizations and their ability to neutralize the growth promoting effects of the 30664188 p35 immunogen were analyzed using the BrdU incorporation assay on NIH 3T3 cells (described in International Patent Application No. WO 01/25433). The results for thirteen of the clones are presented in Table 1. An additional fully human monoclonal antibody, CURA2-1.17, was also identified that immunospecifically binds p35. In addition, ten other clones exhibited IC₅₀ values >1000 ng/mL. Importantly, all of the monoclonal antibodies identified in this work had no inhibitory activity when

added with PDGF BB to the comparable BrdU incorporation assay, up to 1000 ng/mL. Thus the neutralizing fully human monoclonal antibodies identified were specific for the p35 antigen.

In the BrdU assay, murine NIH 3T3 (ATCC No. CRL-1658, Manassas, VA) fibroblast cells were cultured in DMEM supplemented with 10% fetal bovine serum or 10% calf serum respectively.

5 Fibroblasts were grown to confluence at 37°C in 10% CO₂/air. Cells were then starved in DMEM for 24 hours. Enriched conditioned medium was added (10 microL/100 microL of culture) for 18 h. BrdU (10 microM) was then added and incubated with the cells for 5 h. BrdU incorporation was assayed by colorimetric immunoassay according to the manufacturer's specifications (Boehringer Mannheim, Indianapolis, IN).

10 Figures 44-47 show BrdU incorporation assay results from experiments in which the neutralization of various human anti-PDGFD monoclonal antibodies of the invention was assessed. Figure 44 is a bar graphic representation comparing the levels of BrdU incorporation in NIH 3T3 cells upon exposure to various human anti-PDGFD monoclonal antibodies of the invention. Figures 45-47 are bar graphic representations comparing the levels of BrdU incorporation in NIH 3T3 cells upon
15 exposure to various human anti-PDGFD monoclonal antibodies of the invention at varying doses as compared to a control run utilizing PDGFBB at varying concentrations.

TABLE 1

CURA2 MAb	IC ₅₀ (ng/mL)
1.6	75
1.9	100
1.18	>1000
1.19	75
1.22	100
1.29	150
1.35	1000
1.40	>1000
1.45	750
1.46	500
1.51	1000
1.59	500
6.4	75

20

EXAMPLE 2

An Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of PDGFD Antigen in a Sample was developed. In the assay, wells of a microtiter plate, such as a 96-well microtiter plate or a
25 384-well microtiter plate, were adsorbed for several hours with a first fully human monoclonal antibody CURA2-1.6 (see Example 1) directed against the antigen. The immobilized CURA2-1.6

serves as a capture antibody for any of the antigen that may be present in a test sample. The wells were rinsed and treated with a blocking agent such as milk protein or albumin to prevent nonspecific adsorption of the analyte.

Subsequently the wells were treated with a test sample suspected of containing the antigen, or with a solution containing a standard amount of the antigen. Such a sample may be, for example, a serum sample from a subject suspected of having levels of circulating antigen considered to be diagnostic of a pathology.

After rinsing away the test sample or standard, the wells were treated with a second fully human monoclonal antibody CURA2-1.17 (see Example 1) that has been labeled by conjugation with biotin. The labeled CURA2-1.17 serves as a detecting antibody. After rinsing away excess second antibody, the wells were treated with avidin-conjugated horseradish peroxidase (HRP) and a suitable chromogenic substrate. The concentration of the antigen in the test samples was determined by comparison with a standard curve developed from the standard samples. The results obtained for such a standard curve are shown in Table 2.

This ELISA assay provides a highly specific and very sensitive assay for the antigen in a test sample.

TABLE 2

Two site, or sandwich, ELISA for the detection of a p35 antigen in a test sample.

PDGFD (ng/ml)

20

conc.nanog/ml	OD 490
1000	2.354
300	2.145
100	1.017
30	0.375
10	0.172
3	0.1
1	0.072

EXAMPLE 3

In order to determine the concentration of the PDGFD antigen in the serum of cancer patients, serum from human subjects diagnosed as suffering from various types of cancer, or as harboring various kinds of tumor, were obtained. In particular, serum from five patients suffering from cancer of the tongue, five patients suffering from Hodgkin's lymphoma, five patients suffering from prostate cancer, three patients suffering from lung cancer, four patients suffering from renal cancer, five patients suffering from melanoma and five patients suffering from myeloma were examined. The concentration of the antigen in the serum of these patients was assessed using an ELISA procedure

30

described in Example 2. The results are shown in Table 3. The results show that samples from 5 of the 5 tongue cancer patients contain high levels of the antigen, samples from 2 of 5 Hodgkin disease patients contain detectable amounts of the antigen (one of these at a high level), samples from 2 of 3 lung cancer patients contain detectable levels of antigen, a sample from 1 of 5 patients with prostate cancer contains a high level of the antigen, and a sample from 1 of 4 renal cancer patients contains a detectable concentration of the antigen. In addition to the results in Table 3, it was found that 1 of 5 patients with scleroderma has a low concentration of the antigen.

The results in this Example indicate that an immunoassay directed against circulating the antigen is a useful diagnostic procedure in the detection of certain cancers. The use of the assay in staging such cancers and in assessing a response to therapeutic treatment is also suggested by these results.

TABLE 3

Sera number	Designation	Concentration PDGFD (ng/ml)
809001	Melanoma	< 3
809002	Melanoma	< 3
809003	Melanoma	< 3
809004	Melanoma	< 3
809005	Melanoma	< 3
809006	Renal Cancer	< 3
809007	Renal Cancer	< 3
809008	Renal Cancer	< 3
809010	Renal Cancer	5.8
809010	Lung Cancer	< 3
809011	Lung Cancer	20
809012	Lung Cancer	10.04
809013	Myeloma	< 3
809014	Myeloma	< 3
809015	Myeloma	< 3
809016	Myeloma	< 3
809017	Myeloma	< 3
809018	Tongue Cancer	116.6
809019	Tongue Cancer	114.9
809020	Tongue Cancer	70.9
809021	Tongue Cancer	86.3
809022	Tongue Cancer	101.3
809023	Hodgkins	< 3
809024	Hodgkins	< 3
809025	Hodgkins	6.9
809026	Hodgkins	< 3
809027	Hodgkins	82.8
809028	Prostate Cancer	81.8
809029	Prostate Cancer	< 3
809030	Prostate Cancer	< 3

Sera number	Designation	Concentration PDGFD (ng/ml)
809031	Prostate Cancer	< 3
809032	Prostate Cancer	< 3
BRH00861	Cardiovascular	
BRH00862	Cardiovascular	
BRH00863	Cardiovascular	
BRH00864	Cardiovascular	
BRH00865	Cardiovascular	
817001	Scleroderma	
817002	Scleroderma	15.4
817003	Scleroderma	
817004	Scleroderma	
817005	Scleroderma	

EXAMPLE 4

It will be appreciated that based on the results set forth and discussed in Examples 2 and 3, through use of the present invention, it is possible to stage a cancer in a subject based on expression levels of the PDGFD antigen. For a given type of cancer, samples of blood are taken from subjects diagnosed as being at various stages in the progression of the disease, and/or at various points in the therapeutic treatment of the cancer. The concentration of the PDGFD antigen present in the blood samples is determined using a method that specifically determines the amount of the antigen that is present. Such a method includes an ELISA method, such as the method described in Examples 2 and 3. Using a population of samples that provides statistically significant results for each stage of progression or therapy, a range of concentrations of the antigen that may be considered characteristic of each stage is designated.

In order to stage the progression of the cancer in a subject under study, or to characterize the response of the subject to a course of therapy, a sample of blood is taken from the subject and the concentration of the PDGFD antigen present in the sample is determined. The concentration so obtained is used to identify in which range of concentrations the value falls. The range so identified correlates with a stage of progression or a stage of therapy identified in the various populations of diagnosed subjects, thereby providing a stage in the subject under study.

EXAMPLE 5

A sandwich ELISA was developed to quantify PDGF D levels in human serum. The 2 fully human mabs (1.6 and 1.17) used in the sandwich ELISA, recognized different epitopes on the PDGF D molecule (data not shown). The ELISA was performed as follows: 50 μ l of capture antibody (mAb 1.6) in coating buffer (0.1 M NaHCO₃, pH 9.6) at a concentration of 2 μ g/ml was coated on ELISA plates (Fisher). After incubation at 4°C overnight, the plates were treated with 200 μ l of blocking buffer (0.5% BSA, 0.1% Tween 20, 0.01% Thimerosal in PBS) for 1 hr at 25°C. The plates were

washed (3x) using 0.05% Tween 20 in PBS (washing buffer, WB). Normal or patient sera (Clinomics, Bioreclamation) were diluted in blocking buffer containing 50% human serum. The plates were incubated with serum samples overnight at 4°C, washed with WB, and then incubated with 100 µl/well of biotinylated detection antibody mAb 1.17 for 1 hr at 25°C. After washing, the plates were incubated with HRP-Streptavidin for 15 min, washed as before, and then treated with 100 µl/well of o-phenylenediamine in H₂O₂ (Sigma developing solution) for color generation. The reaction was stopped with 50 µl/well of H₂SO₄ (2M) and analyzed using an ELISA plate reader at 492 nm. Concentration of PDGF D in serum samples was calculated by comparison to dilutions of purified PDGF D using a four parameter curve fitting program.

EXAMPLE 6

PDGF D immunohistochemistry was performed with biotinylated fully human mAb 6.4 and streptavidin-HRP was used for detection. Briefly, tissues were deparaffinized using conventional techniques, and treated with trypsin (0.15%) for 10 min at 37 °C. Sections were incubated with 10% normal goat serum for 10 minutes. Normal goat serum solution was drained and wiped to remove excess solution. Sections were incubated with the biotinylated anti-PDGF D mAb at 5 µg/ml for 30 min at 25 °C, and washed thoroughly with PBS. After incubation with streptavidin-HRP conjugate for 10 min, a solution of diaminobenzidine (DAB) was applied onto the sections to visualize the immunoreactivity. For the isotype control, sections were incubated with biotinylated isotype matched negative control mAb at 5 µg/ml for 30 minutes at 25 °C instead of biotinylated PDGF D mAb.

EXAMPLE 7

In the following discussion, structural information related to antibodies prepared in accordance with the invention is provided.

In order to analyze structures of antibodies produced in accordance with the invention, we cloned genes encoding the heavy and light chain fragments out of the particular hybridoma. Gene cloning and sequencing was accomplished as follows:

Poly(A)⁺ mRNA was isolated from approximately 2 X 10⁵ hybridoma cells derived from immunized XenoMouse mice using a Fast-Track kit (Invitrogen). The generation of random primed cDNA was followed by PCR. Human V_H or human V_K family specific variable region primers (Marks et. al., 1991) or a universal human V_H primer, MG-30 (CAGGTGCAGCTGGAGCAGTCIGG) (SEQ ID NO:51) was used in conjunction with primers specific for the human:

Cy2 constant region (MG-40d; 5'-GCT GAG GGA GTA GAG TCC TGA GGA-3' (SEQ ID NO:52));

Cy1 constant region (HG1; 5' CAC ACC GCG GTC ACA TGG C (SEQ ID NO:53)); or

Cy3 constant region (HG3; 5' CTA CTC TAG GGC ACC TGT CC (SEQ ID NO:54))

or the human C κ constant region (h κ P2; as previously described in Green et al., 1994). Sequences of human Mabs-derived heavy and kappa chain transcripts from hybridomas were obtained by direct sequencing of PCR products generated from poly(A⁺) RNA using the primers described above. PCR products were also cloned into pCRII using a TA cloning kit (Invitrogen) and both
5 strands were sequenced using Prism dye-terminator sequencing kits and an ABI 377 sequencing machine. All sequences were analyzed by alignments to the "V BASE sequence directory" (Tomlinson et al., MRC Centre for Protein Engineering, Cambridge, UK) using MacVector and Geneworks software programs.

Figure 3 is a series of representations of the heavy chain and light chain variable region
10 nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.6 of the invention, with Figure 3A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 3B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 3A, Figure 3C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 3D representing the amino acid
15 sequence encoded by the nucleotide sequence shown in Figure 3C.

Figure 4 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.11 of the invention, with Figure 4A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 4B representing the amino acid sequence
20 encoded by the nucleotide sequence shown in Figure 4A, Figure 4C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 4D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 4C.

Figure 5 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma
25 cell line designated Cur 2-1.17 of the invention, with Figure 5A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 5B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 5A, Figure 5C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 5D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 5C.

Figure 6 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.18 of the invention, with Figure 6A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 6B representing the amino acid sequence
30 encoded by the nucleotide sequence shown in Figure 6A, Figure 6C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 6D representing the amino acid
35 sequence encoded by the nucleotide sequence shown in Figure 6C.

Figure 7 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.19 of the invention, with Figure 7A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 7B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 7A, Figure 7C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 7D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 7C.

Figure 8 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.23 of the invention, with Figure 8A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 8B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 8A, Figure 8C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 8D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 8C.

Figure 9 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.24 of the invention, with Figure 9A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 9B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 9A, Figure 9C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 9D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 9C.

Figure 10 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.25 of the invention, with Figure 10A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 10B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 10A, Figure 10C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 10D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 10C.

Figure 11 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.29 of the invention, with Figure 11A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 11B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 11A, Figure 11C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 11D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 11C.

Figure 12 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.33 of the invention, with Figure 12A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 12B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 12A, Figure 12C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 12D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 12C.

Figure 13 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.38 of the invention, with Figure 13A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 13B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 13A, Figure 13C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 13D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 13C.

Figure 14 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.39 of the invention, with Figure 14A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 14B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 14A, Figure 14C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 14D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 14C.

Figure 15 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.40 of the invention, with Figure 15A representing the nucleotide sequence encoding the variable region of the heavy chain and Figure 15B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 15A.

Figure 16 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.45 of the invention, with Figure 16A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 16B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 16A, Figure 16C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 16D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 16C.

Figure 17 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.46 of the invention, with Figure 17A representing the nucleotide sequence

encoding the variable region of the heavy chain, Figure 17B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 17A, Figure 17C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 17D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 17C.

5 Figure 18 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.48 of the invention, with Figure 18A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 18B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 18A, Figure 18C representing the nucleotide
10 sequence encoding the variable region of the light chain, and Figure 18D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 18C.

 Figure 19 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.49 of the invention, with Figure 19A representing the nucleotide sequence
15 encoding the variable region of the heavy chain, Figure 19B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 19A, Figure 19C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 19D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 19C.

 Figure 20 is a series of representations of the heavy chain and light chain variable region
20 nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.51 of the invention, with Figure 20A representing the nucleotide sequence encoding the variable region of the heavy chain, Figure 20B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 20A, Figure 20C representing the nucleotide
25 sequence encoding the variable region of the light chain, and Figure 20D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 20C.

 Figure 21 is a series of representations of the heavy chain and light chain variable region nucleotide and amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-6.4 of the invention, with Figure 21A representing the nucleotide sequence
30 encoding the variable region of the heavy chain, Figure 21B representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 21A, Figure 21C representing the nucleotide sequence encoding the variable region of the light chain, and Figure 21D representing the amino acid sequence encoded by the nucleotide sequence shown in Figure 21C.

 Figure 22 is a table showing VDJ gene utilization of antibodies of the invention and indicating nucleotide/amino acid changes between the antibodies and the V, D, or J genes from which
35 they are derived in the antibodies FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 regions.

As will be observed in Figure 22A, the following antibodies have the following V heavy chain gene utilization:

VH 1-8: 1.19.1, 6.4.1, 1.18, 1.40.1, 1.45, 1.46.1, 1.49.1

VH 1-18: 1.33, 1.48.1

5

VH 3-21: 1.6.1

VH 3-33: 1.17.1, 1.24.1, 1.38.1

VH 3-53: 1.11.1

VH 5-51: 1.23.1, 1.25.1, 1.29, 1.39.1, 1.51.1

10 As will be observed in Figure 22B, the following antibodies have the following V light chain gene utilization:

VL L5: 1.48

VL A19: 1.49, 1.11, 1.29

VL A20: 1.45, 1.33, 1.38

VL A27: 6.4.1, 1.51

15

VL A30: 1.19, 1.18, 1.6, 1.23, 1.25, 1.29, 1.39, 1.17, 1.24, 1.46

For convenience, sequences of the protein sequences of the foregoing VH and VK genes are provided:

VH 1-8:

20 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTG
YAKQFQGRVTMTNRNTSISTAYMELSSLRSEDVAVYYCARG (SEQ ID NO:1)

VH 1-18:

25 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY
AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR (SEQ ID NO:2)

VH 3-21:

30 EVQLVESGGGLVKPGGSLRLSCLASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSYIYYADS
VKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAR (SEQ ID NO:3)

VH 3-33:

35 QVQLVESGGGVVQPGSLRLSCLASGFTFSSYGMHWVRQAPGKGLEWVAVIWDGSKNY
ADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO:4)

VH 3-53:

EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADS
VKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO:5)

5 VH 5-51:

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIYPGDSDTRYSP
SFQGGVTTISADKSISTAYLQWSSLKASDTAMYYCAR (SEQ ID NO:6)

VK L5:

10 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFS
GSGSGTDFTLTISLQPEDFATYYCQQANSFP (SEQ ID NO:7)

VK A19:

DIVMTQSPLSLPVTGPGEASISCRSSQSLHNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVP
15 DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTP (SEQ ID NO:8)

VK A20:

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASLQSGVPSRFS
GSGSGTDFTLTISLQPEDVATYYCQKYN SAP (SEQ ID NO:9)

20

VK A27:

EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIYGASSRATGIPDRFS
GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSP (SEQ ID NO:10)

25 VK A30:

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFS
GSGSGTEFTLTISLQPEDFATYYCLQHNSYP (SEQ ID NO:11)

30 Figure 23 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.6 of the invention and the V gene from which it is derived, with Figure 23A representing the alignment of the heavy chain amino acid sequence alignment and Figure 23B representing the alignment of the light chain amino acid sequence.

35 Figure 24 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.11 of the invention and the V gene from which it is derived, with Figure 24A representing the

alignment of the heavy chain amino acid sequence alignment and Figure 24B representing the alignment of the light chain amino acid sequence.

Figure 25 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
5 Cur 2-1.17 of the invention and the V gene from which it is derived, with Figure 25A representing the alignment of the heavy chain amino acid sequence alignment and Figure 25B representing the alignment of the light chain amino acid sequence.

Figure 26 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
10 Cur 2-1.18 of the invention and the V gene from which it is derived, with Figure 26A representing the alignment of the heavy chain amino acid sequence alignment and Figure 26B representing the alignment of the light chain amino acid sequence.

Figure 27 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
15 Cur 2-1.19 of the invention and the V gene from which it is derived, with Figure 27A representing the alignment of the heavy chain amino acid sequence alignment and Figure 27B representing the alignment of the light chain amino acid sequence.

Figure 28 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
20 Cur 2-1.23 of the invention and the V gene from which it is derived, with Figure 28A representing the alignment of the heavy chain amino acid sequence alignment and Figure 28B representing the alignment of the light chain amino acid sequence.

Figure 29 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
25 Cur 2-1.24 of the invention and the V gene from which it is derived, with Figure 29A representing the alignment of the heavy chain amino acid sequence alignment and Figure 29B representing the alignment of the light chain amino acid sequence.

Figure 30 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
30 Cur 2-1.25 of the invention and the V gene from which it is derived, with Figure 30A representing the alignment of the heavy chain amino acid sequence alignment and Figure 30B representing the alignment of the light chain amino acid sequence.

Figure 31 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
35 Cur 2-1.29 of the invention and the V gene from which it is derived, with Figure 31A representing the

alignment of the heavy chain amino acid sequence alignment and Figure 31B representing the alignment of the light chain amino acid sequence.

Figure 32 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
5 Cur 2-1.33 of the invention and the V gene from which it is derived, with Figure 32A representing the alignment of the heavy chain amino acid sequence alignment and Figure 32B representing the alignment of the light chain amino acid sequence.

Figure 33 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
10 Cur 2-1.38 of the invention and the V gene from which it is derived, with Figure 33A representing the alignment of the heavy chain amino acid sequence alignment and Figure 33B representing the alignment of the light chain amino acid sequence.

Figure 34 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
15 Cur 2-1.39 of the invention and the V gene from which it is derived, with Figure 34A representing the alignment of the heavy chain amino acid sequence alignment and Figure 34B representing the alignment of the light chain amino acid sequence.

Figure 35 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
20 Cur 2-1.45 of the invention and the V gene from which it is derived, with Figure 35A representing the alignment of the heavy chain amino acid sequence alignment and Figure 35B representing the alignment of the light chain amino acid sequence.

Figure 36 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
25 Cur 2-1.46 of the invention and the V gene from which it is derived, with Figure 36A representing the alignment of the heavy chain amino acid sequence alignment and Figure 36B representing the alignment of the light chain amino acid sequence.

Figure 37 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
30 Cur 2-1.48 of the invention and the V gene from which it is derived, with Figure 37A representing the alignment of the heavy chain amino acid sequence alignment and Figure 37B representing the alignment of the light chain amino acid sequence.

Figure 38 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated
35 Cur 2-1.49 of the invention and the V gene from which it is derived, with Figure 38A representing the

alignment of the heavy chain amino acid sequence alignment and Figure 38B representing the alignment of the light chain amino acid sequence.

Figure 39 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-1.51 of the invention and the V gene from which it is derived, with Figure 39A representing the alignment of the heavy chain amino acid sequence alignment and Figure 39B representing the alignment of the light chain amino acid sequence.

Figure 40 is a series of alignments of the heavy chain and light chain variable region amino acid sequences of the human anti-PDGFD antibody expressed by the hybridoma cell line designated Cur 2-6.4 of the invention and the V gene from which it is derived, with Figure 40A representing the alignment of the heavy chain amino acid sequence alignment and Figure 40B representing the alignment of the light chain amino acid sequence.

Figure 41 is a table showing VDJ gene utilization of the 1.19.1 and 6.4.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 42 is a table showing VDJ gene utilization of the 1.6.1, 1.11.1, and 1.23.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 43 is a table showing VDJ gene utilization of the 1.19.1, 6.4.1, 1.6.1, 1.11.1, 1.23.1, 1.17.1, 1.18, 1.24.1, 1.25.1, 1.29, 1.33, 1.38.1, 1.39.1, 1.40.1, 1.45, 1.46.1, 1.46.2, 1.48.1, 1.49.1, and 1.51.1 antibodies of the invention and indicating nucleotide changes between the antibodies and the VH, DH, and JH and VK and JK genes from which they are derived.

Figure 48 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention indicating locations of the CDRs of the antibodies.

Figure 49 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention indicating locations of the CDRs of the antibodies.

Figure 50 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 1-8 gene with CDRs indicated.

Figure 51 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 1-18 gene with CDRs indicated.

Figure 52 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 3-33 gene with CDRs indicated.

Figure 53 is a representation of a ClustalW sequence alignment between the heavy chain amino acid sequences of antibodies of the invention that possess heavy chains derived from the VH 5-51 gene with CDRs indicated.

5 Figure 54 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A19 gene with CDRs indicated.

Figure 55 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A20 gene with CDRs indicated.

10 Figure 56 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A27 gene with CDRs indicated.

Figure 57 is a representation of a ClustalW sequence alignment between the light chain amino acid sequences of antibodies of the invention that possess light chains derived from the VK A30 gene with CDRs indicated.

15 In each of Figures 48-57, CDR domains were determined in accordance with the Kabat numbering system. *See Kabat Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, Md. (1987 and 1991)).

EXAMPLE 8

20 In the following discussion, structural information related to relative epitopes that antibodies prepared in accordance with the invention bind to is provided.

Certain antibodies in accordance with the present invention were "binned" in accordance relative epitope to which they bind. In order to conduct such binning, we followed the protocol described in U.S. Patent Application No. 60/337,245, filed December 3, 2001, entitled Antibody
25 Categorization Based On Binding Characteristics. As shown in the following Tables, we detected antibodies that bound to at least three distinct epitopes on the PDGFD antigen. Results are shown for two different experiments utilizing the binning procedure described in the foregoing patent application as well as results derived from competition studies using BiaCore affinity cross-competition studies.

Epitope Type			
I	II	III	IV
1.6	1.9	1.45	1.33
1.19	1.22	1.46	
	1.29		
	6.4		
Epitope Type			
I	II	III	IV
1.6	1.9	1.19	1.33
	1.29	1.22	
	1.45	6.4	
	1.46		
Epitope Type (by BiaCore)			
I	II	IV	?
1.6	1.9	6.4	1.33
1.45	1.19		1.46
	1.22		
	1.29		

EQUIVALENTS

- 5 The foregoing description and Examples detail certain preferred embodiments of the invention and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof.

WHAT WE CLAIM IS:

1. A human monoclonal antibody that binds to PDGFD and comprises a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOS: 13, 15, 17, 19, 21, 23, 25,
5 27, 29, 31, 33, 35, 37, 38, 40, 42, 44, 46, and 48.
2. The antibody of Claim 1, further comprising a light chain amino acid sequence selected from the group consisting of SEQ ID NOS:14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 39, 41, 43, 45, 47, and 49.
3. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence
10 comprises the sequence of SED ID NO:13 and the light chain amino acid comprises the sequence of SEQ ID NO:14.
4. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:15 and the light chain amino acid comprises the sequence of SEQ ID NO:16.
- 15 5. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:17 and the light chain amino acid comprises the sequence of SEQ ID NO:18.
6. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:19 and the light chain amino acid comprises the sequence of
20 SEQ ID NO:20.
7. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:21 and the light chain amino acid comprises the sequence of SEQ ID NO:22.
8. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence
25 comprises the sequence of SED ID NO:23 and the light chain amino acid comprises the sequence of SEQ ID NO:24.
9. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:25 and the light chain amino acid comprises the sequence of SEQ ID NO:26.
- 30 10. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:27 and the light chain amino acid comprises the sequence of SEQ ID NO:28.
11. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:29 and the light chain amino acid comprises the sequence of
35 SEQ ID NO:30.

12. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:31 and the light chain amino acid comprises the sequence of SEQ ID NO:32.

13. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence
5 comprises the sequence of SED ID NO:33 and the light chain amino acid comprises the sequence of SEQ ID NO:34.

14. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:35 and the light chain amino acid comprises the sequence of SEQ ID NO:36.

10 15. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:37.

16. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:38 and the light chain amino acid comprises the sequence of SEQ ID NO:39.

15 17. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:40 and the light chain amino acid comprises the sequence of SEQ ID NO:41.

18. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:42 and the light chain amino acid comprises the sequence of
20 SEQ ID NO:43.

19. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:44 and the light chain amino acid comprises the sequence of SEQ ID NO:45.

20. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence
25 comprises the sequence of SED ID NO:46 and the light chain amino acid comprises the sequence of SEQ ID NO:47.

21. The human monoclonal antibody of claim 2, wherein the heavy chain amino sequence comprises the sequence of SED ID NO:48 and the light chain amino acid comprises the sequence of
30 SEQ ID NO:49.

1 / 88

CTAAAAAATATGTTCTCTACAACACCAAGGCTCATTAAAAATATTTTAAATATTAATATACAT
TTCTTCTGTCAGAAATACATAAACTTTATTATATCAGCGCAGGGCGGCGCGGCTCGGTCC
CGGGAGCAGAACCCGGCTTTTCTTGGAGCGACGCTGTCTCTAGTCGCTGATCCCAAATGCA
CCGGCTCATCTTTGTCTACACTCTAATCTGCGCAAACCTTTGTCAGCTGTCGGGACACTTCTG
CAACCCCGCAGAGCGCATCCATCAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGAGAGC
AATCACCTCACAGACTTGTACCGAAGAGATGAGACCATCCAGGTGAAAGGAAACGGCTACGT
GCAGAGTCCTAGATTCCCGAACAGCTACCCAGGAACCTGCTCCTGACATGGCGGCTTCACT
CTCAGGAGAATACACGGATACAGCTAGTGTGACAATCAGTTTGGATTAGAGGAAGCAGAA
AATGATATCTGTAGGTATGATTTTGTGGAAGTTGAAGATATATCCGAAACCAGTACCATTAT
TAGAGGACGATGGTGTGGACACAAGGAAGTTCCTCCAAGGATAAAATCAAGAACGAACCAA
TTAAATACATTCAAGTCCGATGACTACTTTGTGGCTAAACCTGGATTCAAGATTATTAT
TCTTTGCTGGAAGATTTCCAACCCGCAGCAGCTTCAGAGACCAACTGGGAATCTGTCACAAG
CTCTATTTTCAGGGGTATCCTATAACTCTCCATCAGTAACGGATCCCACTCTGATTGCGGATG
CTCTGGACAAAAAATTCAGAAATTTGATACAGTGAAGATCTGCTCAAGTACTTCAATCCA
GAGTCATGGCAAGAAGATCTTGAGAATATGTATCTGGACACCCCTCGGTATCGAGGCAGGTC
ATACCATGACCGGAAGTCAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTACA
GTTGCACTCCAGGAATTACTCGGTCAATATAAGAGAAGAGCTGAAGTTGGCCAATGTGGTC
TTCTTTCCACGTTGCCCTCCTCGTGCAGCGCTGTGGAGGAAATTGTGGCTGTGGAACGTCAA
CTGGAGGTCTGTCACATGCAATTCAGGGAAAACCGTGAAAAAGTATCATGAGGTATTACAGT
TTGAGCCTGGCCACATCAAGAGGAGGGGTAGAGCTAAGACCATGGCTCTAGTTGACATCCAG
TTGGATCACCATGAACGATGTGATTGTATCTGCAGCTCAAGACCACCTCGATAAGAGAATGT
GCACATCCTTACATTAAGCCTGAAAGAACCTTTAGTTTAAGGAGGGTGAGATAAGAGACCT
TTTCCTACCAGCAACCAAACCTTACTACTAGCCTGCAATGCAATGAACACAAGTGGTTGCTGA
GTCTCAGCCTTGCTTTTGTAAATGCCATGGCAAGTAGAAAGGTATATCATCAACTTCTATACC
TAAGAATATAGGATTGCATTTAATAATAGTGTGAGGTTATATATGCACAAACACACACAG
AAATATATTATGTCTATGTGTATATAGATCAAATGTTTTTTTTTGGTATATATAACCAGGTA
CACCAGAGCTTACATATGTTTGAGTTAGACTCTTAAATCCTTTGCCAAAATAAGGGATGGT
CAAATATATGAAACATGTCTTTAGAAAATTTAGGAGATAAATTTATTTTAAATTTTGAAAC
ACAAAACAATTTTGAATCTTGCTCTCTTAAAGAAAGCATCTTGTATATTTAAATCAAAGA
TGAGGCTTTCTTACATATACATCTTAGTTG (SEQ ID NO:50)

FIG. 1

2 / 88

1 CTAAAAAATATGTTCTCTACAACACCAAGGCTCATTAAAAATATT
46 TAAATATTAATATACATTCTTCTGTCTCAGAAATACATAAACTTT
91 ATTATATCAGCGCAGGGCGGCGGCGTCCCGGGAGCAGAA
136 CCCGGCTTTTTCTTGGAGCGACGCTGTCTCTAGTCGCTGATCCCA

181 AATGCACCGGCTCATCTTTGTCTACACTCTAATCTGCGCAAACCTT
MetHisArgLeuIlePheValTyrThrLeuIleCysAlaAsnPhe

226 TTGCAGCTGTCTGGGACACTTCTGCAACCCCGCAGAGCGCATCCAT
CysSerCysArgAspThrSerAlaThrProGlnSerAlaSerIle

271 CAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGAGAGCAATCA
LysAlaLeuArgAsnAlaAsnLeuArgArgAspGluSerAsnHis

316 CCTCACAGACTTGTACCGAAGAGATGAGACCATCCAGGTGAAAGG
LeuThrAspLeuTyrArgArgAspGluThrIleGlnValLysGly

361 AAACGGCTACGTGCAGAGTCCTAGATTCCCGAACAGCTACCCCG
AsnGlyTyrValGlnSerProArgPheProAsnSerTyrProArg

406 GAACCTGCTCCTGACATGGCGGCTTCACTCTCAGGAGAATACAG
AsnLeuLeuLeuThrTrpArgLeuHisSerGlnGluAsnThrArg

451 GATACAGCTAGTGTGTTGACAATCAGTTTGGATTAGAGGAAGCAGA
IleGlnLeuValPheAspAsnGlnPheGlyLeuGluGluAlaGlu

496 AAATGATATCTGTAGGTATGATTTTGTGGAAGTTGAAGATATATC
AsnAspIleCysArgTyrAspPheValGluValGluAspIleSer

541 CGAAACCAGTACCATTATTAGAGGACGATGGTGTGGACACAAGGA
GluThrSerThrIleIleArgGlyArgTrpCysGlyHisLysGlu

586 AGTTCCTCCAAGGATAAAATCAAGAACGAACCAAATTTAAATCAC
ValProProArgIleLysSerArgThrAsnGlnIleLysIleThr

FIG. 2A

3 / 88

631 ATTCAAGTCCGATGACTACTTTGTGGCTAAACCTGGATTCAAGAT
PheLysSerAspAspTyrPheValAlaLysProGlyPheLysIle

676 TTATTATTCTTTGCTGGAAGATTTCCAACCCGAGCAGCTTCAGA
TyrTyrSerLeuLeuGluAspPheGlnProAlaAlaAlaSerGlu

721 GACCAACTGGGAATCTGTCACAAGCTCTATTTTCAGGGGTATCCTA
ThrAsnTrpGluSerValThrSerSerIleSerGlyValSerTyr

766 TAACTCTCCATCAGTAACGGATCCCACTCTGATTGCGGATGCTCT
AsnSerProSerValThrAspProThrLeuIleAlaAspAlaLeu

811 GGACAAAAAATTGCAGAATTTGATACAGTGGAAGATCTGCTCAA
AspLysLysIleAlaGluPheAspThrValGluAspLeuLeuLys

856 GTACTTCAATCCAGAGTCATGGCAAGAAGATCTTGAGAATATGTA
TyrPheAsnProGluSerTrpGlnGluAspLeuGluAsnMetTyr

901 TCTGGACACCCCTCGGTATCGAGGCAGGTCATACCATGACCGGAA
LeuAspThrProArgTyrArgGlyArgSerTyrHisAspArgLys

946 GTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTA
SerLysValAspLeuAspArgLeuAsnAspAspAlaLysArgTyr

991 CAGTTGCACTCCCAGGAATTACTCGGTCAATATAAGAGAAGAGCT
SerCysThrProArgAsnTyrSerValAsnIleArgGluGluLeu

1036 GAAGTTGGCCAATGTGGTCTTCTTTCCACGTTGCCTCCTCGTGCA
LysLeuAlaAsnValValPhePheProArgCysLeuLeuValGln

1081 GCGCTGTGGAGGAAATTGTGGCTGTGGAAGTGTCAACTGGAGGTC
ArgCysGlyGlyAsnCysGlyCysGlyThrValAsnTrpArgSer

1126 CTGCACATGCAATTCAGGGAAAACCGTGAAAAAGTATCATGAGGT
CysThrCysAsnSerGlyLysThrValLysLysTyrHisGluVal

1171 ATTACAGTTTGAGCCTGGCCACATCAAGAGGAGGGGTAGAGCTAA
LeuGlnPheGluProGlyHisIleLysArgArgGlyArgAlaLys

FIG. 2B

4 / 88

1216 GACCATGGCTCTAGTTGACATCCAGTTGGATCACCATGAACGATG
ThrMetAlaLeuValAspIleGlnLeuAspHisHisGluArgCys

1261 TGATTGTATCTGCAGCTCAAGACCACCTCGATAAGAGAATGTGCA
AspCysIleCysSerSerArgProProArg (SEQ ID NO:12)

1306 CATCCTTACATTAAGCCTGAAAGAACCTTTAGTTTAAGGAGGGTG
1351 AGATAAGAGACCCTTTTCCTACCAGCAACCAAACCTTACTACTAGC
1396 CTGCAATGCAATGAACACAAGTGGTTGCTGAGTCTCAGCCTTGCT
1441 TTGTTAATGCCATGGCAAGTAGAAAGGTATATCATCAACTTCTAT
1486 ACCTAAGAATATAGGATTGCATTTAATAATAGTGTTTGAGGTTAT
1531 ATATGCACAAACACACACAGAAATATATTCATGTCTATGTGTATA
1576 TAGATCAAATGTTTTTTTTTGGTATATATAACCAGGTACACCAGAG
1621 CTTACATATGTTTGAGTTAGACTCTTAAATCCTTTGCCAAATA
1666 AGGGATGGTCAAATATATGAAACATGTCTTTAGAAAATTTAGGAG
1711 ATAAATTTATTTTTTAAATTTTGAAACACAAAACAATTTTGAATCT
1756 TGCTCTCTTAAAGAAAGCATCTTGTATATTAAAAATCAAAGATG
1801 AGGCTTTCTTACATATACATCTTAGTTG (SEQ ID NO:50)

FIG. 2C

5 / 88

A -- Cur2 1.6 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTC
CTGTGCAGCCTCTGGATTCAACTTCAGAACCTATAACATGAACTGGGTCCGCCAGGCTCCAG
GGAAGGGGCTGGAGTGGGTCTCATCCATTAGTAGTAGTAGTAACATATACTACGCAGAC
TCAGTGAAGGGCCGATTACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAAT
GAACAGCCTGAGAGCCGAGGACACGGCTGTATATTACTGTGCGAGAGATATTATGATTACGT
TTGGGGGAATTATCGCCTCGTTCTACTTTGACTACTGGGGCCAGGGAACCCCTGGTCACCGTC
TCCTCAG (SEQ ID NO:55)

B -- Cur2 1.6 heavy chain amino acid sequence

EVQLVESGGGLVKPGGSLRLSCAASGFNFRTYNMNWVRQAPGKGLEWVSSISSSSSNIYYAD
SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDIMITFGGIIASFYFDYWGQGTLVTV
SS (SEQ ID NO:13)

C -- Cur2 1.6 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTTTCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTCACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGG
TGGAGATCAAAC (SEQ ID NO:56)

D -- Cur2 1.6 light chain amino acid sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWFQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLOHNSYPLTFGGGTKVEIK (SEQ ID NO:14)

FIG. 3

6 / 88

A -- Cur2 1.11 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTC
CTGTGCAGCCTCTGGGTTTACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCTCCAG
GGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCAGACTCC
GTGAAGGGCCGATTACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAA
CAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGGGAACGGTGACTACGAATTACT
ACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG
(SEQ ID NO:57)

B -- Cur2 1.11 heavy chain amino acid sequence

EVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADS
VKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAGTVTTNYYYGMDVWGQGTTVTVSS
(SEQ ID NO:15)

C -- Cur2 1.11 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGAGAGCCGGCCTCCAT
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCAAAGTAATGGATACAACTATTTGGATTGGTACC
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG
GTCCCTGACAGGTTCAAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT
GGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACTCTCACTTTCGGCG
GAGGGACCAAGGTGGAGATCAAAC (SEQ ID NO:58)

D -- Cur2 1.11 light chain amino acid sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLLOSNGYNYLDWYLQKPGQSPQLLIYLGSNRASG
VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLTFGGGTKVEIK
(SEQ ID NO:16)

FIG. 4

7 / 88

A -- Cur2 1.17 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCCTGAGACTCTC
CTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAG
GCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGAC
TCCGTGAAGGGCCGATTACCATCTCCAGAGACAATCCAAGAACACGCTGTATCTGCAAAT
GAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATCAAGGATACAGAT
ATGCTGGTTACTACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:59)

B -- Cur2 1.17 heavy chain protein sequence

QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWDGSKNYAD
SVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDQGYRYAGYYYDYGM DVWGQGT TTVTV
SS (SEQ ID NO:17)

C -- Cur2 1.17 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGG
TGGAGATCAAAC (SEQ ID NO:60)

D -- Cur2 1.17 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK (SEQ ID NO:18)

FIG. 5

8 / 88

A -- Cur2 1.18 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCAAACAGTGGTAACACAGGCTATGCACAG
AAGTTCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGAGGGTATAGCAGTGG
CTGGGACATACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:61)

B -- Cur2 1.18 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQ
KFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCAREGIAVAGTYYYYYYGMDEVWGQGTITVTV
SS (SEQ ID NO:19)

C -- Cur2 1.18 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTTCTGTCTACAGCATAATAGTTACCCATTCACTTTCGGCCCTGGGACCAAAG
TGGATATCAAAC (SEQ ID NO:62)

D -- Cur2 1.18 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYFCLQHNSYPFTFGPGTKVDIK (SEQ ID NO:20)

FIG. 6

9/88

A -- Cur2 1.19 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCACTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACAGGCTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGACGTTATGATTACGT
TTGGGGGAGTTATCGTGCCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:63)

B -- Cur2 1.19 heavy chain amino acid sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQ
KFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARDVMITFGGVIVHYGMDVWGQGTITVTV
SS (SEQ ID NO:21)

C -- Cur2 1.19 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTC
AGCGGCAGTGGATCTGGGACAGATTTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTGACCCGTGCAGTTTTGGCCAGGGGACCAAGC
TGGAGATCAGAC (SEQ ID NO:64)

D -- Cur2 1.19 light chain amino acid sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTDFTLTISSLQPEDFATYYCLQHNSDPCSFQGTKLEIR (SEQ ID NO:22)

FIG. 7

10 / 88

A -- Cur2 1.23 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTC
CTGTGAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCCG
TCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTG
GAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGTATCGTATTACT
ATGTTTCGGGGAGTTATTATAACGTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC
TCCTCAG (SEQ ID NO:65)

B -- Cur2 1.23 heavy chain amino acid sequence

EVQLVQSGAEVKKPGESLKISCEGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSP
SFQGQVTISADKSISTAYLQWSSLKASDTAMYICARHVSYYYVSGSYYNVFDYWGQGT LVTV
SS (SEQ ID NO:23)

C -- Cur2 1.23 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGATACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAACGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCATCTCACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGG
TGGAATCAAAC (SEQ ID NO:66)

D -- Cur2 1.23 light chain amino acid sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQIPGKAPKRLIYAASSLQRGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ ID NO:24)

FIG. 8

11 / 88

A -- Cur2 1.24.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC
CTGTGCAGCGTCTGGATTTCAGTTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAG
GCAAGGGGCTGGAGTGGGTGGCAGATATATGGTATGATGGAAGTAATAAATACTATGCAGAC
TCCGTGAAGGGCCGATTACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT
GAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTATTGTGCGAGAGATCAGGGATACAGCT
ATGGTTACGTCTACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:67)

B -- Cur2 1.24.1 heavy chain protein sequence

QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKLEWVADIWYDGSNKYYAD
SVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDQGYSGYVYYDYGMDVWGQGT'VTV
SS (SEQ ID NO:25)

C -- Cur2 1.24.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTC
AGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGTGGACGTTCCGCCAAGGGACCAAGG
TGGAAATCAAAC (SEQ ID NO:68)

D -- Cur2 1.24.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGI RNDLGWYQQKPKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTITSSLPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ ID NO:26)

FIG. 9

12 / 88

A -- Cur2 1.25.1 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTC
CTGTAAGGGTTCTGGATACAGGTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCCG
TCCTTCCAAGGCCAGGTCAACATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTG
GAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGGATCGTATTATT
ATGGTTCGGAGACTTATTATAATGTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC
TCCTCAG (SEQ ID NO:69)

B -- Cur2 1.25.1 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSP
SFQGQVTISADKSISTAYLQWSSLKASDTAMYICARHGSYYYGSETYYNVFDYWGQGLVTV
SS (SEQ ID NO:27)

C -- Cur2 1.25.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGG
TGGAATCAAAC (SEQ ID NO:70)

D -- Cur2 1.25.1 light chain protein sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ ID NO:28)

FIG. 10

13 / 88

A -- Cur2 1.29 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTC
CTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCG
TCCTTCCAAGGCCAGGCCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTG
GAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACACGTGGATGTAGGGG
CTACGATTGGGGGATATTACTATTACTACCACGGTATGGACGTCTGGGGCCAAGGGACCACG
GTCACCGTCTCCTCAG (SEQ ID NO:71)

B -- Cur2 1.29 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSP
SFQGQATISADKSISTAYLQWSSLKASDTAMYCARHVDVGATIGGYYYYYHGM DVWGQGT
VTVSS (SEQ ID NO:29)

C -- Cur2 1.29 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTCACCCCTGGAGAGCCGGCCTCCAT
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAAC TATTTGGATTGGTACC
TGCAGAAGCCAGGGCAGTCTCCACAAC TCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG
GTCCCTGACAGGTT CAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT
GGAGGCTGACGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAATCTCTCATGTGCAGTT
TTGGCCAGGGGACCAAGCTGGAGATCAAAC (SEQ ID NO:72)

D -- Cur2 1.29 light chain protein sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLLSNGYNYLDWYLQKPGQSPQLLIYLG SNRASG
VPDRFSGSGSGTDFTLKISRVEADVG VYYCMQALQSLMCSFGQGTKLEIK
(SEQ ID NO:30)

FIG. 11

14 / 88

A -- Cur2 1.33 heavy chain nucleotide sequence

CAGGTTTCAGCTGGTGCAGTCGGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCCCTG
GACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAACTATGCACAG
AAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCT
GAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGATCATTACTATGATA
GTAGTGATTATCTCTACTACTACTACGGTTTGGACGTCTGGGGCCAAGGGACCACGGTCACC
GTCTCCTCAG (SEQ ID NO:73)

B -- Cur2 1.33 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQ
KLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDHYDSSDYLYYYYGLDVWGQGTTVT
VSS (SEQ ID NO:31)

C -- Cur2 1.33 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCAGGGA
AAGTTCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAATCAGGGGTCCCATCTCGGTTT
AGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGT
TGCAACTTATTACTGTCAAAGTATAACAGTGCCCCGCTCAC'TTTCGGCGGAGGGACCAAGG
TGGAGATCAAAC (SEQ ID NO:74)

D -- Cur2 1.33 light chain protein sequence

DIQMTQSPSSLSASVGDRTITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLQSGVPSRF
SGSGSGTDFTLTISLQPEDVATYYCQKYNAPLTFGGGTKVEIK (SEQ ID NO:32)

FIG. 12

15 / 88

A -- Cur2 1.38.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC
CTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAG
GCAAGGGGCTGGAGTGGGTGGCAATTATATGGTATGATGGAAATGATAAATACTATGCAGAC
TCCGTGAAGGGCCGCTTCACCGTCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT
GAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGATATTACTATGATA
GTAGTGATTATCTCTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACC
GTCTCCTCAG (SEQ ID NO:75)

B -- Cur2 1.38.1 heavy chain protein sequence

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGNCKYYAD
SVKGRFTVSRDNSKNTLYLQMNSLRAEDTAVYYCARGYYYDSSDYLYYYYGMDVWGQGTTVT
VSS (SEQ ID NO:33)

C -- Cur2 1.38.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCAGGGA
AAGTTCCTAACCTCCTGATCTATGCTGCATCCACTTTGCAATCAGGGGTCCCATCTCGGTTC
AGTGGCAGTGGATCTGGGACAGATTTCTCTCTCACCATCAGCAGCCTGCAGCCTGAAGATGT
TGCAGCTTATTACTGTCAAAGTGTAACAGTGCCCCGTGGACGTTCCGGCCAAGGGACCACGG
TGGAGATCAAAC (SEQ ID NO:76)

D -- Cur2 1.38.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPNLLIYAASLTQSGVPSRF
SGSGSGTDFSLTISSLPEDVAAYYCQKCNSAPWTFGQGTTFVEIK (SEQ ID NO:34)

FIG. 13

16/88

A -- Cur2 1.39.1 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAACAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTC
CTGTAAGGGTTCTGGATACAGGTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCCG
TCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTG
GAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGGATCGTATTACT
ATAATTTCGGGGAGTTATTATAACGTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC
TCCTCAG (SEQ ID NO:77)

B -- Cur2 1.39.1 heavy chain protein sequence

EVQLVQSGTEVKKPGESLKISCKGSGYRFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSP
SFQGQVTISADKSISTAYLQWSSLKASDTAMYICARHGSYYNNSGSYYNVFDYWGQGLVTV
SS (SEQ ID NO:35)

C -- Cur2 1.39.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGG
TGGAATCAAAC (SEQ ID NO:78)

D -- Cur2 1.39.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ ID NO:36)

FIG. 14

17/88

A -- Cur2 1.40.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCACTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACAGGCTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCCTAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATATTGTAGTGGTGG
TAGCTGCTACCAACTACTACAACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:79)

B -- Cur2 1.40.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYDINWVRQATGQGLEWMGWMNPNSGNTGYAQ
KFQGRVTMTRNTSLSTAYMELSSLRSEDVAVYYCARDIVVVVAATNYYNGMDVWGQGTTVTV
SS (SEQ ID NO:37)

FIG. 15

18 / 88

A -- Cur2 1.45 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCCTAACAGTGGTAACACAGGCTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGCAGTGGATACAGCT
ATGGTTACGACTACTACTACGGTATGGACGTCTGGGGCCAAGGACCACGGTCACCGTCTCC
TCAG (SEQ ID NO:80)

B -- Cur2 1.45 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQ
KFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARGSGYSYGIDYDYYGMDVWGQGTITVTVS
S (SEQ ID NO:38)

C -- Cur2 1.45 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CAATTGCCGGGCGAGTCAGGGCATTAGCAATGATTTAGCCTGGTATCAGCAGAAACCAGGGA
AAGTTCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAATTAGGGGTCCCATCTCGGTTT
AGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGT
TGCAACTTATTACTGTCAAAAGTATAACAGTGCCCCATTCACTTTCGGCCCTGGGACCAAAG
TGGATATCAAAC (SEQ ID NO:81)

D -- Cur2 1.45 light chain protein sequence

DIQMTQSPSSLSASVGDRTINCRASQGISNDLAWYQQKPGKVPKLLIYAASLTQLGVPSRF
SGSGSGTDFTLTISSLQPEDVATYYCQKYNAPFTFGPGTKVDIK (SEQ ID NO:39)

FIG. 16

19/88

A -- Cur2 1.46.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACTCCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAAATGGTAACACAGGCTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATATTGTAGTGGTGG
TAACTGCTACGGACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTC
TCCTCAG (SEQ ID NO:82)

B -- Cur2 1.46.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYSFTSYDINWVRQATGQGLEWMGWMNPNNNGNTGYAQ
KFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARDIVVVVTATDYYYGMDVWGQGTITVTV
SS (SEQ ID NO:40)

C -- Cur2 1.46.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCGCCTGATTTTTGCTGCATCCAGTTTGCCAAGTGGGGTCCCATCAAGGTTC
AGCGGCAGTGGATCTGGGACAGAATTCACCTCTACAATCAGCAGCCTGCAGCCTGAAGATTT
TGCAACTTATTACTGTCTACAGCATAGTGGTTACCCTCCGACGTTCCGCCAAGGGACCAAGG
TGGAAATCAAAC (SEQ ID NO:83)

D -- Cur2 1.46.1 light chain protein sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQKPGKAPKRLIFAASSLPSGVPSRF
SGSGSGTEFTLTISSLQPEDFATYYCLQHSGYPPFTFGQGTKVEIK (SEQ ID NO:41)

FIG. 17

20/88

A -- Cur2 1.48.1 heavy chain nucleotide sequence

CAGGTTTCAGCTGGTGCAGTCGGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCCCTG
GACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAACTATGCACAG
AAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTACATGGAGCT
GAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGATGTTGAATATTACT
ATGATGGTAGTGGTTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC
TCAG (SEQ ID NO:84)

B -- Cur2 1.48.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQ
KLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDVEYYYDGSYYYYFDYWGQGTLLVTVS
S (SEQ ID NO:42)

C -- Cur2 1.48.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCAT
CACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGA
AAGCCCCTAAGCTCCTGATCTATGCTGCATCCATTTTGCAAAGTGGGGTCCCATCAAGGTTT
AGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAGGATTT
TGCATCTTACTATTGTCAACAGTCTAACAGTTTCCCTCGGACGTTCCGGCCAAGGGACCAAGG
TGGAGATCAAAC (SEQ ID NO:85)

D -- Cur2 1.48.1 light chain protein sequence

DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASILQSGVPSRF
SGSGSGTDFTLTISLQPEDFASYQCQQSNSFPRTFGQGTKVEIK (SEQ ID NO:43)

FIG. 18

21 / 88

A -- Cur2 1.49.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTGACACAGGCTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTTCTGTGCGAGAATGAGGGATATAGTGG
CTACGAGCTATTACTACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACC
GTCTCCTCAG (SEQ ID NO:86)

B -- Cur2 1.49.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGDTGYAQ
KFQGRVTMTRNTSISTAYMELSSLRSEDVAVYFCARMRDIVATSYYYFYGMVDVWGQGTITV
VSS (SEQ ID NO:44)

C -- Cur2 1.49.1 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCCGTACCCCTGGAGAGCCGGCCTCCAT
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC
TGCTGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAGTCGGGCCTCCGGG
GTCCCTGACAGGTTTCACTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT
GGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAACCTACAAACTATCACCTTCGGCC
AAGGGACACGACTGGAGATTAAAC (SEQ ID NO:87)

D -- Cur2 1.49.1 light chain protein sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLHNSGYNLYLDWYLLKPGQSPQLLIYLGSSRASG
VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQTITFGQGRLEIK
(SEQ ID NO:45)

FIG. 19

22 / 88

A -- Cur2 1.51 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCTGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATCTC
CTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATGCCCCG
GGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATGCCAAATACAGCCCG
TCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTG
GAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACACTATGATTACGTTT
GGAGGAATTATCGGTATACAGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTC
TCCTCAG (SEQ ID NO:88)

B -- Cur2 1.51.1 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDAKYSP
SFQGVVTISADKSISTAYLQWSSLKASDTAMYICARHYDYVWRNYRYTGWFDPWGQGLVTV
SS (SEQ ID NO:46)

C -- Cur2 1.51.1 light chain nucleotide sequence

GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTG
GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGGCCACTGGCATCCCAGACAGG
TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGA
TTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTATTCACCTTCGGCCCTGGGACCA
AAGTGGATATCAAAC (SEQ ID NO:89)

D -- Cur2 1.51.1 light chain protein sequence

EIVLTQSPGTLSSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASNRATGIPDR
FSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSLFTFGPGTKVDIK (SEQ ID NO:47)

FIG. 20

23 / 88

A -- Cur2 6.4 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTC
CTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTG
GACAAGGGCTTGAGTGGATGGGATGGATAAACCTAATAGTGGTAACACAGACTATGCACAG
AAGTTCCAGGGCAGAGTCACCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAGCT
GAGCAGCCTGAGATCTGAGGACACGGCCATATATTATTGTGTGAGAGGCTTTGGATACAGCT
ATAATTACGACTACTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCC
TCAGT (SEQ ID NO:90)

B -- Cur2 6.4 heavy chain amino acid sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDYAQ
KFQGRVTMTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNYDYYYGMDVWGQGTTVTVS
S (SEQ ID NO:48)

C -- Cur2 6.4 light chain nucleotide sequence

GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT
CTCCTGCAGGGCCAGTCAGAGTGTTAGTAGTAGTTACTTAGCCTGGTACCAGCAGAAGCCTG
GCCAGGCTCCCAGGCTCCTCATCTATGCTACATCCAGCAGGGCCACTGGCATCCCAGACAGG
TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGA
TTTTGCAGTGTATTACTGTCAGCAGTATGGTAGTTCACCGTGCAGTTTTGGCCAGGGGACCA
AGCTGGAAATCAAGC (SEQ ID NO:91)

D -- Cur2 6.4 light chain amino acid sequence

EIVLTQSPGTLSSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIPDR
FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCSFQGQGTKLEIK (SEQ ID NO:49)

FIG. 21

24 / 88

Clone	Germline genes used				No. of Nucleotide/ Amino acid changes						
					FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
CR2		V	D	J	V					D & J	
1.19.1	VH	V1-8	D3-16	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK2	0/0	0/0	0/0	0/0	1/1	1/1	0/0
6.4.1	VH	V1-8	D5-18	JH6B	0/0	0/0	0/0	3/2	5/3	0/0	0/0
	VK	A27		JK2	0/0	3/0	1/0	2/2	0/0	1/0	0/0
1.18	VH	V1-8	D6-19	JH6B	1/0	0/0	0/0	1/0	0/0	0/0	0/0
	VK	A30		JK3	0/0	0/0	0/0	0/0	1/1	0/0	0/0
1.40.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	mix									
1.45	VH	V1-8	DK4	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK3	1/1	1/1	0/0	1/1	0/0	0/0	0/0
1.46.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	A30		JK1	0/0	0/0	2/1	1/1	0/0	2/2	0/0
1.49.1	VH	V1-8	D5-12	JH6B	1/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A19		JK5	0/0	0/0	1/1	1/1	0/0	1/1	0/0
1.33	VH	V1-18	D21-9	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.48.1	VH	V1-18	D21-9	JH4B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	L5		JK1	0/0	0/0	0/0	1/1	2/1	1/1	0/0
1.6.1	VH	V3-21	D3-16	JH4B	0/0	4/4	0/0	1/1	1/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	1/1	0/0	0/0	0/0	0/0
1.17.1	VH	V3-33	D5-18	JH6B	2/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.24.1	VH	V3-33	D5-18	JH6B	0/0	2/1	0/0	1/1	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	1/0	0/0	0/0
1.38.1	VH	V3-33	D21-9	JH6B	1/0	0/0	0/0	3/3	2/1	0/0	0/0
	VK	A20		JK1	0/0	0/0	1/1	0/0	2/2	1/1	0/0
1.11.1	VH	V3-53	D4-17	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A19		JK4	0/0	1/1	0/0	0/0	0/0	0/0	0/0
1.23.1	VH	V5-51	D3-10	JH4B	1/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	1/1	1/1	0/0	0/0	0/0
1.25.1	VH	V5-51	D3-10	JH4B	1/0	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.29	VH	V5-51	D5-12	JH6B	1/0	0/0	0/0	0/0	1/1	0/0	0/0
	VK	A19		JK2	0/0	0/0	1/0	0/0	1/1	0/0	0/0
1.39.1	VH	V5-51	D3-10	JH4B	2/1	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.51.1	VH	5-51	D3-16	JH5B	2/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A27		JK3	0/0	0/0	0/0	1/1	0/0	0/0	0/0

FIG. 22A

25 / 88

Clone	Germline genes used				No. of Nucleotide/ Amino acid changes						
					FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
CR2		V	D	J	V					D & J	
1.40.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	mix									
1.48.1	VH	V1-18	D21-9	JH4B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	L5		JK1	0/0	0/0	0/0	1/1	2/1	1/1	0/0
1.49.1	VH	V1-8	D5-12	JH6B	1/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A19		JK5	0/0	0/0	1/1	1/1	0/0	1/1	0/0
1.11.1	VH	V3-53	D4-17	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A19		JK4	0/0	1/1	0/0	0/0	0/0	0/0	0/0
1.29	VH	V5-51	D5-12	JH6B	1/0	0/0	0/0	0/0	1/1	0/0	0/0
	VK	A19		JK2	0/0	0/0	1/0	0/0	1/1	0/0	0/0
1.45	VH	V1-8	DK4	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK3	1/1	1/1	0/0	1/1	0/0	0/0	0/0
1.33	VH	V1-18	D21-9	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.38.1	VH	V3-33	D21-9	JH6B	1/0	0/0	0/0	3/3	2/1	0/0	0/0
	VK	A20		JK1	0/0	0/0	1/1	0/0	2/2	1/1	0/0
6.4.1	VH	V1-8	D5-18	JH6B	0/0	0/0	0/0	3/2	5/3	0/0	0/0
	VK	A27		JK2	0/0	3/0	1/0	2/2	0/0	1/0	0/0
1.51.1	VH	5-51	D3-16	JH5B	2/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A27		JK3	0/0	0/0	0/0	1/1	0/0	0/0	0/0
1.19.1	VH	V1-8	D3-16	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK2	0/0	0/0	0/0	0/0	1/1	1/1	0/0
1.18	VH	V1-8	D6-19	JH6B	1/0	0/0	0/0	1/0	0/0	0/0	0/0
	VK	A30		JK3	0/0	0/0	0/0	0/0	1/1	0/0	0/0
1.6.1	VH	V3-21	D3-16	JH4B	0/0	4/4	0/0	1/1	1/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	1/1	0/0	0/0	0/0	0/0
1.23.1	VH	V5-51	D3-10	JH4B	1/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	1/1	1/1	0/0	0/0	0/0
1.25.1	VH	V5-51	D3-10	JH4B	1/0	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.39.1	VH	V5-51	D3-10	JH4B	2/1	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.17.1	VH	V3-33	D5-18	JH6B	2/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.24.1	VH	V3-33	D5-18	JH6B	0/0	2/1	0/0	1/1	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	1/0	0/0	0/0
1.46.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	A30		JK1	0/0	0/0	2/1	1/1	0/0	2/2	0/0

FIG. 22B

	Section 1										
	(1)	1	10	20	30	40	51				
CUR2-1.6.1_HC	(1)	EVQLVESGGGLVAPGQSLRLSCAASGCFNRINNNWVRQAPGKGLVWVSSA									
VH3-21	(1)	EVQLVESGGGLVAPGQSLRLSCAASGCFNRINNNWVRQAPGKGLVWVSSA									
Consensus	(1)	EVQLVESGGGLVAPGQSLRLSCAASGCFNRINNNWVRQAPGKGLVWVSSA									
	(52)	52	60	70	80	90	102				
CUR2-1.6.1_HC	(52)	SSSSNNIYYADSVKGRFTISRDNKNSLYIQMNSLRAEETAVYVCARDIMI									
VH3-21	(52)	SSSSNNIYYADSVKGRFTISRDNKNSLYIQMNSLRAEETAVYVCARDIMI									
Consensus	(52)	SSSS IYYADSVKGRFTISRDNKNSLYIQMNSLRAEETAVYVCARDIMI									
	(103)	103	110	126							
CUR2-1.6.1_HC	(103)	TFGGIIASFYFDYWGQGTLLTVSS									
VH3-21	(99)	-----									
Consensus	(103)	TFGGIIASFYFDYWGQGTLLTVSS									

FIG. 23A

Section 1											
	(1)	1	10	20	30	40	52				
CR2-1.17.1_LC A30 Consensus	(1)	DIQMTQSPSSLSASVGDRVTITTCRASQGIIRNDLGNVQKPECKAPKRLITYAAS									
	(1)	DIQMTQSPSSLSASVGDRVTITTCRASQGIIRNDLGNVQKPECKAPKRLITYAAS									
	(1)	DIQMTQSPSSLSASVGDRVTITTCRASQGIIRNDLGNVQKPECKAPKRLITYAAS									
	(1)	DIQMTQSPSSLSASVGDRVTITTCRASQGIIRNDLGNVQKPECKAPKRLITYAAS									
Section 2											
	(53)	53	60	70	80	90	104				
CR2-1.17.1_LC A30 Consensus	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP									
	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP									
	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP									
	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP									
Section 3											
	(105)	105107									
CR2-1.17.1_LC A30 Consensus	(105)	EIK									
	(96)	---									
	(105)										

FIG. 25B

32 / 88

Section 1		1	10	20	30	40	52
CR2-1.18_HC	(1)	QVQLVQSGAEVKKPKCAASVKVSCKASGYTFSTSYDINWVRQATGCGLEWMGWMN					
VH1-8	(1)	QVQLVQSGAEVKKPKCAASVKVSCKASGYTFSTSYDINWVRQATGCGLEWMGWMN					
Consensus	(1)	QVQLVQSGAEVKKPKCAASVKVSCKASGYTFSTSYDINWVRQATGCGLEWMGWMN					
Section 2		53	60	70	80	90	104
CR2-1.18_HC	(53)	PNSGNTGYAOKFQGRVTMTTRNTSISTAYMELSSLRSEDTA					
VH1-8	(53)	PNSGNTGYAOKFQGRVTMTTRNTSISTAYMELSSLRSEDTA					
Consensus	(53)	PNSGNTGYAOKFQGRVTMTTRNTSISTAYMELSSLRSEDTA					
Section 3		105	110	126			
CR2-1.18_HC	(105)	GTYYYYGMDVWGQGT			TVTVSS		
VH31-8	(99)	-----			-----		
Consensus	(105)	-----			-----		

FIG. 26A

[illegible]

FIG. 26B

Section 1		1	10	20	30	40	52
CR2-1.24.1_LC A30 Consensus	(1)	(1)	DIQMTQSPSSLSASVGGDRVITITCRASQGIRNDLGWYQOKPGKAPKRLIYAAS				
	(1)	(1)	DIQMTQSPSSLSASVGGDRVITITCRASQGIRNDLGWYQOKPGKAPKRLIYAAS				
	(1)	(1)	DIQMTQSPSSLSASVGGDRVITITCRASQGIRNDLGWYQOKPGKAPKRLIYAAS				
	(1)	(1)	DIQMTQSPSSLSASVGGDRVITITCRASQGIRNDLGWYQOKPGKAPKRLIYAAS				
Section 2		53	60	70	80	90	104
CR2-1.24.1_LC A30 Consensus	(53)	(53)	SIQSGVPSRFSGSGSGTEFTLTISISLOPEDEATYYCLOHNSYP				
	(53)	(53)	SIQSGVPSRFSGSGSGTEFTLTISISLOPEDEATYYCLOHNSYP				
	(53)	(53)	SIQSGVPSRFSGSGSGTEFTLTISISLOPEDEATYYCLOHNSYP				
	(53)	(53)	SIQSGVPSRFSGSGSGTEFTLTISISLOPEDEATYYCLOHNSYP				
Section 3		(105)	105107				
CR2-1.24.1_LC A30 Consensus	(105)	(105)	EIK				
	(96)	(96)	---				
	(105)	(105)					

FIG. 29B

	Section 1									
	(1)	1	10	20	30	40	51			
VH5-51	(1)	EVQLVQSGAEVKKPQESTKISKKGSGYSTSYWIGWVRQMPGKGLEWMGII								
CR2-1.25.1_HC	(1)	EVQLVQSGAEVKKPQESTKISKKGSGYSTSYWIGWVRQMPGKGLEWMGII								
Consensus	(1)	EVQLVQSGAEVKKPQESTKISKKGSGYFTSYWIGWVRQMPGKGLEWMGII								
	Section 2									
	(52)	52	60	70	80	90	102			
VH5-51	(52)	YPGDSDDTRYSPSFQGGVTTISADKSIISTAYLQWSSSLKASDTAMYYCAR								
CR2-1.25.1_HC	(52)	YPGDSDDTRYSPSFQGGVTTISADKSIISTAYLQWSSSLKASDTAMYYCARHGSY								
Consensus	(52)	YPGDSDDTRYSPSFQGGVTTISADKSIISTAYLQWSSSLKASDTAMYYCAR								
	Section 3									
	(103)	103	110	126						
VH5-51	(99)	-----								
CR2-1.25.1_HC	(103)	YVGSETYYNVFDYWGQGLTVTVSS								
Consensus	(103)	YVGSETYYNVFDYWGQGLTVTVSS								

FIG. 30A

	Section 1										
	(1)	1	10	20	30	40	52				
VH5-51	(1)	EVQLVQSGAEVKKPGESLKISCKGSGYFTSYWIGWVRQMPGKGLEWMGIIY									
CR2-1.29.1_HC	(1)	EVQLVQSGAEVKKPGESLKISCKGSGYFTSYWIGWVRQMPGKGLEWMGIIY									
Consensus	(1)	EVQLVQSGAEVKKPGESLKISCKGSGYFTSYWIGWVRQMPGKGLEWMGIIY									
	Section 2										
	(53)	53	60	70	80	90	104				
VH5-51	(53)	PGDSDTRYSPSFGQVTTISADKSTSTAYLQWSSSLKASDTAMYYCAR									
CR2-1.29.1_HC	(53)	PGDSDTRYSPSFGQVTTISADKSTSTAYLQWSSSLKASDTAMYYCARHVDVGA									
Cons nsus	(53)	PGDSDTRYSPSFGQVTTISADKSTSTAYLQWSSSLKASDTAMYYCAR									
	Section 3										
	(105)	105	110	129							
VH5-51	(99)	-----									
CR2-1.29.1_HC	(105)	TIGGYYYHGMVDVWGQGTITVTVSS									
Consensus	(105)	-----									

FIG. 31A

	Section 1									
		10	20	30	40	52				
VH1-18	(1)	QVQLVQSGAEVKKPKASVKISCKASGYTFSTSYGISWVRQAPGQGLEWMGWLIS								
CR2-1.33_HC	(1)	QVQLVQSGAEVKKPKASVKISCKASGYTFSTSYGISWVRQAPGQGLEWMGWLIS								
Consensus	(1)	QVQLVQSGAEVKKPKASVKISCKASGYTFSTSYGISWVRQAPGQGLEWMGWLIS								
	Section 2									
	53	60	70	80	90	104				
VH1-18	(53)	AYNGNTNYYAQKIQGRVTMTTDTSTSTAYMELRSLSRDDTAVYYCAR								
CR2-1.33_HC	(53)	AYNGNTNYYAQKIQGRVTMTTDTSTSTAYMELRSLSRDDTAVYYCAR								
Consensus	(53)	AYNGNTNYYAQKIQGRVTMTTDTSTSTAYMELRSLSRDDTAVYYCAR								
	Section 3									
	(105)	105	110	127						
VH1-18	(99)	-----								
CR2-1.33_HC	(105)	SDYLYYYYGLDVWGQGTITVTVSS								
Consensus	(105)	SDYLYYYYGLDVWGQGTITVTVSS								

FIG. 32A

Section 1										Section 2										Section 3		
	1	10	20	30	40	51		52	60	70	80	90	102		103	110	127					
VH3-33	(1)	QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKGL					WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR					
CR2-1.38.1_HC	(1)	QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKGL					WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR					
Consensus	(1)	QVQLVESGGGVQPGSRSLRLSCAASGFTFSYGMHWVRQAPGKGL					WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR					
VH3-33	(52)	WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR										
CR2-1.38.1_HC	(52)	WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR										
Consensus	(52)	WYDGSNRYADSVKGRFTSRD					NSKNTLYLQMN					SLRAEDTAVYVCAR										
VH3-33	(103)	QSSD					LYYYGMDVWGQGT					TVTVSS										
CR2-1.38.1_HC	(99)	-----					-----					-----										
Consensus	(103)	QSSD					LYYYGMDVWGQGT					TVTVSS										

FIG. 33A




FIG. 33B

48 / 88

	Section 1										
	(1)	1	10	20	30	40	51				
VH5-51	(1)	EVQLVQSGAEVKKPQEGESLKISCKGSGY	SE	TS	WIGWVRQMPCKG	GLEWMGII					
CR2-1.39.1_HC	(1)	EVQLVQSGAEVKKPQEGESLKISCKGSGY	SE	TS	WIGWVRQMPCKG	GLEWMGII					
Consensus	(1)	EVQLVQSG	EVKKPQEGESLKISCKGSGY	FTSYWIGWVRQMPCKG	GLEWMGII						
	(52)	52	60	70	80	90	102				
VH5-51	(52)	YPGDSDTTRYSPSFQGGQVTISADKSI	STAYLQWSSLKASDTAMYYCAR	---							
CR2-1.39.1_HC	(52)	YPGDSDTTRYSPSFQGGQVTISADKSI	STAYLQWSSLKASDTAMYYCAR	HGSY							
Consensus	(52)	YPGDSDTTRYSPSFQGGQVTISADKSI	STAYLQWSSLKASDTAMYYCAR								
	(103)	103	110	126							
VH5-51	(99)	-----									
CR2-1.39.1_HC	(103)	YNSGSGSYNVFDYWGQGT	LVTVSS								
Consensus	(103)										

FIG. 34A


49 / 88

Section 1		1	10	20	30	40	52
(1)	A30	DIQMTQSPSSLSASVGDRTITTCRASQGITRNDLGMVQKPGKAPKRLIYAAS					
(1)	CR2-1.39.1_LC	DIQMTQSPSSLSASVGDRTITTCRASQGITRNDLGMVQKPGKAPKRLIYAAS					
(1)	Consensus	DIQMTQSPSSLSASVGDRTITTCRASQGITRNDLGMVQKPGKAPKRLIYAAS					
Section 2		53	60	70	80	90	104
(53)	A30	SLQSGVPSRFSGSGTEFTLTISSLQPEDFATYYICLQHNSYP					
(53)	CR2-1.39.1_LC	SLQSGVPSRFSGSGTEFTLTISSLQPEDFATYYICLQHNSYP					
(53)	Consensus	SLQSGVPSRFSGSGTEFTLTISSLQPEDFATYYICLQHNSYP					
Section 3		(105)	105	107			
(105)	A30	---					
(96)	CR2-1.39.1_LC	EIK					
(105)	Consensus						

FIG. 34B

	Section 1										
	1	10	20	30	40	50	60	70	80	90	100
VH1-8	(1)	QVQLVQSGAEVKKPKASVKVSCKASG	TFST	DIINWVRQATGQGLEWMGWNIN							
CR2-1.45_HC	(1)	QVQLVQSGAEVKKPKASVKVSCKASG	TFST	DIINWVRQATGQGLEWMGWNIN							
Consensus	(1)	QVQLVQSGAEVKKPKASVKVSCKASG	TFST	DIINWVRQATGQGLEWMGWNIN							
	Section 2										
	53	60	70	80	90	100	110	120	130	140	150
VH1-8	(53)	PNSGNTGYAOKFOGRVTMTTRNTSI	STAYMELSSLRSEDTAVYYCAR								
CR2-1.45_HC	(53)	PNSGNTGYAOKFOGRVTMTTRNTSI	STAYMELSSLRSEDTAVYYCAR								
Consensus	(53)	PNSGNTGYAOKFOGRVTMTTRNTSI	STAYMELSSLRSEDTAVYYCAR								
	Section 3										
	105	110	120	130	140	150	160	170	180	190	200
VH1-8	(105)	GYDYYGMDVWGQGT	TVTVSS								
CR2-1.45_HC	(105)	GYDYYGMDVWGQGT	TVTVSS								
Consensus	(105)	GYDYYGMDVWGQGT	TVTVSS								

FIG. 35A



	(1)	1	10	20	30	40	51	Section 1
VH1-8	(1)	QVQLVQSGAEVKKPGASVKVSCKA	SG	INETS	DINWVRQATGQGLEWMGWMM			
CR2-1.46.1_HC	(1)	QVQLVQSGAEVKKPGASVKVSCKA	SG	INETS	DINWVRQATGQGLEWMGWMM			
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKA	SG	INETS	DINWVRQATGQGLEWMGWMM			
	(52)	52	60	70	80	90	102	Section 2
VH1-8	(52)	NPNISGNITGYAQKFQGRVTMTNRNTS	ISTAYMELSSLRSEDTAVYYCAR					
CR2-1.46.1_HC	(52)	NPNINGNTGYAQKFQGRVTMTNRNTS	ISTAYMELSSLRSEDTAVYYCAR					
Consensus	(52)	NPN GNTGYAQKFQGRVTMTNRNTS	ISTAYMELSSLRSEDTAVYYCAR					
	(103)	103	110	126				Section 3
VH1-8	(99)	-----						
CR2-1.46.1_HC	(103)	VVTATDY YYGMDVWGQGTTVTVSS						
Consensus	(103)	-----						

FIG. 36A




FIG. 36B

	Section 1												Section 2												Section 3											
	(1)	10	20	30	40	52	(53)	60	70	80	90	104	(105)	105107	(105)	105107	(105)	---	(105)																	
CR2-1.48.1_LC	(1)	DIQMTQSPSSVSASVGDRVTITCRASQGISSSLAWYQOKPGKAPKLLIYAAS											(53)	ILQSGVPSRFSGSGSDTFTLTSSLOPEDFASVCOQNSFPRTFGQGTKV											(105)	---										
L5	(1)	DIQMTQSPSSVSASVGDRVTITCRASQGISSSLAWYQOKPGKAPKLLIYAAS											(53)	SLQSGVPSRFSGSGSDTFTLTSSLOPEDFASVCOQNSFP											(105)	---										
Consensus	(1)	DIQMTQSPSSVSASVGDRVTITCRASQGISSSLAWYQOKPGKAPKLLIYAAS											(53)	LQSGVPSRFSGSGSDTFTLTSSLOPEDFASYCQQANSFP											(105)	---										
CR2-1.48.1_LC	(105)	105107											(105)	EIK-											(105)	---										
L5	(96)	---											(96)	---											(96)	---										
Consensus	(105)	---											(105)	---											(105)	---										

FIG. 37B


FIG. 38B

Section 1									
	(1)	1	10	20	30	40	51		
CR2-1.51.1_HC	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLFWMGII							
VH5-51	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLFWMGII							
Consensus	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLFWMGII							
Section 2									
	(52)	52	60	70	80	90	102		
CR2-1.51.1_HC	(52)	YPGDSDAKYSPSFQGGQVTTISADKSIISTAYLQWSSSLKASDTAMYYCARHYDY							
VH5-51	(52)	YPGDSDAKYSPSFQGGQVTTISADKSIISTAYLQWSSSLKASDTAMYYCAR							
Consensus	(52)	YPGDSD KYSPSFQGGQVTTISADKSIISTAYLQWSSSLKASDTAMYYCAR							
Section 3									
	(103)	103	110	126					
CR2-1.51.1_HC	(103)	VWRNYRYTGWFDPWGQGLTVTVSS							
VH5-51	(99)	-----							
Consensus	(103)								

FIG. 39A

Section 1		
	(1) 1	52
CR2-1.51.1_LC	(1) EIVLTQSPGTTLSLSPGERATLSCRA	40
A27	(1) EIVLTQSPGTTLSLSPGERATLSCRA	30
Consensus	(1) EIVLTQSPGTTLSLSPGERATLSCRA	20
	(1) EIVLTQSPGTTLSLSPGERATLSCRA	10
	(1) EIVLTQSPGTTLSLSPGERATLSCRA	1
Section 2		
	(53) 53	104
CR2-1.51.1_LC	(53) SINRATGCTPDRFSGSGGTFTLTISRLE	90
A27	(53) SINRATGCTPDRFSGSGGTFTLTISRLE	80
Consensus	(53) SINRATGCTPDRFSGSGGTFTLTISRLE	70
	(53) SINRATGCTPDRFSGSGGTFTLTISRLE	60
	(53) SINRATGCTPDRFSGSGGTFTLTISRLE	53
Section 3		
	(105) 105 108	
CR2-1.51.1_LC	(105) VDIK	
A27	(97) ----	
Consensus	(105)	

FIG. 39B



62 / 88

CLONE #	VH	# DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.19.1	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTAGTTTG GCGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6B	-12	ACTACG (SEQ ID NO:94)
1.19.2	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTAGTTTG GCGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6B	-12	ACTACG (SEQ ID NO:94)
1.19.3	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTAGTTTG GCGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6B	-12	ACTACG (SEQ ID NO:94)
6.4.1	DP-15/1-8	0	CGAGAG (SEQ ID NO:95)	3	CTT	D5-18	12	TGGATACAGCTA (SEQ ID NO:96)	2	TA	JH6B	0	ATTACTAC (SEQ ID NO:97)
6.4.2	DP-15/1-8	0	CGAGAG (SEQ ID NO:95)	3	CTT	D5-18	12	TGGATACAGCTA (SEQ ID NO:96)	2	TA	JH6B	0	ATTACTAC (SEQ ID NO:97)
6.4.3	DP-15/1-8	0	CGAGAG (SEQ ID NO:95)	3	CTT	D5-18	12	TGGATACAGCTA (SEQ ID NO:96)	2	TA	JH6B	0	ATTACTAC (SEQ ID NO:97)

FIG. 41A

63 / 88

CLONE #	vk	#del	vk end	#n	N SEQ	JK	# del	JK end
1.19.1	A30	-3	TTAACC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)
1.19.2	A30	-3	TTAACC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)
1.19.3	A30	-3	TTAACC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)
6.4.1	A27/A27A	-3	CTCAAC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)
6.4.2	A27/A27A	-3	CTCAAC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)
6.4.3	A27/A27A	-3	CTCAAC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)

FIG. 41B

64 / 88

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATGGC TCGTT (SEQ ID NO:106)	JH4 B	-1	CTACTT (SEQ ID NO:107)
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATGGC TCGTT (SEQ ID NO:106)	JH4 B	-1	CTACTT (SEQ ID NO:107)
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATGGC TCGTT (SEQ ID NO:106)	JH4 B	-1	CTACTT (SEQ ID NO:107)
1.11.1	DP-42/3-53	-5	AGAGA (SEQ ID NO:108)	3	GGA	D4-17	10	ACGGTACTA (SEQ ID NO:109)	5	CGAAT (SEQ ID NO:110)	JH6 B	-2	TACTACTA (SEQ ID NO:111)
1.11.2	DP-42/3-53	-5	AGAGA (SEQ ID NO:108)	3	GGA	D4-17	10	ACGGTACTA (SEQ ID NO:109)	5	CGAAT (SEQ ID NO:110)	JH6 B	-2	TACTACTA (SEQ ID NO:111)
1.23.1	DP-73/5-51	0	GAGACA (SEQ ID NO:112)	18	TGTATCGTATTACT ATGT (SEQ ID NO:113)	D3-10	19	TTCGGGGAGTAA TTATAAC (SEQ ID NO:114)	2	GT	JH4 B	-4	CTTGA (SEQ ID NO:115)
1.23.2	DP-73/5-51	0	GAGACA (SEQ ID NO:112)	18	TGTATCGTATTACT ATGT (SEQ ID NO:113)	D3-10	19	TTCGGGGAGTAA TTATAAC (SEQ ID NO:114)	2	GT	JH4 B	-4	CTTGA (SEQ ID NO:115)

FIG. 42A

65 / 88

CLONE #	Vk	#del	vk end	#n	N SEQ	JK	# del	JK end
1.6.1	A30	-3	TTAACC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.6.2	A30	-3	TTAACC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.6.3	A30	-3	TTAACC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.11.1	A3/A19/DEK	-4	AAACTC (SEQ ID NO:118)	0	0	JK4	-2	TCACCTTC (SEQ ID NO:119)
1.11.2	A3/A19/DEK	-4	AAACTC (SEQ ID NO:118)	0	0	JK4	-2	TCACCTTC (SEQ ID NO:119)
1.23.1	A30	-3	TTAACC (SEQ ID NO:120)	0	0	JK1	0	GTCGAC (SEQ ID NO:120)
1.23.2	A30	-3	TTAACC (SEQ ID NO:120)	0	0	JK1	0	GTCGAC (SEQ ID NO:120)

FIG. 42B

66 / 88

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.17.1	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.17.2	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.17.3	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.18	DP-15/1-8	1	CGAGAG (SEQ ID NO:125)	1	A	D6-19	19	GGTATAGGAGT GCTGG (SEQ ID NO:126)	4	GACA	JH6B	-2	TACTAC (SEQ ID NO:127)
1.24.1	DP-50/3-33	0	GAGAGA (SEQ ID NO:128)	4	TCAG	DK4	18	GGATACGCTAT GCTAC (SEQ ID NO:129)	2	GT	JH6B	-4	CTACTA (SEQ ID NO:130)
1.24.2	DP-50/3-33	0	GAGAGA (SEQ ID NO:128)	4	TCAG	DK4	18	GGATACGCTAT GCTAC (SEQ ID NO:129)	2	GT	JH6B	-4	CTACTA (SEQ ID NO:130)
1.25.1	DP-73/5-51	0	GAGAGA (SEQ ID NO:131)	6	TGGATC (SEQ ID NO:132)	D3-10	30	GTATATTATGG TTCCGAGACTTA TTATAA (SEQ ID NO:133)	3	TGT	JH4B	-4	CTTGA (SEQ ID NO:135)

FIG. 43A

67 / 88

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.25.2	DP-73/5-51	0	GAGACA (SEQ ID NO:131)	6	TGGATC (SEQ ID NO:132)	D3-10	30	GTATTATTATGG TTCCGAGACTTA TTATAA (SEQ ID NO:133)	3	TGT	JH4B	-4	CTTTGA (SEQ ID NO:134)
1.29	DP-73/5-51	0	GAGACA (SEQ ID NO:135)	1	C	D5-12	21	GTCGATGTAGG GCTACGATT (SEQ ID NO:136)	7	GCGGAT (SEQ ID NO:137)	JH6B	0	ATTACTAC (SEQ ID NO:138)
1.33	DP-14/1-18	0	GAGACA (SEQ ID NO:139)	2	TC	D21-9	18	ATTACTATGATA GTAGIG (SEQ ID NO:140)	7	ATTATCT (SEQ ID NO:141)	JH6B	-4	CTACTA (SEQ ID NO:142)
1.38.1	DP-50/3-33	1	CGAGAG (SEQ ID NO:143)	2	GA	D21-9	19	TATTACTATGAT AGTAGIG (SEQ ID NO:144)	7	ATTATCT (SEQ ID NO:145)	JH6B	-4	CTACTA (SEQ ID NO:146)
1.39.1	DP-73/5-51	0	GAGACA (SEQ ID NO:147)	6	TGGATC (SEQ ID NO:148)	D3-10	31	GTATTACTATGAA TTCCGGGAGTTA TTATAAC (SEQ ID NO:149)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:150)
1.39.2	DP-73/5-51	0	GAGACA (SEQ ID NO:147)	6	TGGATC (SEQ ID NO:148)	D3-10	31	GTATTACTATGAA TTCCGGGAGTTA TTATAAC (SEQ ID NO:149)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:150)

FIG. 43B

68 / 88

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.40.1	DP-15/1-8	1	CGAGAG (SEQ ID NO:151)	0	0	D2	25	ATATTGTAGTGG TGGTAGCTGCTA C (SEQ ID NO:152)	2	CA	JH6B	-6	ACTACT (SEQ ID NO:153)
1.40.2	DP-15/1-8	1	CGAGAG (SEQ ID NO:151)	0	0	D2	25	ATATTGTAGTGG TGGTAGCTGCTA C (SEQ ID NO:152)	2	CA	JH6B	-6	ACTACT (SEQ ID NO:153)
1.45	DP-15/1-8	0	CGAGAG (SEQ ID NO:154)	2	CA	DK4	20	GTTGATACAGCT ATGGTTAC (SEQ ID NO:155)	1	G	JH6B	-6	ACTACT (SEQ ID NO:156)
1.46.1	DP-15/1-8	1	CGAGAG (SEQ ID NO:157)	0	0	D2	25	ATATTGTAGT GGGTAGCTGCTC TAC (SEQ ID NO:158)	2	GG	JH6B	-6	ACTACT (SEQ ID NO:159)
1.46.2	DP-15/1-8	1	CGAGAG (SEQ ID NO:157)	0	0	D2	25	ATATTGTAGTGG TGGTAGCTGCTA C (SEQ ID NO:158)	2	GG	JH6B	-6	ACTACT (SEQ ID NO:159)
1.48.1	DP-14/1-18	1	CGAGAG (SEQ ID NO:160)	7	TGTTGAA (SEQ ID NO:161)	D21-9	20	TATTACTAATGAT GGTAGCTGCTAT (SEQ ID NO:162)	1	T	JH4B	0	ACTACT (SEQ ID NO:163)

FIG. 43C

69 / 88

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.48.2	DP-14/1-18	1	CGAGAG (SEQ ID NO:160)	7	TGTTGAA (SEQ ID NO:161)	D21-9	20	TATTACTAATGAT GGTAGTGGTAT (SEQ ID NO:162)	1	T	JH4B	0	ACTACT (SEQ ID NO:163)
1.49.1	DP-15/1-8	2	GCGAGA (SEQ ID NO:164)	5	ATGAG (SEQ ID NO:165)	D5-12	17	GGATATAGTGGC TACGA (SEQ ID NO:166)	3	GCT	JH6B	0	ATTACTAC (SEQ ID NO:167)
1.49.2	DP-15/1-8	2	GCGAGA (SEQ ID NO:164)	5	ATGAG (SEQ ID NO:165)	D5-12	17	GGATATAGTGGC TACGA (SEQ ID NO:166)	3	GCT	JH6B	0	ATTACTAC (SEQ ID NO:167)
1.51.1	DP-73/5-51	0	CAGACA (SEQ ID NO:168)	1	C	D3-16	31	TAATGATTACGTT TGGAGGAATTAT CGGTATA (SEQ ID NO:169)	5	CAGGG (SEQ ID NO:170)	JH5B	-5	TGGTTC (SEQ ID NO:171)
1.51.2	DP-73/5-51	0	CAGACA (SEQ ID NO:168)	1	C	D3-16	31	TAATGATTACGTT TGGAGGAATTAT CGGTATA (SEQ ID NO:169)	5	CAGGG (SEQ ID NO:170)	JH5B	-5	TGGTTC (SEQ ID NO:171)

CLONE #	vk	#del	vk end	#n	N SEQ	Jk	# del	JK end
---------	----	------	--------	----	-------	----	-------	--------

1.17.1	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)
1.17.2	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)

FIG. 43D

70 / 88

CLONE #	vk	#del	vk end	#n	N SEQ	JK	# del	JK end
1.17.3	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)
1.18	A30	3	TTACCC (SEQ ID NO:174)	0	0	JK3	0	ATTAC (SEQ ID NO:175)
1.24.1	A30	3	TTACCC (SEQ ID NO:176)	0	0	JK1	0	GTGGAC (SEQ ID NO:177)
1.24.2	A30	3	TTACCC (SEQ ID NO:176)	0	0	JK1	0	GTGGAC (SEQ ID NO:177)
1.25.1	A30	3	TTACCC (SEQ ID NO:178)	0	0	JK1	0	GTGGAC (SEQ ID NO:179)
1.25.2	A30	3	TTACCC (SEQ ID NO:178)	0	0	JK1	0	GTGGAC (SEQ ID NO:179)
1.29	A3/A19/DPK	7	CTACAA (SEQ ID NO:180)	14	TCCTCTCATG TGCAG (SEQ ID NO:181)	JK2	-7	TTTGG (SEQ ID NO:182)
1.33	A20/DPK4	3	TGCCCC (SEQ ID NO:183)	0	0	JK4	0	GCTCAC (SEQ ID NO:184)
1.38.1	A20/DPK4	3	TGCCCC (SEQ ID NO:185)	0	0	JK1	0	GTGGAC (SEQ ID NO:186)
1.39.1	A30	3	TTACCC (SEQ ID NO:187)	0	0	JK1	0	GTGGAC (SEQ ID NO:188)



FIG. 43E

71 / 88


CLONE #	vk	#del	vk end	#n	N SEQ	JK	# del	JK end
1.39.2	A30	3	TTACCC (SEQ ID NO:187)	0	0	JK1	0	GTGGAC (SEQ ID NO:188)
1.45	A20/DPK4	3	TGCCCC (SEQ ID NO:189)	0	0	JK3	0	ATTCAC (SEQ ID NO:190)
1.46.1	A30	0	CCCTCC (SEQ ID NO:191)	0	0	JK1	-3	GACGTT (SEQ ID NO:192)
1.46.2	A30	0	CCCTCC (SEQ ID NO:191)	0	0	JK1	-3	GACGTT (SEQ ID NO:192)
1.48.1	L5/DPK5/V	1	TCCCTC (SEQ ID NO:193)	0	0	JK1	-2	GGACGTT (SEQ ID NO:194)
1.48.2	L5/DPK5/V	1	TCCCTC (SEQ ID NO:193)	0	0	JK1	-2	GGACGTT (SEQ ID NO:194)
1.49.1	A3/A19/DPK	5	CAAACT (SEQ ID NO:195)	0	0	JK5	-1	ATCACC (SEQ ID NO:196)
1.49.2	A3/A19/DPK	5	CAAACT (SEQ ID NO:195)	0	0	JK5	-1	ATCACC (SEQ ID NO:196)
1.51.1	A27/A27A	4	GCTCAC (SEQ ID NO:197)	1	T	JK3	0	ATTCAC (SEQ ID NO:198)
1.51.1	A27/A27A	4	GCTCAC (SEQ ID NO:197)	1	T	JK3	0	ATTCAC (SEQ ID NO:198)

FIG. 43F


72 / 88







3066 Mab Neutralization 3066 Brdu Proliferation NIH 3T3 11-22-00



3066 Mab Neutralization PDGF BB Brdu Proliferation NIH 3T3 11-22-00







1.19 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	T	G	Y	60			
6.4 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	D	Y	60			
1.18 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.40 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.45 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.46 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.49 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.33 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.48 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	A	S	K	S	C	A	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	I	G	Y	60			
1.6 H	1	Q	V	L	V	S	G	G	A	E	V	K	K	P	G	S	A	S	C	N	E	R	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	S	I	S	S	S	S	I	Y	60
1.17 H	1	Q	V	L	V	S	G	G	A	E	V	K	K	P	G	S	A	S	C	N	E	R	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	S	I	S	S	S	S	I	Y	60
1.24 H	1	Q	V	L	V	S	G	G	A	E	V	K	K	P	G	S	A	S	C	N	E	R	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	S	I	S	S	S	S	I	Y	60
1.38 H	1	Q	V	L	V	S	G	G	A	E	V	K	K	P	G	S	A	S	C	N	E	R	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	S	I	S	S	S	S	I	Y	60
1.11 H	1	Q	V	L	V	S	G	G	A	E	V	K	K	P	G	S	A	S	C	N	E	R	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	S	I	S	S	S	S	I	Y	59
1.23 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	S	K	S	C	G	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	S	G	S	-	T	Y	60	
1.25 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	S	K	S	C	G	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	S	G	S	T	Y	60		
1.29 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	S	K	S	C	G	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	S	G	S	T	Y	60		
1.39 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	S	K	S	C	G	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	S	G	S	T	Y	60		
1.51 H	1	Q	V	L	V	Q	S	G	A	E	V	K	K	P	G	S	K	S	C	G	S	G	F	T	S	D	I	N	V	R	Q	A	T	C	G	L	E	W	M	G	W	N	P	N	S	G	S	G	S	T	Y	60		

CDR1

CDR2

CDR2

CDR1

FIG. 48A

1.19 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--DVM--ITFGG	VIV	--YGM	DVM	116			
6.4 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--GFG--YSYN	YD	--YGM	DVM	115			
1.18 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--EG--IAVAGT	YY	YGM	DVM	116			
1.40 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--DIV--VVVAAT	N	YGM	DVM	116			
1.45 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--GSG--YSYG	YD	YGM	DVM	115			
1.46 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--DIV--VVVTAT	D	YGM	DVM	116			
1.49 H	61	AQKFQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--MRD--IVATS	YY	YGM	DVM	117			
1.33 H	61	AQKLQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	--DHY--YDSSD	YL	YGL	DVM	117			
1.48 H	61	AQKLQGRVT	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	DVEYY--YDGS	GY	---	W	115			
1.6 H	61	ADSVGRET	SRNTS	IS	STAY	SLR	SLR	DTA	YYCARD	IMI	---	TFG	GLIASFY	FD	W	116	
1.17 H	61	ADSVGRET	SRNTS	IS	STAY	SLR	SLR	DTA	YYCARD	QGY	---	RYA	GY	YDY	YGM	DVM	116
1.24 H	61	ADSVGRET	SRNTS	IS	STAY	SLR	SLR	DTA	YYCARD	QGY	---	SYG	YV	YDY	YGM	DVM	116
1.38 H	61	ADSVGRET	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	GYYD	---	SSD	YL	YY	YGM	DVM	117
1.11 H	60	ADSVGRET	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAG	TVTT	---	---	N	YY	YGM	DVM	110
1.23 H	61	SPSFQGV	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	HVS	---	YVSGS	YY	--NV	FD	W	116
1.25 H	61	SPSFQGV	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	HGS	---	YVSGS	YY	--NV	FD	W	116
1.29 H	61	SPSFQGV	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	HVDVGAT	IG	YY	YGM	DVM	119		
1.39 H	61	SPSFQGV	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	HGS	---	YVSGS	YY	--NV	FD	W	116
1.51 H	61	SPSFQGV	SRNTS	IS	STAY	SLR	SLR	DTA	YYCAR	HYD	---	VWRNYR	YT	--GW	FD	W	116

CDR3

CDR3

FIG. 48B

1.19 H	117	GQGT	TVTVSS	126
6.4 H	116	GQGT	TVTVSS	125
1.18 H	117	GQGT	TVTVSS	126
1.40 H	117	GQGT	TVTVSS	126
1.45 H	116	GQGT	TVTVSS	125
1.46 H	117	GQGT	TVTVSS	126
1.49 H	118	GQGT	TVTVSS	127
1.33 H	118	GQGT	TVTVSS	127
1.48 H	116	GQGT	TVTVSS	125
1.6 H	117	GQGT	TVTVSS	126
1.17 H	117	GQGT	TVTVSS	126
1.24 H	117	GQGT	TVTVSS	126
1.38 H	118	GQGT	TVTVSS	127
1.11 H	111	GQGT	TVTVSS	120
1.23 H	117	GQGT	TVTVSS	126
1.25 H	117	GQGT	TVTVSS	126
1.29 H	120	GQGT	TVTVSS	129
1.39 H	117	GQGT	TVTVSS	126
1.51 H	117	GQGT	TVTVSS	126

FIG. 48C

1.48	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.49	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.11	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.29	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.45	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.33	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.38	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
6.4	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.51	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.19	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.18	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.16	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.23	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.25	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.39	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.17	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.24	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55
1.46	L	1	DIQMTQSPSSLSASVGDRVTI	CRASQGIS	-----WLAWYQQKPGK	PKLLIYAASILQ	55

FIG. 49A

1.48	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAS	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.49	L	61	SGVPDRFSGSGSGT	FTLKISR	RLA	ED	VG	YVCM	TLQ	IT	--	FGQ	TKV	EIK	111
1.11	L	61	SGVPDRFSGSGSGT	FTLKISR	RLA	ED	VG	YVCM	ALQ	TLT	--	FGG	TKV	EIK	111
1.29	L	61	SGVDFRFSGSGSGT	FTLKISR	RLA	ED	VG	YVCM	ALQ	SLM	CS	FGQ	TKV	EIK	113
1.45	L	56	IGVPSRFSGSGSGT	FTLTIS	SLQPED	VAT	YVCC	SS	SFF	RI	FGP	GTKV	EIK	107	
1.33	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	VAT	YVCC	SS	SFF	RI	FGG	GTKV	EIK	107	
1.38	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	VAA	YVCC	SS	SFF	RI	FGQ	CTV	EIK	107	
6.4	L	57	SGVPDRFSGSGSGT	FTLTISR	RLA	ED	VG	YVCC	SS	SFF	RI	FGQ	TKV	EIK	108
1.51	L	57	SGVPDRFSGSGSGT	FTLTISR	RLA	ED	VG	YVCC	SS	SFF	RI	FGP	GTKV	EIK	108
1.19	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.18	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGP	GTKV	EIK	107	
1.16	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGG	GTKV	EIK	107	
1.23	L	56	RGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.25	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.39	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.17	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGG	GTKV	EIK	107	
1.24	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	
1.46	L	56	SGVPSRFSGSGSGT	FTLTIS	SLQPED	FAT	YVCC	SS	SFF	RI	FGQ	TKV	EIK	107	

CDR3

FIG. 49B

1.19 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
6.4 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
1.18 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
1.40 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
1.45 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
1.46 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
1.49 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGMNPN	60
		[CDR1] [CDR2]	
1.19 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	119
6.4 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	118
1.18 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	119
1.40 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	119
1.45 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	118
1.46 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	119
1.49 H	61	AQKFQGRVTMTTRNTSISTAYMELSSLRSED	120
		[CDR3]	
1.19 H	120	TTVTVSS	126
6.4 H	119	TTVTVSS	125
1.18 H	120	TTVTVSS	126
1.40 H	120	TTVTVSS	126
1.45 H	119	TTVTVSS	125
1.46 H	120	TTVTVSS	126
1.49 H	121	TTVTVSS	127

FIG. 50

82 / 88

1.33 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY	60
1.48 H	1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY	60
		[CDR1] [CDR2]	
1.33 H	61	AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR	118
1.48 H	61	AQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR	116
		[CDR3]	
1.33 H	119	QGT	127
1.48 H	117	QGT	125

FIG. 51

1.17 H	1	QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMHWVRQAPGKGLEWVA	60
1.24 H	1	QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMHWVRQAPGKGLEWVA	60
1.38 H	1	QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMHWVRQAPGKGLEWVA	60
		[CDR1] [CDR2]	
1.17 H	61	ADSVKGRFTSRDNSKNTLYLQMNSLRAEDTAVYYCARDQGY-RVAGY	119
1.24 H	61	ADSVKGRFTSRDNSKNTLYLQMNSLRAEDTAVYYCARDQGY-SYGY	119
1.38 H	61	ADSVKGRFTSRDNSKNTLYLQMNSLRAEDTAVYYCARDQGY-DSSD	120
		[CDR3]	
1.17 H	120	TTVTVSS	126
1.24 H	120	TTVTVSS	126
1.38 H	121	TTVTVSS	127

FIG. 52

1.23 H	1	EVQLVQSGAEVKKPQGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS	60
1.25 H	1	EVQLVQSGAEVKKPQGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS	60
1.29 H	1	EVQLVQSGAEVKKPQGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS	60
1.39 H	1	EVQLVQSGAEVKKPQGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS	60
1.51 H	1	EVQLVQSGAEVKKPQGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS	60
		[CDR1] [CDR2]	
1.23 H	61	SPSFQGGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHVSYYVSG---SYNNVFDYMG	117
1.25 H	61	SPSFQGGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHGSYYVSGE---TYYNVFDYMG	117
1.29 H	61	SPSFQGGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHVDVGATIGGYYYYYGMDVWG	120
1.39 H	61	SPSFQGGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHGSYYVSG---SYNNVFDYMG	117
1.51 H	61	SPSFQGGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHYDVVRNY---RNTGWFDPWG	117
		[CDR3]	
1.23 H	118	QGTLLVTVSS	126
1.25 H	118	QGTLLVTVSS	126
1.29 H	121	QGTLLVTVSS	129
1.39 H	118	QGTLLVTVSS	126
1.51 H	118	QGTLLVTVSS	126

FIG. 53

1.49	L	1	DIVMTQSP	1	60
1.11	L	1	DIVMTQSP	1	60
1.29	L	1	DIVMTQSP	1	60
			[CDR1]	[CDR2]	
1.49	L	61	SGVPDR	111	
1.11	L	61	SGVPDR	111	
1.29	L	61	SGVPDR	113	
			[CDR3]		

FIG. 54

1.45	L	1	DIQMTQSPSSLSASVGDRVTINCRASQGISNDLAWYQOKPGKVPKLLIYAASTLQLGVP	60
1.33	L	1	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQOKPGKVPKLLIYAASTLQSGVP	60
1.38	L	1	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQOKPGKVPENLLIYAASTLQSGVP	60
			[CDR1]	[CDR2]
1.45	L	61	RFSGSGSGTDFTLTISSLQPEDVATYYCQKYNISAPFTFGPGTKVFIK	107
1.33	L	61	RFSGSGSGTDFTLTISSLQPEDVATYYCQKYNISAPLTFGCGTKVFIK	107
1.38	L	61	RFSGSGSGTDFTLTISSLQPEDVAAYYCQKONSAPWTFGQGTTFIK	107
			[CDR3]	

FIG. 55

6.4 L	1	EIVLTQSPGTLSSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSSRATGIP	60
1.51 L	1	EIVLTQSPGTLSSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASINRATGIP	60
		[CDR1]	[CDR2]
6.4 L	61	DRFSGSGCTDFTLTISRLEPEDFAVYYCQQYGSSPCPGFGQGTKITIK	108
1.51 L	61	DRFSGSGCTDFTLTISRLEPEDFAVYYCQQYGSSLEFGPGTKITIK	108
		[CDR3]	

FIG. 56

88 / 88

1.1.19	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.18	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAFKRLIYAASSLQSGVPS	60	
1.1.16	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.23	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.25	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.39	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.17	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.24	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
1.1.46	L	1	DIQMTQSPSSLSASVGDRAVTITCRASQGI	NDLGWYQQKPGKAPKRLIYAASSLQSGVPS	60	
			[CDR1]	[CDR2]		
1.1.19	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHNSDPQSFQGTKEIR	107	
1.1.18	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYPTFTFGPGTKVEIK	107
1.1.16	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYPLTFGGGTKVEIK	107
1.1.23	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYFWTFGQGTKEIK	107
1.1.25	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYFWTFGQGTKEIK	107
1.1.39	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYFWTFGQGTKEIK	107
1.1.17	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYPLTFGGGTKVEIK	107
1.1.24	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYFWTFGQGTKEIK	107
1.1.46	L	61	RFSGSGSGTEFTLTISSLQPEDFATYYC	LQHN	SYGYPPTFTFGGTKVEIK	107
			[CDR3]			

FIG. 57

SEQUENCE LISTING

<110> ABGENIX, INC.
 CORVALAN, Jose, R.F.
 JIA, Xiao-Chi
 FENG, Xiao
 YANG, Xiao-Dong
 CHEN, Francine
 GAZIT, Gadi
 WEBER, Richard
 BEZABEH, Binyam

<120> ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

<130> ABGENIX.051VPC

<140> US 10/041,860

<141> 2002-01-07

<160> 377

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 99

<212> PRT

<213> homo sapiens

<400> 1

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Asp	Ile	Asn	Trp	Val	Arg	Gln	Ala	Thr	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Trp	Met	Asn	Pro	Asn	Ser	Gly	Asn	Thr	Gly	Tyr	Ala	Gln	Lys	Phe
	50					55				60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asn	Thr	Ser	Ile	Ser	Thr	Ala	Tyr
65					70					75				80	
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Gly													

<210> 2

<211> 98

<212> PRT

<213> homo sapiens

<400> 2

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Trp	Ile	Ser	Ala	Tyr	Asn	Gly	Asn	Thr	Asn	Tyr	Ala	Gln	Lys	Leu
	50					55				60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Thr	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr

65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
Ala Arg

```
<210> 3
<211> 98
<212> PRT
<213> homo sapiens
```

<400> 3															
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly
1				5				10						15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Ser	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ser	Ser	Ile	Ser	Ser	Ser	Ser	Ser	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55					60				
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr
65					70					75					80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85						90					95	
Ala Arg															

```
<210> 4
<211> 98
<212> PRT
<213> homo sapiens
```

<400> 4															
Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Gly	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ala	Val	Ile	Trp	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55					60				
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70					75				80	
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala Arg															

```
<210> 5
<211> 97
<212> PRT
<213> homo sapiens
```

```

<400> 5
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1                               5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Asn
      20                               25 30

```

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg

<210> 6
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 6
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 7
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 7
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro
 85 90 95

<210> 8
 <211> 100
 <212> PRT
 <213> homo sapiens

<400> 8
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly


```

      1           5           10           15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20           25           30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35           40           45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85           90           95
Leu Gln Thr Pro
      100

```

<210> 9
 <211> 95
 <212> PRT
 <213> homo sapiens

```

<400> 9
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
      1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
      20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
      35           40           45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
      85           90           95

```

<210> 10
 <211> 96
 <212> PRT
 <213> homo sapiens

```

<400> 10
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
      1           5           10           15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
      20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35           40           45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
      50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
      65           70           75           80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
      85           90           95

```

<210> 11
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 11

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85           90           95

```

<210> 12
 <211> 381
 <212> PRT
 <213> homo sapiens

```

<400> 12
Pro Met His Arg Leu Ile Phe Val Tyr Thr Leu Ile Cys Ala Asn Phe
 1           5           10           15
Cys Ser Cys Arg Asp Thr Ser Ala Thr Pro Gln Ser Ala Ser Ile Lys
 20           25           30
Ala Leu Arg Asn Ala Asn Leu Arg Arg Asp Glu Ser Asn His Leu Thr
 35           40           45
Asp Leu Tyr Arg Arg Asp Glu Thr Ile Gln Val Lys Gly Asn Gly Tyr
 50           55           60
Val Gln Ser Pro Arg Phe Pro Asn Ser Tyr Pro Arg Asn Leu Leu Leu
 65           70           75           80
Thr Trp Arg Leu His Ser Gln Glu Asn Thr Arg Ile Gln Leu Val Phe
 85           90           95
Asp Asn Gln Phe Gly Leu Glu Glu Ala Glu Asn Asp Ile Cys Arg Tyr
 100          105          110
Asp Phe Val Glu Val Glu Asp Ile Ser Glu Thr Ser Thr Ile Ile Arg
 115          120          125
Gly Arg Trp Cys Gly His Lys Glu Val Pro Pro Arg Ile Lys Ser Arg
 130          135          140
Thr Asn Gln Ile Lys Ile Thr Phe Lys Ser Asp Asp Tyr Phe Val Ala
 145          150          155          160
Leu Ala Lys Pro Gly Phe Lys Ile Tyr Tyr Ser Leu Leu Glu Asp Phe
 165          170          175
Gln Pro Ala Ala Ala Ser Glu Thr Asn Trp Glu Ser Val Thr Ser Ser
 180          185          190
Ile Ser Gly Val Ser Tyr Asn Ser Pro Ser Val Thr Asp Pro Thr Leu
 195          200          205
Ile Ala Asp Ala Leu Asp Lys Lys Ile Ala Glu Phe Asp Thr Val Glu
 210          215          220
Asp Leu Leu Lys Tyr Phe Asn Pro Glu Ser Trp Gln Glu Asp Leu Glu
 225          230          235          240
Asn Met Tyr Leu Asp Thr Pro Arg Tyr Arg Gly Arg Ser Tyr His Asp
 245          250          255
Arg Lys Ser Lys Val Ala Ser Pro Leu Asp Arg Leu Asn Asp Asp Ala
 260          265          270
Lys Arg Tyr Ser Cys Thr Pro Arg Asn Tyr Ser Val Ala Ser Asn Ile
 275          280          285
Arg Glu Glu Leu Lys Leu Ala Asn Val Val Phe Phe Pro Arg Cys Leu
 290          295          300
Leu Val Gln Arg Cys Gly Glu Asn Cys Gly Cys Gly Thr Val Ala Ser
 305          310          315          320
Asn Trp Arg Ser Cys Thr Cys Asn Ser Gly Lys Thr Val Lys Lys Tyr

```

```

                325                330                335
His Glu Val Leu Gln Phe Glu Pro Gly His Ile Lys Arg Arg Gly Arg
                340                345                350
Ala Lys Thr Met Ala Leu Val Ala Ser Pro Ile Gln Leu Asp His His
                355                360                365
Glu Arg Cys Asp Cys Ile Cys Ser Ser Arg Pro Pro Arg
                370                375                380

```

<210> 13
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 13
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1                5                10                15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Arg Thr Tyr
                20                25                30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
                35                40                45
Ser Ser Ile Ser Ser Ser Ser Ser Asn Ile Tyr Tyr Ala Asp Ser Val
                50                55                60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65                70                75                80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                90                95
Ala Arg Asp Ile Met Ile Thr Phe Gly Gly Ile Ile Ala Ser Phe Tyr
                100                105                110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
                115                120                125

```

<210> 14
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 14
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1                5                10                15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
                20                25                30
Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
                35                40                45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
                50                55                60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65                70                75                80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
                85                90                95
Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
                100                105

```

<210> 15
 <211> 120
 <212> PRT
 <213> homo sapiens

<400> 15

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
 20 25 30
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Gly Thr Val Thr Thr Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 16
 <211> 111
 <212> PRT
 <213> homo sapiens

<400> 16
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 17
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 17
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Gln Gly Tyr Arg Tyr Ala Gly Tyr Tyr Tyr Asp Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

115

120

125

<210> 18
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 18
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 19
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 19
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Glu Gly Ile Ala Val Ala Gly Thr Tyr Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 20
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 20
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gln His Asn Ser Tyr Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 21
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 21
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Val Met Ile Thr Phe Gly Gly Val Ile Val His Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 22
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 22
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Asp Pro Cys
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Arg
 100 105

<210> 23
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 23

```

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1           5           10           15
Ser Leu Lys Ile Ser Cys Glu Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
          20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
          35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
          50           55           60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
          85           90           95
Ala Arg His Val Ser Tyr Tyr Tyr Val Ser Gly Ser Tyr Tyr Asn Val
          100          105          110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
          115          120          125

```

<210> 24

<211> 107

<212> PRT

<213> homo sapiens

<400> 24

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

<210> 25

<211> 126

<212> PRT

<213> homo sapiens

<400> 25

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
          20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35           40           45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
          50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg Asp Gln Gly Tyr Ser Tyr Gly Tyr Val Tyr Tyr Asp Tyr Gly
          100          105          110

```

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 26
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 26
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 27
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 27
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Gly Ser Tyr Tyr Tyr Gly Ser Glu Thr Tyr Tyr Asn Val
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 28
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 28
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile


```

          35          40          45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
   50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

<210> 29
 <211> 129
 <212> PRT
 <213> homo sapiens

```

<400> 29
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1          5          10          15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
          20          25          30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
          35          40          45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50          55          60
Gln Gly Gln Ala Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65          70          75          80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
          85          90          95
Ala Arg His Val Asp Val Gly Ala Thr Ile Gly Gly Tyr Tyr Tyr Tyr
          100          105          110
Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
          115          120          125
Ser

```

<210> 30
 <211> 113
 <212> PRT
 <213> homo sapiens

```

<400> 30
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80
Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Ser Leu Met Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile
          100          105          110
Lys

```

<210> 31
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 31
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp His Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr
 100 105 110
 Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 32
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 32
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 33
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 33
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Ile Ile Trp Tyr Asp Gly Asn Asp Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

```

65          70          75          80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95
Ala Arg Gly Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr
          100          105          110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
          115          120          125

```

<210> 34
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 34
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1          5          10          15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile
          35          40          45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Val Ala Ala Tyr Tyr Cys Gln Lys Cys Asn Ser Ala Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Thr Val Glu Ile Lys
          100          105

```

<210> 35
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 35
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
1          5          10          15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
          20          25          30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
          35          40          45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
          50          55          60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65          70          75          80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
          85          90          95
Ala Arg His Gly Ser Tyr Tyr Tyr Asn Ser Gly Ser Tyr Tyr Asn Val
          100          105          110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
          115          120          125

```

<210> 36
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 36

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

<210> 37
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
          20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Leu Ser Thr Ala Tyr
65          70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg Asp Ile Val Val Val Val Ala Ala Thr Asn Tyr Tyr Asn Gly
          100          105          110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
          115          120          125

```

<210> 38
 <211> 125
 <212> PRT
 <213> homo sapiens

```

<400> 38
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65          70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg Gly Ser Gly Tyr Ser Tyr Gly Tyr Asp Tyr Tyr Tyr Gly Met
          100          105          110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

```

115

120

125

<210> 39
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 39
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Gly Ile Ser Asn Asp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Leu Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 40
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 40
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Asn Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Thr Ala Thr Asp Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 41
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 41
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45

Phe Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Ser Gly Tyr Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 42
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 42
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Val Glu Tyr Tyr Tyr Asp Gly Ser Gly Tyr Tyr Tyr Phe
 100 105 110
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 43
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 43
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ser Asn Ser Phe Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 44
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 44

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asp Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg Met Arg Asp Ile Val Ala Thr Ser Tyr Tyr Tyr Tyr Phe Tyr
 100 105 110
 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 45

<211> 111

<212> PRT

<213> homo sapiens

<400> 45

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Leu Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
 85 90 95
 Leu Gln Thr Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
 100 105 110

<210> 46

<211> 126

<212> PRT

<213> homo sapiens

<400> 46

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Lys Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Tyr Asp Tyr Val Trp Arg Asn Tyr Arg Tyr Thr Gly Trp
 100 105 110

Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 47
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 47
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
 85 90 95
 Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 48
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95
 Val Arg Gly Phe Gly Tyr Ser Tyr Asn Tyr Asp Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 49
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 49
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu


```
<210> 52
<211> 24
<212> DNA
<213> homo sapiens
```

<400> 52
 gctgaggag tagagtcctg agga 24

<210> 53
 <211> 19
 <212> DNA
 <213> homo sapiens

<400> 53
 cacaccgcgg tcacatggc 19

<210> 54
 <211> 20
 <212> DNA
 <213> homo sapiens

<400> 54
 ctactctagg gcacctgtcc 20

<210> 55
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 55
 gaggtgcagc tgggtggagtc tgggggaggc ctggtcaagc ctgggggggtc cctgagactc 60
 tcctgtgcag cctctggatt caacttcaga acctataaca tgaactgggt ccgccaggct 120
 ccagggaagg ggtctgagtg ggtctcatcc attagtagta gtagtagtaa catatactac 180
 gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctactgtat 240
 ctgcaaatac acagcctgag agccgaggac acggctgtat attactgtgc gagagatatt 300
 atgattacgt ttgggggaat tatcgctcgt ttctactttg actactgggg ccagggaacc 360
 ctggtcaccg tctcctcag 379

<210> 56
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 56
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtttca gcagaaacca 120
 gggaaagccc ctaagcgctt gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtctacag cataatagtt acccgctcac tttcggcgga 300
 gggaccaagg tggagatcaa ac 322

<210> 57
 <211> 361
 <212> DNA
 <213> homo sapiens

<400> 57
 gaggtgcagc tgggtgcagtc tggaggaggc ttgatccagc ctgggggggtc cctgagactc 60
 tcctgtgcag cctctgggtt caccgtcagt agcaactaca tgagctgggt ccgccaggct 120
 ccagggaagg ggtctgagtg ggtctcagtt atttatagcg gtggtagcac atactacgca 180
 gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gctgtatctt 240
 caaatgaaca gcctgagagc cgaggacacg gccgtgtatt actgtgcggg aacggtgact 300
 acgaattact actacggtat ggacgtctgg ggccaaggga ccacggtcac cgtctcctca 360
 g 361

<210> 58
 <211> 334
 <212> DNA
 <213> homo sapiens

<400> 58
 gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
 atctcctgca ggtctagtca gagcctcctg caaagtaatg gatacaacta tttggattgg 120
 tacctgcaga agccagggca gtctccacag ctctgatct atttgggttc taatcgggcc 180
 tccgggggtcc ctgacagggt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
 agcagagtgg aggctgagga tgttgggggt tattactgca tgcaagctct acaactctc 300
 actttcggcg gagggaccaa ggtggagatc aaac 334

<210> 59
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 59
 caggtgcagc tgggtggagtc ggggggagggc gtggtccagc ctgggaagtc cctgagactc 60
 tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
 ccaggcaagg ggctggagtg ggtggcagtt atatgggatg atggaagtaa taaatactat 180
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
 ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatcaa 300
 ggatacagat atgctgggta ctactacgac tacggtatgg acgtctgggg ccaagggacc 360
 acggtcaccg tctcctcag 379

<210> 60
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 60
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gggcattaga aatgatthag gctggtatca gcagaaacca 120
 gggaaagccc ctaagcgccct gatctatgct gcaccagtt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtggatc tgggacagaa ttactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtctacag cataatagtt acccgctcac tttcggcgga 300
 gggaccaagg tggagatcaa ac 322

<210> 61
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 61
 caggtgcagc tgggtgcagtc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120
 actggacaag ggcttgagtg gatgggatgg atgaaccaa acagtggtaa cacaggctat 180
 gcacagaagt tccagggcag agtcaccatg accaggaaca cctccataag cacagcctac 240
 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagagggt 300
 atagcagtgg ctgggacata ctactactac tacggtatgg acgtctgggg ccaagggacc 360
 acggtcaccg tctcctcag 379

<210> 62
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 62
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60

```

atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagcgccct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
agggttcagcg gcagtggtatc tgggacagaa ttcaactctca caatcagcag cctgcagcct 240
gaagattttg caacttattt ctgtctacag cataatagtt acccattcac tttcggccct 300
gggaccaaaag tggatatcaa ac 322

```

<210> 63
 <211> 379
 <212> DNA
 <213> homo sapiens

```

<400> 63
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120
actggacaag ggcttgagtg gatgggatgg atgaacccta acagtggtaa cacaggctat 180
gcacagaagt tccagggcag agtcaccatg accaggaaca cctccataag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagacgtt 300
atgattacgt ttgggggagt tatcgtgcac tacgggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctcag 379

```

<210> 64
 <211> 322
 <212> DNA
 <213> homo sapiens

```

<400> 64
gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagcgccct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
agggttcagcg gcagtggtatc tgggacagat ttcaactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacag cataatagtg acccgtgcag ttttggccag 300
gggaccaagc tggagatcag ac 322

```

<210> 65
 <211> 379
 <212> DNA
 <213> homo sapiens

```

<400> 65
gaggtgcagc tgggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60
tcctgtgagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120
cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180
agcccgctct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240
ctgcagtgga gcagcctgaa ggcctcggac accgcatgt attactgtgc gagacatgta 300
tcgtattact atgtttcggg gagttattat aacgtctttg actactgggg ccaggggaacc 360
ctggtcaccg tctcctcag 379

```

<210> 66
 <211> 322
 <212> DNA
 <213> homo sapiens

```

<400> 66
gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagatacca 120
gggaaagccc ctaagcgccct gatctatgct gcatccagtt tgcaactggg ggtcccatca 180
agggttcagcg gcagtggtatc tgggacagaa ttcaactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacag cataatagtt acccgtggac gttcggccaa 300
gggaccaagc tggaaatcaa ac 322

```

<210> 67

<211> 379
 <212> DNA
 <213> homo sapiens

<400> 67
 cagggtgcagc tgggtggagtc tgggggaggc gtgggtccagc ctgggaggtc cctgagactc 60
 tcctgtgcag cgtctggatt cagtttcagt agctatggca tgcactgggt ccgccaggct 120
 ccaggcaagg ggctggagtg ggtggcagat atatggtatg atggaagtaa taaatactat 180
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cagctgtat 240
 ctgcaaatac acagcctgag agccgaggac acggctgtgt attattgtgc gagagatcag 300
 ggatacagct atggtttacgt ctactacgac tacggtatgg acgtctgggg ccaagggacc 360
 acggtcaccg tctcctcag 379

<210> 68
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 68
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gggcattaga aatgatttag gctgggtatca gcagaaacca 120
 gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtggatc tgggacagag ttactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtctacag cataatagtt acccgtaggac gttcggccaa 300
 gggaccaagg tggaaatcaa ac 322

<210> 69
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 69
 gaggtgcagc tgggtgcagtc gggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60
 tcctgtaagg gttctggata caggtttacc agctactgga tcggctgggt gcgccagatg 120
 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180
 agcccgctcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240
 ctgcagtggg gcagcctgaa ggcctcggac accgcatgt attactgtgc gagacatgga 300
 tcgtattatt atggttcgga gacttattat aatgtctttg actactgggg ccagggaacc 360
 ctggtcaccg tctcctcag 379

<210> 70
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 70
 gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gggcattaga aatgatttag gctgggtatca gcagaaacca 120
 gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtggatc tgggacagaa ttactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtctacag cataatagtt acccgtaggac gttcggccaa 300
 gggaccaagg tggaaatcaa ac 322

<210> 71
 <211> 388
 <212> DNA
 <213> homo sapiens

<400> 71
 gaggtgcagc tgggtgcagtc gggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60
 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120

```

ccccggaaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180
agcccgtcct tccaaggcca ggccaccatc tcagccgaca agtccatcag caccgcctac 240
ctgcagtggg gcagcctgaa ggcctcggac accgccatgt attactgtgc gagacacgtg 300
gatgtagggg ctacgattgg gggatattac tattactacc acggtatgga cgtctggggc 360
caagggacca cggtcaccgt ctcctcag                                     388

```

<210> 72
 <211> 340
 <212> DNA
 <213> homo sapiens

```

<400> 72
gatattgtga tgactcagtc tccaactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtc gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctctgatct atttgggttc taatcggggc 180
tccgggggtcc ctgacagggt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgacga tgttgggggt tattactgca tgcaagctct acaatctctc 300
atgtgcagtt ttggccaggg gaccaagctg gagatcaaac                                     340

```

<210> 73
 <211> 382
 <212> DNA
 <213> homo sapiens

```

<400> 73
caggttcagc tgggtcagtc gggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc agctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagatcat 300
tactatgata gtagtgatta tctctactac tactacgggt tggacgtctg gggccaaggg 360
accacgggtca ccgtctcctc ag                                     382

```

<210> 74
 <211> 322
 <212> DNA
 <213> homo sapiens

```

<400> 74
gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcgagtc gggcattagc aattatttag cctggtatca gcagaaacca 120
gggaaagttc ctaagctcct gatctatgct gcattccact tgcaatcagg ggtcccatct 180
cggttcagtg gcagtggatc tgggacagat ttcaactctc ccatcagcag cctgcagcct 240
gaagatgttg caacttatta ctgtcaaaaag tataacagtg ccccgctcac tttcggcgga 300
gggaccaagg tggagatcaa ac                                     322

```

<210> 75
 <211> 382
 <212> DNA
 <213> homo sapiens

```

<400> 75
caggtgcagc tgggtggagtc ggggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcaatt atatgggatg atggaaatga taaatactat 180
gcagactccg tgaagggccg ctccaccgtc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagaggatat 300
tactatgata gtagtgatta tctctactac tactacggta tggacgtctg gggccaaggg 360
accacgggtca ccgtctcctc ag                                     382

```

<210> 76

<211> 322
 <212> DNA
 <213> homo sapiens

<400> 76
 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcgagtca gggcattagc aattatttag cctggtatca gcagaaacca 120
 gggaaagtcc ctaacctcct gatctatgct gcatccactt tgcaatcagg ggtcccatct 180
 cgggttcagt gcatggatc tgggacagat ttctctctca ccatcagcag cctgcagcct 240
 gaagatgttg cagcttatta ctgtcaaaaag tgtaacagtg ccccgtaggac gttcggccaa 300
 gggaccacgg tggagatcaa ac 322

<210> 77
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 77
 gaggtgcagc tgggtgcagtc gggaacagag gtgaaaaagc ccggggagtc tctgaagatc 60
 tcctgtaagg gttctggata cagggtttacc agctactgga tcggctgggt gcgccagatg 120
 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga taccagatac 180
 agcccgctct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240
 ctgcagtggg gcagcctgaa ggcctcggac accgccatgt attactgtgc gagacatgga 300
 tcgtattact ataattcggg gaggttattat aacgtctttg actactgggg ccagggaacc 360
 ctggtcaccg tctcctcag 379

<210> 78
 <211> 322
 <212> DNA
 <213> homo sapiens

<400> 78
 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca 120
 gggaaagccc ctaagcgctt gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtgatc tgggacagaa ttactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtctacag cataatagtt acccgtaggac gttcggccaa 300
 gggaccaagg tggaaatcaa ac 322

<210> 79
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 79
 cagggtgcagc tgggtgcagtc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc acttatgata tcaactgggt gcgacaggcc 120
 actggacaag ggcttgagtg gatgggatgg atgaacccta acagtggtaa cacaggctat 180
 gcacagaagt tccagggcag agtcaccatg accaggaaca cctccctaag cacagcctac 240
 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatatt 300
 gtagtggtgg tagctgctac caactactac aacggtatgg acgtctgggg ccaaggggacc 360
 acggtcaccg tctcctcag 379

<210> 80
 <211> 376
 <212> DNA
 <213> homo sapiens

<400> 80
 cagggtgcagc tgggtgcagtc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120

```

actggacaag ggcttgagtg gatgggatgg atgaacccta acagtggtaa cacaggctat 180
gcacagaagt tccagggcag agtcaccatg accaggaaca cctccataag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggcagt 300
ggatacagct atggttacga ctactactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctcag                                     376

```

<210> 81
 <211> 322
 <212> DNA
 <213> homo sapiens

```

<400> 81
gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcaattgcc gggcgagtca gggcattagc aatgatttag cctgggtatca gcagaaacca 120
gggaaagtgc ctaagctcct gatctatgct gcatccactt tgcaattagg ggtcccatct 180
cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
gaagatgttg caacttatta ctgtcaaaaag tataacagtg ccccatcac tttcggccct 300
gggaccaaag tggatatcaa ac                                     322

```

<210> 82
 <211> 379
 <212> DNA
 <213> homo sapiens

```

<400> 82
caggtgcagc tgggtgcagtc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata ctccctcacc agttatgata tcaactgggt gcgacaggcc 120
actggacaag ggcttgagtg gatgggatgg atgaacccta acaatggtaa cacaggctat 180
gcacagaagt tccagggcag agtcaccatg accaggaaca cctccataag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatatt 300
gtagtgtgtg taactgctac ggactactac tacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctcag                                     379

```

<210> 83
 <211> 322
 <212> DNA
 <213> homo sapiens

```

<400> 83
gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca gggcattaga aatgatttag gctgggtatca gcagaaacca 120
gggaaagccc ctaagcgcct gatttttgcct gcatccagtt tgccaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacag catagtgggt accctccgac gttcggccaa 300
gggaccaagg tggaatcaa ac                                     322

```

<210> 84
 <211> 376
 <212> DNA
 <213> homo sapiens

```

<400> 84
caggttcagc tgggtgcagtc gggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctgggta cacctttacc agctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcgctt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagatgtt 300
gaatattact atgatggtag tggttattac tactttgact actggggcca gggaaacctg 360
gtcaccgtct cctcag                                     376

```

<210> 85

<211> 322
 <212> DNA
 <213> homo sapiens

<400> 85
 gacatccaga tgacccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
 atcacttgtc gggcgagtc gggattagc agctggtag cctggatca gcagaaacca 120
 gggaaagccc ctaagctcct gatctatgct gcatccattt tgcaaagtgg ggtcccatca 180
 aggttcagcg gcagtgatc tgggacagat ttcactctca ccatcagcag cctgcagcct 240
 gaggattttg catcttacta ttgtcaacag tctaacagtt tccctcggac gttcggccaa 300
 gggaccaagg tggagatcaa ac 322

<210> 86
 <211> 382
 <212> DNA
 <213> homo sapiens

<400> 86
 caggtgcagc tgggtgcagtc gggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120
 actggacaag ggtttgagtg gatgggatgg atgaacccta acagtgggtga cacaggctat 180
 gcacagaagt tccagggcag agtcaccatg accaggaaca cctccataag cacagcctac 240
 atggagctga gcagcctgag atctgaggac acggccgtgt atttctgtgc gagaatgagg 300
 gatatagtgg ctacgagcta ttactactac ttctacggta tggacgtctg gggccaaggg 360
 accacggtca ccgtctcctc ag 382

<210> 87
 <211> 334
 <212> DNA
 <213> homo sapiens

<400> 87
 gatattgtga tgactcagtc tccactctcc ctgcccgta cccctggaga gccggcctcc 60
 atctcctgca ggtctagtc gagcctcctg catagtaatg gatacaacta tttggattgg 120
 tacctgctga agccagggca gtctccacag ctctgatct atttgggttc tagtcgggcc 180
 tccggggctc ctgacagggt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
 agcagagtgg aggctgagga tgttgggggt tattactgca tgcaaactct acaaactatc 300
 accttcggcc aagggacacg actggagatt aaac 334

<210> 88
 <211> 379
 <212> DNA
 <213> homo sapiens

<400> 88
 gaggtgcagc tgggtgcagtc gggagctgag gtgaaaaagc ccggggagtc tctgaagatc 60
 tcctgtaagg gttctggata cagctttacc agctactgga tcggctgggt gcgccagatg 120
 cccgggaaag gcctggagtg gatggggatc atctatcctg gtgactctga tgccaaatac 180
 agcccgctcct tccaaggcca ggtcaccatc tcagccgaca agtccatcag caccgcctac 240
 ctgcagtgga gcagcctgaa ggcctcggac accgcatgt attactgtgc gagacactat 300
 gattacgttt ggaggaatta tcggtataca ggggtggttcg acccctgggg ccagggaacc 360
 ctggtcaccg tctcctcag 379

<210> 89
 <211> 325
 <212> DNA
 <213> homo sapiens

<400> 89
 gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
 ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa 120

```

cctggccagg ctcccaggct cctcatctat ggtgcatcca acagggccac tggcatccca 180
gacagggttca gtggcagtggt gtctgggaca gacttcactc tcaccatcag cagactggag 240
cctgaagatt ttgcagtgtg ttactgtcag cagtatggta gctcactatt cactttcggc 300
cctgggacca aagtggatat caaac 325

```

```

<210> 90
<211> 377
<212> DNA
<213> homo sapiens

```

```

<400> 90
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata caccttcacc agttatgata tcaactgggt gcgacaggcc 120
actggacaag ggcttgagtg gatgggatgg ataaacccta atagtggtaa cacagactat 180
gcacagaagt tccagggcag agtcaccatg accagggaca cctccataag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccatat attattgtgt gagaggcttt 300
ggatacagct ataattacga ctactattac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctcagt 377

```

```

<210> 91
<211> 325
<212> DNA
<213> homo sapiens

```

```

<400> 91
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagt agtagttact tagcctggta ccagcagaag 120
cctggccagg ctcccaggct cctcatctat gctacatcca gcagggccac tggcatccca 180
gacagggttca gtggcagtggt gtctgggaca gacttcactc tcaccatcag cagactggag 240
cctgaagatt ttgcagtgtg ttactgtcag cagtatggta gttcaccgtg cagttttggc 300
caggggacca agctggaaat caagc 325

```

```

<210> 92
<211> 6
<212> DNA
<213> homo sapiens

```

```

<400> 92
cgagag 6

```

```

<210> 93
<211> 28
<212> DNA
<213> homo sapiens

```

```

<400> 93
ttatgattac gtttggggga gttatcgt 28

```

```

<210> 94
<211> 6
<212> DNA
<213> homo sapiens

```

```

<400> 94
actacg 6

```

```

<210> 95
<211> 6
<212> DNA
<213> homo sapiens

```

<400> 95 gagagg	6
<210> 96 <211> 12 <212> DNA <213> homo sapiens	
<400> 96 tggatacagc ta	12
<210> 97 <211> 8 <212> DNA <213> homo sapiens	
<400> 97 attactac	8
<210> 98 <211> 6 <212> DNA <213> homo sapiens	
<400> 98 ttaccc	6
<210> 99 <211> 6 <212> DNA <213> homo sapiens	
<400> 99 gtgcag	6
<210> 100 <211> 6 <212> DNA <213> homo sapiens	
<400> 100 ttttgg	6
<210> 101 <211> 6 <212> DNA <213> homo sapiens	
<400> 101 ctcacc	6
<210> 102 <211> 6 <212> DNA <213> homo sapiens	
<400> 102 gtgcag	6
<210> 103 <211> 6	

<212> DNA
<213> homo sapiens

<400> 103
tttttg 6

<210> 104
<211> 6
<212> DNA
<213> homo sapiens

<400> 104
gagaga 6

<210> 105
<211> 22
<212> DNA
<213> homo sapiens

<400> 105
tattatgatt acgtttgggg ga 22

<210> 106
<211> 14
<212> DNA
<213> homo sapiens

<400> 106
attatcgctt cggt 14

<210> 107
<211> 6
<212> DNA
<213> homo sapiens

<400> 107
ctactt 6

<210> 108
<211> 5
<212> DNA
<213> homo sapiens

<400> 108
agaga 5

<210> 109
<211> 10
<212> DNA
<213> homo sapiens

<400> 109
acggtgacta 10

<210> 110
<211> 5
<212> DNA
<213> homo sapiens

<400> 110
cgaat 5

<210> 111
<211> 7
<212> DNA
<213> homo sapiens

<400> 111
tactact

7

<210> 112
<211> 6
<212> DNA
<213> homo sapiens

<400> 112
gagaca

6

<210> 113
<211> 18
<212> DNA
<213> homo sapiens

<400> 113
tgtatcgtat tactatgt

18

<210> 114
<211> 19
<212> DNA
<213> homo sapiens

<400> 114
ttcggggagt tattataac

19

<210> 115
<211> 6
<212> DNA
<213> homo sapiens

<400> 115
ctttga

6

<210> 116
<211> 6
<212> DNA
<213> homo sapiens

<400> 116
ttaccc

6

<210> 117
<211> 7
<212> DNA
<213> homo sapiens

<400> 117
gctcact

7

<210> 118
<211> 6
<212> DNA
<213> homo sapiens

<400> 118 aaactc	6
<210> 119 <211> 8 <212> DNA <213> homo sapiens	
<400> 119 tcactttc	8
<210> 120 <211> 6 <212> DNA <213> homo sapiens	
<400> 120 ttaccc	6
<210> 121 <211> 6 <212> DNA <213> homo sapiens	
<400> 121 gagaga	6
<210> 122 <211> 7 <212> DNA <213> homo sapiens	
<400> 122 ggataca	7
<210> 123 <211> 9 <212> DNA <213> homo sapiens	
<400> 123 atatgctgg	9
<210> 124 <211> 8 <212> DNA <213> homo sapiens	
<400> 124 ttactact	8
<210> 125 <211> 6 <212> DNA <213> homo sapiens	
<400> 125 cgagag	6
<210> 126	

<211> 18
<212> DNA
<213> homo sapiens

<400> 126
gggtatagca gtggctgg 18

<210> 127
<211> 6
<212> DNA
<213> homo sapiens

<400> 127
tactac 6

<210> 128
<211> 6
<212> DNA
<213> homo sapiens

<400> 128
gagaga 6

<210> 129
<211> 18
<212> DNA
<213> homo sapiens

<400> 129
ggatacagct atggttac 18

<210> 130
<211> 6
<212> DNA
<213> homo sapiens

<400> 130
ctacta 6

<210> 131
<211> 6
<212> DNA
<213> homo sapiens

<400> 131
gagaca 6

<210> 132
<211> 6
<212> DNA
<213> homo sapiens

<400> 132
tggatc 6

<210> 133
<211> 30
<212> DNA
<213> homo sapiens

<400> 133

gtattattat gggtcggaga cttattataa

30

<210> 134

<211> 6

<212> DNA

<213> homo sapiens

<400> 134

ctttga

6

<210> 135

<211> 6

<212> DNA

<213> homo sapiens

<400> 135

gagaca

6

<210> 136

<211> 21

<212> DNA

<213> homo sapiens

<400> 136

gtggatgtag gggctacgat t

21

<210> 137

<211> 6

<212> DNA

<213> homo sapiens

<400> 137

ggggat

6

<210> 138

<211> 8

<212> DNA

<213> homo sapiens

<400> 138

attactac

8

<210> 139

<211> 6

<212> DNA

<213> homo sapiens

<400> 139

gagaga

6

<210> 140

<211> 18

<212> DNA

<213> homo sapiens

<400> 140

attactatga tagtagtg

18

<210> 141

<211> 7

<212> DNA

<213> homo sapiens

<400> 141
attatct

7

<210> 142
<211> 6
<212> DNA
<213> homo sapiens

<400> 142
ctacta

6

<210> 143
<211> 6
<212> DNA
<213> homo sapiens

<400> 143
cgagag

6

<210> 144
<211> 19
<212> DNA
<213> homo sapiens

<400> 144
tattactatg atagtagtg

19

<210> 145
<211> 7
<212> DNA
<213> homo sapiens

<400> 145
attatct

7

<210> 146
<211> 6
<212> DNA
<213> homo sapiens

<400> 146
ctacta

6

<210> 147
<211> 6
<212> DNA
<213> homo sapiens

<400> 147
gagaca

6

<210> 148
<211> 6
<212> DNA
<213> homo sapiens

<400> 148
tggatc

6

<210> 149
<211> 31
<212> DNA
<213> homo sapiens

<400> 149
gtattactat aattcgggga gttattataa c 31

<210> 150
<211> 6
<212> DNA
<213> homo sapiens

<400> 150
ctttga 6

<210> 151
<211> 6
<212> DNA
<213> homo sapiens

<400> 151
cgagag 6

<210> 152
<211> 25
<212> DNA
<213> homo sapiens

<400> 152
atattgtagt ggtggtagct gctac 25

<210> 153
<211> 6
<212> DNA
<213> homo sapiens

<400> 153
actact 6

<210> 154
<211> 6
<212> DNA
<213> homo sapiens

<400> 154
gagagg 6

<210> 155
<211> 20
<212> DNA
<213> homo sapiens

<400> 155
gtggatacag ctatggttac 20

<210> 156
<211> 6
<212> DNA
<213> homo sapiens

<400> 156 actact	6
<210> 157 <211> 6 <212> DNA <213> homo sapiens	
<400> 157 cgagag	6
<210> 158 <211> 25 <212> DNA <213> homo sapiens	
<400> 158 atattgtagt ggtggtagct gctac	25
<210> 159 <211> 6 <212> DNA <213> homo sapiens	
<400> 159 actact	6
<210> 160 <211> 6 <212> DNA <213> homo sapiens	
<400> 160 cgagag	6
<210> 161 <211> 7 <212> DNA <213> homo sapiens	
<400> 161 tgttgaa	7
<210> 162 <211> 24 <212> DNA <213> homo sapiens	
<400> 162 tattactatg atggtagtgg ttat	24
<210> 163 <211> 6 <212> DNA <213> homo sapiens	
<400> 163 actact	6
<210> 164 <211> 6	

<212> DNA
<213> homo sapiens

<400> 164
gcgaga

6

<210> 165
<211> 5
<212> DNA
<213> homo sapiens

<400> 165
atgag

5

<210> 166
<211> 17
<212> DNA
<213> homo sapiens

<400> 166
ggatatagtg gctacga

17

<210> 167
<211> 8
<212> DNA
<213> homo sapiens

<400> 167
attactac

8

<210> 168
<211> 6
<212> DNA
<213> homo sapiens

<400> 168
gagaca

6

<210> 169
<211> 31
<212> DNA
<213> homo sapiens

<400> 169
tatgattacg tttggaggaa ttatcggtat a

31

<210> 170
<211> 5
<212> DNA
<213> homo sapiens

<400> 170
caggg

5

<210> 171
<211> 6
<212> DNA
<213> homo sapiens

<400> 171
tggttc

6

<210> 172
<211> 6
<212> DNA
<213> homo sapiens

<400> 172
ttaccc

6

<210> 173
<211> 7
<212> DNA
<213> homo sapiens

<400> 173
gctcact

7

<210> 174
<211> 6
<212> DNA
<213> homo sapiens

<400> 174
ttaccc

6

<210> 175
<211> 6
<212> DNA
<213> homo sapiens

<400> 175
attcac

6

<210> 176
<211> 6
<212> DNA
<213> homo sapiens

<400> 176
ttaccc

6

<210> 177
<211> 6
<212> DNA
<213> homo sapiens

<400> 177
gtggac

6

<210> 178
<211> 6
<212> DNA
<213> homo sapiens

<400> 178
ttaccc

6

<210> 179
<211> 6
<212> DNA
<213> homo sapiens

<400> 179 gtggac	6
<210> 180 <211> 6 <212> DNA <213> homo sapiens	
<400> 180 ctacaa	6
<210> 181 <211> 14 <212> DNA <213> homo sapiens	
<400> 181 tctctcatgt gcag	14
<210> 182 <211> 6 <212> DNA <213> homo sapiens	
<400> 182 ttttgg	6
<210> 183 <211> 6 <212> DNA <213> homo sapiens	
<400> 183 tgcccc	6
<210> 184 <211> 6 <212> DNA <213> homo sapiens	
<400> 184 gctcac	6
<210> 185 <211> 6 <212> DNA <213> homo sapiens	
<400> 185 tgcccc	6
<210> 186 <211> 6 <212> DNA <213> homo sapiens	
<400> 186 gtggac	6
<210> 187	

<211> 6
<212> DNA
<213> homo sapiens

<400> 187
ttaccc

6

<210> 188
<211> 6
<212> DNA
<213> homo sapiens

<400> 188
gtggac

6

<210> 189
<211> 6
<212> DNA
<213> homo sapiens

<400> 189
tgcccc

6

<210> 190
<211> 6
<212> DNA
<213> homo sapiens

<400> 190
attcac

6

<210> 191
<211> 6
<212> DNA
<213> homo sapiens

<400> 191
ccctcc

6

<210> 192
<211> 6
<212> DNA
<213> homo sapiens

<400> 192
gacgtt

6

<210> 193
<211> 6
<212> DNA
<213> homo sapiens

<400> 193
tccttc

6

<210> 194
<211> 7
<212> DNA
<213> homo sapiens

<400> 194

ggacggtt

7

<210> 195
 <211> 6
 <212> DNA
 <213> homo sapiens

<400> 195
 caaact

6

<210> 196
 <211> 6
 <212> DNA
 <213> homo sapiens

<400> 196
 atcacc

6

<210> 197
 <211> 6
 <212> DNA
 <213> homo sapiens

<400> 197
 gctcac

6

<210> 198
 <211> 6
 <212> DNA
 <213> homo sapiens

<400> 198
 attcac

6

<210> 199
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 199
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Val Met Ile Thr Phe Gly Gly Val Ile Val His Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 200
 <211> 125
 <212> PRT

<213> homo sapiens

<400> 200

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
      35           40           45
Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe
      50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
      85           90           95
Val Arg Gly Phe Gly Tyr Ser Tyr Asn Tyr Asp Tyr Tyr Tyr Gly Met
      100          105          110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 201

<211> 126

<212> PRT

<213> homo sapiens

<400> 201

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
      35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
      50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg Glu Gly Ile Ala Val Ala Gly Thr Tyr Tyr Tyr Tyr Tyr Gly
      100          105          110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 202

<211> 126

<212> PRT

<213> homo sapiens

<400> 202

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
      20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
      35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
      50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Leu Ser Thr Ala Tyr
      65           70           75           80

```

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Ala Ala Thr Asn Tyr Tyr Asn Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 203
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 203
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Ser Gly Tyr Ser Tyr Gly Tyr Asp Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 204
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 204
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Asn Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Thr Ala Thr Asp Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 205
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 205

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asp Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg Met Arg Asp Ile Val Ala Thr Ser Tyr Tyr Tyr Tyr Phe Tyr
 100 105 110
 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 206

<211> 117

<212> PRT

<213> homo sapiens

<400> 206

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp His Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr
 100 105 110
 Gly Leu Asp Val Trp
 115

<210> 207

<211> 125

<212> PRT

<213> homo sapiens

<400> 207

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Asp Val Glu Tyr Tyr Tyr Asp Gly Ser Gly Tyr Tyr Tyr Phe
 100 105 110
 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 208
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 208
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Arg Thr Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Ser Ser Ser Ser Asn Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Met Ile Thr Phe Gly Gly Ile Ile Ala Ser Phe Tyr
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 209
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 209
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Gln Gly Tyr Arg Tyr Ala Gly Tyr Tyr Tyr Asp Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 210
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 210
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

```

      1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg Asp Gln Gly Tyr Ser Tyr Gly Tyr Val Tyr Tyr Asp Tyr Gly
      100          105          110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 211
 <211> 127
 <212> PRT
 <213> homo sapiens

```

<400> 211
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
      1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Ile Ile Trp Tyr Asp Gly Asn Asp Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg Gly Tyr Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr
      100          105          110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 212
 <211> 120
 <212> PRT
 <213> homo sapiens

```

<400> 212
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
      1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
      20           25           30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
      50           55           60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
      65           70           75           80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
      85           90           95
Gly Thr Val Thr Thr Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln
      100          105          110

```

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 213
<211> 130
<212> PRT
<213> homo sapiens

<400> 213
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Glu Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Glu Val Gln Leu
50 55 60
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile
65 70 75 80
Ser Cys Glu Gly Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Ile Gly Trp
85 90 95
Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr
100 105 110
Pro Gly Asp Ser Asp Thr Arg Tyr Gly Gln Gly Thr Leu Val Thr Val
115 120 125
Ser Ser
130

<210> 214
<211> 126
<212> PRT
<213> homo sapiens

<400> 214
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg His Gly Ser Tyr Tyr Tyr Gly Ser Glu Thr Tyr Tyr Asn Val
100 105 110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 215
<211> 129
<212> PRT
<213> homo sapiens

<400> 215
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu

```

      1           5           10           15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50           55           60
Gln Gly Gln Ala Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85           90           95
Ala Arg His Val Asp Val Gly Ala Thr Ile Gly Gly Tyr Tyr Tyr Tyr
      100          105          110
Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
      115          120          125
Ser

```

<210> 216
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 216
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
      1           5           10           15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
      20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50           55           60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85           90           95
Ala Arg His Gly Ser Tyr Tyr Tyr Asn Ser Gly Ser Tyr Tyr Asn Val
      100          105          110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115          120          125

```

<210> 217
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 217
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
      1           5           10           15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Lys Tyr Ser Pro Ser Phe
      50           55           60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85           90           95

```

Ala Arg His Tyr Asp Tyr Val Trp Arg Asn Tyr Arg Tyr Thr Gly Trp
 100 105 110
 Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 218
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 218
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ser Asn Ser Phe Pro Arg
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 219
 <211> 111
 <212> PRT
 <213> homo sapiens

<400> 219
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Leu Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
 85 90 95
 Leu Gln Thr Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
 100 105 110

<210> 220
 <211> 111
 <212> PRT
 <213> homo sapiens

<400> 220
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser


```

          35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
  50          55          60
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
  65          70          75          80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
          100          105          110

```

<210> 221
 <211> 113
 <212> PRT
 <213> homo sapiens

```

<400> 221
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
  50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
  65          70          75          80
Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Ser Leu Met Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile
          100          105          110
Lys

```

<210> 222
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 222
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1          5          10          15
Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Gly Ile Ser Asn Asp
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
          35          40          45
Tyr Ala Ala Ser Thr Leu Gln Leu Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
  65          70          75          80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe
          85          90          95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
          100          105

```

<210> 223
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 223

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35           40           45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Leu
85           90           95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100           105

```

<210> 224

<211> 107

<212> PRT

<213> homo sapiens

<400> 224

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile
35           40           45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50           55           60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Val Ala Ala Tyr Tyr Cys Gln Lys Cys Asn Ser Ala Pro Trp
85           90           95
Thr Phe Gly Gln Gly Thr Thr Val Glu Ile Lys
100           105

```

<210> 225

<211> 108

<212> PRT

<213> homo sapiens

<400> 225

```

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1           5           10           15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35           40           45
Ile Tyr Ala Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65           70           75           80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85           90           95
Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100           105

```

<210> 226
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 226
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
 85 90 95
 Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 227
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 227
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Asp Pro Cys
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Arg
 100 105

<210> 228
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 228
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gln His Asn Ser Tyr Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 229
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 229
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 230
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 230
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 231
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 231
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile

```

      35              40              45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
  50              55              60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
  65              70              75              80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
      85              90              95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100              105

```

<210> 232
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 232
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1              5              10              15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20              25              30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35              40              45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50              55              60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65              70              75              80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
      85              90              95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100              105

```

<210> 233
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 233
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1              5              10              15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20              25              30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35              40              45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50              55              60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65              70              75              80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
      85              90              95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
      100              105

```

<210> 234
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 234

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100           105

```

<210> 235
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 235
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Phe Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Ser Gly Tyr Pro Pro
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100           105

```

<210> 236
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 236
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65          70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg Asp Val Met Ile Thr Phe Gly Gly Val Ile Val His Tyr Gly
          100           105           110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
          115           120           125

```

<210> 237
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 237
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95
 Val Arg Gly Phe Gly Tyr Ser Tyr Asn Tyr Asp Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 238
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 238
 Gln Val Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser
 1 5 10 15
 Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp
 20 25 30
 Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly
 35 40 45
 Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln
 50 55 60
 Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met
 65 70 75 80
 Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg Glu Gly Ile Ala Val Ala Gly Thr Tyr Tyr Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 239
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 239
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Leu Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Ala Ala Thr Asn Tyr Tyr Asn Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 240
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 240
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Ser Gly Tyr Ser Tyr Gly Tyr Asp Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 241
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 241
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Asn Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Thr Ala Thr Asp Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 242

<211> 127
 <212> PRT
 <213> homo sapiens

<400> 242

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
		20					25						30		
Asp	Ile	Asn	Trp	Val	Arg	Gln	Ala	Thr	Gly	Gln	Gly	Leu	Glu	Trp	Met
	35					40						45			
Gly	Trp	Met	Asn	Pro	Asn	Ser	Gly	Asp	Thr	Gly	Tyr	Ala	Gln	Lys	Phe
	50				55					60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asn	Thr	Ser	Ile	Ser	Thr	Ala	Tyr
65					70				75						80
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Phe	Cys
			85					90					95		
Ala	Arg	Met	Arg	Asp	Ile	Val	Ala	Thr	Ser	Tyr	Tyr	Tyr	Tyr	Phe	Tyr
		100					105						110		
Gly	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	
		115					120						125		

<210> 243
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 243

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
		20					25						30		
Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
	35					40						45			
Gly	Trp	Ile	Ser	Ala	Tyr	Asn	Gly	Asn	Thr	Asn	Tyr	Ala	Gln	Lys	Leu
	50					55				60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Thr	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr
65					70				75						80
Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85					90					95		
Ala	Arg	Asp	His	Tyr	Tyr	Asp	Ser	Ser	Asp	Tyr	Leu	Tyr	Tyr	Tyr	Tyr
		100					105						110		
Gly	Leu	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	
		115					120						125		

<210> 244
 <211> 69
 <212> PRT
 <213> homo sapiens

<400> 244

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
		20					25						30		
Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
	35					40						45			
Gly	Trp	Ile	Ser	Ala	Tyr	Asn	Gly	Asn	Thr	Asn	Tyr	Gln	Gly	Thr	Leu
	50					55					60				

Val Thr Val Ser Ser
65

<210> 245
<211> 126
<212> PRT
<213> homo sapiens

<400> 245
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Glu Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Arg Tyr Ala Gly Tyr Tyr Tyr Asp Tyr Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125

<210> 246
<211> 126
<212> PRT
<213> homo sapiens

<400> 246
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ser Tyr Gly Tyr Val Tyr Tyr Asp Tyr Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125

<210> 247
<211> 126
<212> PRT
<213> homo sapiens

<400> 247
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

```

                20                25                30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35      40      45
Ala Ile Ile Trp Tyr Asp Gly Asn Asp Lys Tyr Tyr Ala Asp Ser Val
      50      55      60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65      70      75      80
Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
      85      90      95
Arg Gly Tyr Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr Gly
      100      105      110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115      120      125

```

<210> 248
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 248
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
  1      5      10      15
Ser Leu Lys Ile Ser Cys Glu Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20      25      30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35      40      45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50      55      60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65      70      75      80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85      90      95
Ala Arg His Val Ser Tyr Tyr Tyr Val Ser Gly Ser Tyr Tyr Asn Val
      100      105      110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115      120      125

```

<210> 249
 <211> 126
 <212> PRT
 <213> homo sapiens

```

<400> 249
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
  1      5      10      15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
      20      25      30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35      40      45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50      55      60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65      70      75      80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85      90      95
Ala Arg His Gly Ser Tyr Tyr Tyr Gly Ser Glu Thr Tyr Tyr Asn Val
      100      105      110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115      120      125

```

<210> 250
 <211> 129
 <212> PRT
 <213> homo sapiens

<400> 250
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Ala Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Val Asp Val Gly Ala Thr Ile Gly Gly Tyr Tyr Tyr Tyr
 100 105 110
 Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 115 120 125
 Ser

<210> 251
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 251
 Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Gly Ser Tyr Tyr Tyr Asn Ser Gly Ser Tyr Tyr Asn Val
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 252
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 252
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr

```

                20                25                30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35                40                45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Lys Tyr Ser Pro Ser Phe
      50                55                60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
      65                70                75                80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Ala Thr Ala Met Tyr Tyr
      85                90                95
Cys Ala Arg His Tyr Asp Tyr Val Trp Arg Asn Tyr Arg Tyr Thr Gly
      100                105                110
Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115                120                125

```

<210> 253
 <211> 111
 <212> PRT
 <213> homo sapiens

```

<400> 253
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1                5                10                15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20                25                30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Leu Lys Pro Gly Gln Ser
      35                40                45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly Val Pro
      50                55                60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65                70                75                80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
      85                90                95
Leu Gln Thr Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
      100                105                110

```

<210> 254
 <211> 111
 <212> PRT
 <213> homo sapiens

```

<400> 254
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1                5                10                15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser
      20                25                30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
      35                40                45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50                55                60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65                70                75                80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85                90                95
Leu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
      100                105                110

```

<210> 255
 <211> 113

<212> PRT

<213> homo sapiens

<400> 255

```

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1           5           10           15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20           25           30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35           40           45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
          50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80
Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Ser Leu Met Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile
          100          105          110
Lys

```

<210> 256

<211> 107

<212> PRT

<213> homo sapiens

<400> 256

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Gly Ile Ser Asn Asp
          20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
          35           40           45
Tyr Ala Ala Ser Thr Leu Gln Leu Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe
          85          90          95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
          100          105

```

<210> 257

<211> 107

<212> PRT

<213> homo sapiens

<400> 257

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
          20           25           30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
          35           40           45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Leu

```

85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 258
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 258
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Ala Tyr Tyr Cys Gln Lys Cys Asn Ser Ala Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Thr Val Glu Ile Lys
 100 105

<210> 259
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 259
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Ala Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
 85 90 95
 Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 260
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 260
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
 85 90 95
 Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 261
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 261
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Asp Pro Cys
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Arg
 100 105

<210> 262
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 262
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Asp Pro Cys
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Arg
 100 105

<210> 263
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 263
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly


```

      1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
      85           90           95
Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
      100           105

```

<210> 264
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 264
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
      1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45
Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
      85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100           105

```

<210> 265
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 265
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
      1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
      85           90           95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100           105

```

<210> 266
 <211> 107

<212> PRT

<213> homo sapiens

<400> 266

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100           105

```

<210> 267

<211> 107

<212> PRT

<213> homo sapiens

<400> 267

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Leu
          85           90           95
Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
          100           105

```

<210> 268

<211> 107

<212> PRT

<213> homo sapiens

<400> 268

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

```

100

105

<210> 269
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 269
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Phe Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Ser Gly Tyr Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 270
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 270
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Arg Thr Tyr
 20 25 30
 Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Ser Ser Ser Asn Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Met Ile Thr Phe Gly Gly Ile Ile Ala Ser Phe Tyr
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Val Leu Thr Val Ser Ser
 115 120 125

<210> 271
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 271
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 272
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 28, 30, 33, 57
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 28, 30, 33, 57
 <223> Xaa = Any Amino Acid

<400> 272
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Xaa Phe Xaa Ser Tyr
 20 25 30
 Xaa Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ser Ile Ser Ser Ser Ser Ser Xaa Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 273
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 273
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
 20 25 30
 Asp Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu
 35 40 45
 Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
 65 70 75 80
 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95
 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 274

<211> 96

<212> PRT

<213> homo sapiens

<400> 274

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
          20           25           30
Asp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu
          35           40           45
Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
          50           55           60
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
65          70           75           80
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
          85           90           95

```

<210> 275

<211> 96

<212> PRT

<213> homo sapiens

<400> 275

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
          20           25           30
Asp Leu Gly Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu
          35           40           45
Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
          50           55           60
Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln
65          70           75           80
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
          85           90           95

```

<210> 276

<211> 120

<212> PRT

<213> homo sapiens

<400> 276

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
          20           25           30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
          35           40           45
Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
          50           55           60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65          70           75           80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
          85           90           95
Gly Thr Val Thr Thr Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln

```

100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 277
 <211> 97
 <212> PRT
 <213> homo sapiens

<400> 277
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
 20 25 30
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 Arg

<210> 278
 <211> 96
 <212> PRT
 <213> homo sapiens

<400> 278
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
 20 25 30
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

<210> 279
 <211> 111
 <212> PRT
 <213> homo sapiens

<400> 279
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60

```

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Thr Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
          100          105          110

```

<210> 280
 <211> 100
 <212> PRT
 <213> homo sapiens

```

<400> 280
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
          50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Thr Pro
          100

```

<210> 281
 <211> 99
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 31
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 31
 <223> Xaa = Any Amino Acid

```

<400> 281
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1          5          10          15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Xaa Ser
          20          25          30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
          50          55          60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
          85          90          95
Leu Gln Thr

```

<210> 282
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 282
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Gln Gly Tyr Arg Tyr Ala Gly Tyr Tyr Tyr Asp Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 283
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 283
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 284
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 284
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Lys
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr


```
<210> 285
<211> 107
<212> PRT
<213> homo sapiens
```

```
<210> 286
<211> 95
<212> PRT
<213> homo sapiens
```

```
<210> 287
<211> 95
<212> PRT
<213> homo sapiens
```

-76-

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 288
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 288
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Glu Gly Ile Ala Val Ala Gly Thr Tyr Tyr Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 289
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 289
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 290
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 290
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

```

      1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
      35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
      50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
      65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg

```

<210> 291
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 291
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gln His Asn Ser Tyr Pro Phe
      85           90           95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
      100           105

```

<210> 292
 <211> 95
 <212> PRT
 <213> homo sapiens

```

<400> 292
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
      85           90           95

```

<210> 293
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 293

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gln His Asn Ser Tyr Pro
85           90           95

```

<210> 294

<211> 126

<212> PRT

<213> homo sapiens

<400> 294

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85           90           95
Ala Arg Asp Val Met Ile Thr Phe Gly Gly Val Ile Val His Tyr Gly
100          105          110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115          120          125

```

<210> 295

<211> 98

<212> PRT

<213> homo sapiens

<400> 295

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85           90           95
Ala Arg

```

<210> 296
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 296
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 297
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 297
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Asp Pro Cys
 85 90 95
 Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Arg
 100 105

<210> 298
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 298
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

```
<210> 301
<211> 98
<212> PRT
<213> homo sapiens
```

<400> 301

```

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1           5           10           15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50           55           60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85           90           95
Ala Arg

```

<210> 302

<211> 98

<212> PRT

<213> homo sapiens

<220>

<221> VARIANT

<222> 23

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 23

<223> Xaa = Any Amino Acid

<400> 302

```

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1           5           10           15
Ser Leu Lys Ile Ser Cys Xaa Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20           25           30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35           40           45
Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50           55           60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65           70           75           80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85           90           95
Ala Arg

```

<210> 303

<211> 107

<212> PRT

<213> homo sapiens

<400> 303

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20           25           30
Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35           40           45

```

```

Tyr Ala Ala Ser Ser Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly
  50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85          90          95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100          105

```

<210> 304
 <211> 95
 <212> PRT
 <213> homo sapiens

```

<400> 304
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1          5          10          15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20          25          30
Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35          40          45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
          85          90          95

```

<210> 305
 <211> 95
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 56
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 56
 <223> Xaa = Any Amino Acid

```

<400> 305
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1          5          10          15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20          25          30
Leu Gly Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35          40          45
Tyr Ala Ala Ser Ser Leu Gln Xaa Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
          85          90          95

```

<210> 306
 <211> 126

<212> PRT

<213> homo sapiens

<400> 306

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg Asp Gln Gly Tyr Ser Tyr Gly Tyr Val Tyr Tyr Asp Tyr Gly
      100          105          110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 307

<211> 98

<212> PRT

<213> homo sapiens

<400> 307

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Arg

```

<210> 308

<211> 98

<212> PRT

<213> homo sapiens

<400> 308

```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
      20           25           30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Asp Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

```

85 90 95

Ala Arg

<210> 309
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 309
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 310
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 310
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 311
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 311
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asp Asn
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 312
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 312
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 313
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 313
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Gly Ser Tyr Tyr Tyr Gly Ser Glu Thr Tyr Tyr Asn Val
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 314
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 28
 <223> Xaa = Any Amino Acid

<221> VARIANT

<222> 28

<223> Xaa = Any Amino Acid

<400> 314

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Xaa Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 315

<211> 95

<212> PRT

<213> homo sapiens

<400> 315

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 316

<211> 107

<212> PRT

<213> homo sapiens

<400> 316

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100

105

<210> 317
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 317
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 318
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 318
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 319
 <211> 129
 <212> PRT
 <213> homo sapiens

<400> 319
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Ala Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80

Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Val Asp Val Gly Ala Thr Ile Gly Gly Tyr Tyr Tyr Tyr
 100 105 110
 Tyr His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
 115 120 125
 Ser

<210> 320
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 68
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 68
 <223> Xaa = Any Amino Acid

<400> 320
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Xaa Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 321
 <211> 100
 <212> PRT
 <213> homo sapiens

<400> 321
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Thr Pro
 100

<210> 322
 <211> 114
 <212> PRT
 <213> homo sapiens

<400> 322
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Thr Pro Leu Met Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu
 100 105 110
 Ile Lys

<210> 323
 <211> 99
 <212> PRT
 <213> homo sapiens

<400> 323
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30
 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45
 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
 85 90 95
 Leu Gln Ser

<210> 324
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 324
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu

50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 325
 <211> 127
 <212> PRT
 <213> homo sapiens

<400> 325
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp His Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr
 100 105 110
 Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 326
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 326
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 327
 <211> 96
 <212> PRT
 <213> homo sapiens

<400> 327


```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Phe Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn
           20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu
           35           40           45
Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
           50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65           70           75           80
Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
           85           90           95

```

<210> 328
 <211> 108
 <212> PRT
 <213> homo sapiens

```

<400> 328
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Phe Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn
           20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu
           35           40           45
Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
           50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65           70           75           80
Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
           85           90           95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
           100           105

```

<210> 329
 <211> 96
 <212> PRT
 <213> homo sapiens

```

<400> 329
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Phe Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn
           20           25           30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu
           35           40           45
Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
           50           55           60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
65           70           75           80
Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
           85           90           95

```

<210> 330
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 330

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 331

<211> 127

<212> PRT

<213> homo sapiens

<400> 331

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Ile Ile Trp Tyr Asp Gly Asn Asp Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Tyr Tyr Tyr Asp Ser Ser Asp Tyr Leu Tyr Tyr Tyr Tyr
 100 105 110
 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 332

<211> 98

<212> PRT

<213> homo sapiens

<220>

<221> VARIANT

<222> 56, 57

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 56, 57

<223> Xaa = Any Amino Acid

<400> 332

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

```

      35              40              45
Ala Ile Ile Trp Tyr Asp Gly Xaa Xaa Lys Tyr Tyr Ala Asp Ser Val
      50              55              60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65              70              75              80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85              90              95
Ala Arg

```

<210> 333
 <211> 95
 <212> PRT
 <213> homo sapiens

```

<400> 333
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1              5              10              15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
      20              25              30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
      35              40              45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50              55              60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
      65              70              75              80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
      85              90              95

```

<210> 334
 <211> 107
 <212> PRT
 <213> homo sapiens

```

<400> 334
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
  1              5              10              15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
      20              25              30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Asn Leu Leu Ile
      35              40              45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
      50              55              60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
      65              70              75              80
Glu Asp Val Ala Ala Tyr Tyr Cys Gln Lys Cys Asn Ser Ala Pro Trp
      85              90              95
Thr Phe Gly Gln Gly Thr Thr Val Glu Ile Lys
      100              105

```

<210> 335
 <211> 95
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 45, 85, 91

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 45, 85, 91

<223> Xaa = Any Amino Acid

<400> 335

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Asn	Tyr
		20						25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Val	Pro	Xaa	Leu	Leu	Ile
		35					40					45			
Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55				60					
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75					80
Glu	Asp	Val	Ala	Xaa	Tyr	Tyr	Cys	Gln	Lys	Xaa	Asn	Ser	Ala	Pro	
				85					90					95	

<210> 336

<211> 98

<212> PRT

<213> homo sapiens

<400> 336

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Glu
1				5					10					15	
Ser	Leu	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Ser	Tyr
		20						25					30		
Trp	Ile	Gly	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Ile	Ile	Tyr	Pro	Gly	Asp	Ser	Asp	Thr	Arg	Tyr	Ser	Pro	Ser	Phe
	50					55				60					
Gln	Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr
65					70					75					80
Leu	Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
				85					90					95	

Ala Arg

<210> 337

<211> 126

<212> PRT

<213> homo sapiens

<400> 337

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Thr	Glu	Val	Lys	Lys	Pro	Gly	Glu
1				5					10					15	
Ser	Leu	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Arg	Phe	Thr	Ser	Tyr
		20						25					30		
Trp	Ile	Gly	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Ile	Ile	Tyr	Pro	Gly	Asp	Ser	Asp	Thr	Arg	Tyr	Ser	Pro	Ser	Phe
	50					55				60					
Gln	Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Ile	Ser	Thr	Ala	Tyr
65					70					75					80
Leu	Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
				85					90					95	

Ala Arg His Gly Ser Tyr Tyr Tyr Asn Ser Gly Ser Tyr Tyr Asn Val
 100 105 110
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 338
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 9, 28
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 9, 28
 <223> Xaa = Any Amino Acid

<400> 338
 Glu Val Gln Leu Val Gln Ser Gly Xaa Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Xaa Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 339
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 339
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 340
 <211> 107
 <212> PRT
 <213> homo sapiens

<400> 340

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Trp
          85           90           95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
          100           105

```

<210> 341

<211> 95

<212> PRT

<213> homo sapiens

<400> 341

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1           5           10           15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
          20           25           30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
          35           40           45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50           55           60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
          85           90           95

```

<210> 342

<211> 98

<212> PRT

<213> homo sapiens

<400> 342

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20           25           30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65           70           75           80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Ala Arg

```

<210> 343

<211> 125
 <212> PRT
 <213> homo sapiens

<400> 343

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1			5						10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Asp	Ile	Asn	Trp	Val	Arg	Gln	Ala	Thr	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Trp	Met	Asn	Pro	Asn	Ser	Gly	Asn	Thr	Gly	Tyr	Ala	Gln	Lys	Phe
	50					55				60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asn	Thr	Ser	Ile	Ser	Thr	Ala	Tyr
65					70				75					80	
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Gly	Ser	Gly	Tyr	Ser	Tyr	Gly	Tyr	Asp	Tyr	Tyr	Tyr	Gly	Met
			100					105					110		
Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser			
		115					120					125			

<210> 344
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 344

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1			5						10					15	
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Asp	Ile	Asn	Trp	Val	Arg	Gln	Ala	Thr	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35					40					45			
Gly	Trp	Met	Asn	Pro	Asn	Ser	Gly	Asn	Thr	Gly	Tyr	Ala	Gln	Lys	Phe
	50					55				60					
Gln	Gly	Arg	Val	Thr	Met	Thr	Arg	Asn	Thr	Ser	Ile	Ser	Thr	Ala	Tyr
65					70				75					80	
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg														

<210> 345
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 345

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1			5						10					15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Asn	Tyr
			20					25					30		
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Val	Pro	Lys	Leu	Leu	Ile
		35					40					45			
Tyr	Ala	Ala	Ser	Thr	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55				60					
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70				75					80	

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
 85 90 95

<210> 346

<211> 107

<212> PRT

<213> homo sapiens

<400> 346

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Asn Cys Arg Ala Ser Gln Gly Ile Ser Asn Asp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Phe
 85 90 95
 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 347

<211> 95

<212> PRT

<213> homo sapiens

<220>

<221> VARIANT

<222> 22, 32, 56

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 22, 32, 56

<223> Xaa = Any Amino Acid

<400> 347

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Xaa Cys Arg Ala Ser Gln Gly Ile Ser Asn Xaa
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Xaa Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro
 85 90 95

<210> 348

<211> 98

<212> PRT

<213> homo sapiens

<400> 348

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 349
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 349
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Asn Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Ile Val Val Val Val Thr Ala Thr Asp Tyr Tyr Tyr Gly
 100 105 110
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 350
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 55
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 55
 <223> Xaa = Any Amino Acid

<400> 350
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Met Asn Pro Asn Xaa Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 351

<211> 95

<212> PRT

<213> homo sapiens

<400> 351

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro
 85 90 95

<210> 352

<211> 107

<212> PRT

<213> homo sapiens

<400> 352

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
 20 25 30
 Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
 35 40 45
 Phe Ala Ala Ser Ser Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Ser Gly Tyr Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 353

<211> 95

<212> PRT

<213> homo sapiens

<220>

<221> VARIANT

<222> 55, 92, 93

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 55, 92, 93

<223> Xaa = Any Amino Acid

<400> 353

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1             5             10             15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
      20             25             30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
      35             40             45
Tyr Ala Ala Ser Ser Leu Xaa Ser Gly Val Pro Ser Arg Phe Ser Gly
      50             55             60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65             70             75             80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Xaa Xaa Tyr Pro
      85             90             95

```

<210> 354

<211> 126

<212> PRT

<213> homo sapiens

<400> 354

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1             5             10             15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20             25             30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35             40             45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
      50             55             60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65             70             75             80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
      85             90             95
Ala Arg Asp Val Glu Tyr Tyr Tyr Asp Gly Ser Gly Tyr Tyr Tyr Tyr
      100             105             110
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115             120             125

```

<210> 355

<211> 98

<212> PRT

<213> homo sapiens

<400> 355

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1             5             10             15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      20             25             30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
      35             40             45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
      50             55             60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65             70             75             80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

```

85 90 95

Ala Arg

<210> 356
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 356
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
 50 55 60
 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg

<210> 357
 <211> 108
 <212> PRT
 <213> homo sapiens

<400> 357
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ser Asn Ser Phe Pro Arg
 85 90 95
 Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 358
 <211> 95
 <212> PRT
 <213> homo sapiens

<400> 358
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

```

Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro
          85          90          95

```

<210> 359
 <211> 95
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 53
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 53
 <223> Xaa = Any Amino Acid

```

<400> 359
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1          5          10          15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
          20          25          30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
          35          40          45
Tyr Ala Ala Ser Xaa Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80
Glu Asp Phe Ala Ser Tyr Tyr Cys Gln Gln Ser Asn Ser Phe Pro
          85          90          95

```

<210> 360
 <211> 127
 <212> PRT
 <213> homo sapiens

```

<400> 360
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1          5          10          15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20          25          30
Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
          35          40          45
Gly Trp Met Asn Pro Asn Ser Gly Asp Thr Gly Tyr Ala Gln Lys Phe
          50          55          60
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
65          70          75          80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
          85          90          95
Ala Arg Met Arg Asp Ile Val Ala Thr Ser Tyr Tyr Tyr Tyr Phe Tyr
          100          105          110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
          115          120          125

```

<210> 361
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 361
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 362
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 57
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 57
 <223> Xaa = Any Amino Acid

<400> 362
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Xaa Thr Gly Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg

<210> 363
 <211> 111
 <212> PRT
 <213> homo sapiens

<400> 363
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15

```

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20      25      30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Leu Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
      85      90      95
Leu Gln Thr Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
      100      105      110

```

<210> 364
 <211> 100
 <212> PRT
 <213> homo sapiens

```

<400> 364
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20      25      30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Leu Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65      70      75      80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
      85      90      95
Leu Gln Thr Pro
      100

```

<210> 365
 <211> 99
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 43, 58, 96
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 43, 58, 96
 <223> Xaa = Any Amino Acid

```

<400> 365
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1      5      10      15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
      20      25      30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Xaa Lys Pro Gly Gln Ser
      35      40      45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Xaa Arg Ala Ser Gly Val Pro
      50      55      60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65      70      75      80

```

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Xaa
 85 90 95
 Leu Gln Thr

<210> 366
 <211> 126
 <212> PRT
 <213> homo sapiens

<400> 366
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ala Lys Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Tyr Asp Tyr Val Trp Arg Asn Tyr Arg Tyr Thr Gly Trp
 100 105 110
 Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 367
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 367
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 368
 <211> 98
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 58
 <223> Xaa = Any Amino Acid

<221> VARIANT

<222> 58

<223> Xaa = Any Amino Acid

<400> 368

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1 5 10 15
 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
 20 25 30
 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Xaa Lys Tyr Ser Pro Ser Phe
 50 55 60
 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 369

<211> 108

<212> PRT

<213> homo sapiens

<400> 369

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
 85 90 95
 Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 370

<211> 96

<212> PRT

<213> homo sapiens

<400> 370

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro

85

90

95

<210> 371
 <211> 95
 <212> PRT
 <213> homo sapiens

<220>
 <221> VARIANT
 <222> 54
 <223> Xaa = Any Amino Acid

<221> VARIANT
 <222> 54
 <223> Xaa = Any Amino Acid

<400> 371
 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Xaa Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser
 85 90 95

<210> 372
 <211> 125
 <212> PRT
 <213> homo sapiens

<400> 372
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95
 Val Arg Gly Phe Gly Tyr Ser Tyr Asn Tyr Asp Tyr Tyr Tyr Gly Met
 100 105 110
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 373
 <211> 98
 <212> PRT
 <213> homo sapiens

<400> 373

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Asp Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg

<210> 374

<211> 98

<212> PRT

<213> homo sapiens

<220>

<221> VARIANT

<222> 59, 73, 97

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> 59, 73, 97

<223> Xaa = Any Amino Acid

<400> 374

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Xaa Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Arg Xaa Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95
 Xaa Arg

<210> 375

<211> 108

<212> PRT

<213> homo sapiens

<400> 375

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Ala Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser

```

      50              55              60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65              70              75              80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
      85              90              95
Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
      100              105

```

<210> 376
 <211> 96
 <212> PRT
 <213> homo sapiens

```

<400> 376
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1              5              10              15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
      20              25              30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45
Ile Tyr Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
      50              55              60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65              70              75              80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
      85              90              95

```

<210> 377
 <211> 96
 <212> PRT
 <213> homo sapiens

```

<400> 377
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1              5              10              15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
      20              25              30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45
Ile Tyr Ala Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
      50              55              60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65              70              75              80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
      85              90              95

```